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Introduction 
 
Cancer is the most common cause of death in the Netherlands and the Integral Cancer center 
of the Netherlands (IKNL) expects the incidence of cancer to increase in the upcoming years. 
In 2014, 104 patients per 100.000 people were diagnosed with cancer, compared to 57 per 
100.000 people in 1990 [1]. Breast cancer is the highest prevalent cancer in the Netherlands, 
with 1 in 8 women developing breast cancer at some point during their life, and the second 
cause of death in women with more than 3000 deaths per year [2]. (Figure 1) 
 
 
Figure 1. Numbers of cancer-related deaths in the Netherlands in 2014 [1]. 
 
Risk factors associated with breast cancer include obesity, smoking, alcohol use, null parity, 
early menarche, older age at first birth, a positive family history and genetic predisposition [3, 
4]. The treatment of breast cancer is increasingly personalized and depends on the disease 
stage, the tumor type (i.e. hormone receptor status and the amplification level of the Her2 
receptor), the age and the menopausal status of the patient. In general, surgery with or without 
radiotherapy is conducted in patients with primary breast cancer. In patients with a high 
relapse risk, perioperative systemic treatment is given consisting of chemotherapy, and/or 
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endocrine therapy in case of estrogen/progesterone receptor positivity and/or  Her2-targeted 
therapy in case of Her2 receptor overexpression. Peri-operative systemic treatment is 
dependent on relapse risk, tumor characteristics and the age of the patient [5]. Metastatic 
breast cancer (MBC) is considered an incurable disease and systemic treatment with 
cytotoxic, endocrine and/or Her2 targeted agents is the cornerstone of the therapy.  
 
Her2 targeted therapy in breast cancer` 
 
In the literature, numerous subtype classifications for breast cancers exist. In the most 
commonly used system, breast cancer is categorized into the following subtypes: “Luminal 
A” (ER positive, Her2 negative, Ki-67 low, progesterone receptor high, low risk molecular 
signature), “luminal B” (ER positive and Her2 positive or ER positive and Her2 negative with 
either Ki-67 high or progesterone receptor low or high risk molecular signature), “Her2 
positive” (ER negative) and “basal-like” (triple negative) [6]. These subtypes are partly 
decisive for the prognosis and the treatment strategy. The luminal A subtype is considered 
having the best prognosis and the triple negative subtype has the worst prognosis. In the pre-
trastuzumab era, Her2 positive tumors were associated with rapid progression and poor 
prognosis, but since the introduction of Her2-targeted therapy, the survival of patients with 
Her2 positive breast cancer is comparable with hormone positive tumors [7]. Generally, low 
risk luminal A tumors are treated with endocrine therapy, luminal B tumors with endocrine 
therapy and possibly chemotherapy, and for Her2 positive and triple negative tumors, 
chemotherapy is indicated [8]. Treatment strategies differ, however, because of tumor- and 
disease characteristics and the preference of the patient. In the treatment strategies for the 
HER2-positive tumors, HER2 targeting agents such as trastuzumab, pertuzumab, T-DM1 and 
lapatinib play an important role. Trastuzumab is a monoclonal antibody binding to the 
extracellular segment of the Her2 receptor, resulting in inhibition of tumor proliferation [9]. 
 
Trastuzumab was approved for the treatment of Her2 positive MBC in 1998 after a substantial 
improvement of survival in these patients [10-13]. In a phase III trial involving 469 patients 
with Her2 positive MBC, participants were randomly assigned to receive chemotherapy or 
chemotherapy with trastuzumab. Patients receiving trastuzumab had a longer median time to 
disease progression (7.4 months vs. 4.6 months, p < 0.001), a larger percentage of overall 
response (50% vs. 32%, p < 0.001), and longer overall survival (25.1 vs. 20.3 months, p = 
0.046) than patients receiving only chemotherapy [10].   
General introduction and outline of the thesis 
 
13 
 
The approval of trastuzumab for adjuvant treatment followed in 2006 after good efficacy and 
safety in clinical trials [14-18]. In the HERA trial (a phase III randomized open label trial) 
[16], treatment with trastuzumab for 1 or 2 years was compared with observation in 5102 
patients. The addition of trastuzumab to adjuvant chemotherapy resulted in a significantly 
improved disease-free- and overall survival (HR 0.64, 95% CI 0.54 – 0.76 and HR 0.66, 95% 
CI 0.47 – 0.91 respectively) [19]. In the BCIRG-006 trial, trastuzumab with doxorubicin, 
cyclophosphamide and docetaxel or trastuzumab with docetaxel and carboplatin was 
compared with chemotherapeutic monotherapy (doxorubicin, cyclophosphamide and 
docetaxel). Both disease-free and overall survival rates were superior in the trastuzumab arms 
after a follow up of 5 years (84% and 81% vs. 75%, p < 0.001 and 92% and 91% vs. 87%, p = 
0.04) [14].  
 
The change of the initial poor prognosis of Her2 positive breast cancer caused by trastuzumab 
led to an increase in the research of other Her2 targeting agents in both adjuvant and palliative 
setting. Currently, dual blockade of the Her2 receptor with trastuzumab and pertuzumab in 
combination with docetaxel is recommended as first line palliative systemic therapy in 
patients with Her2 positive MBC [20] after showing survival benefit in the CLEOPATRA 
trial [21]. In the EMILIA trial, trastuzumab-emtansine (T-DM1) or lapatinib was combined 
with capecitabine. T-DM1 showed superior efficacy than lapatinib in patients with 
progressive disease after treatment with trastuzumab and a taxane (HR for progression 0.65, 
95% CI 0.55 – 0.77, p < 0.001, HR for overall survival 0.68, 95% CI 0.55 – 0.85, p < 0.001) 
[22]. Consequently, T-DM1 combined with standard chemotherapy is currently recommended 
as second line therapy in Her2 positive MBC [20]. Blockade of the Her2 receptor with more 
than one anti-Her2 agent in the adjuvant setting currently does not belong to the standard care 
yet, but recent trials suggest a possible benefit of the addition of pertuzumab to standard 
adjuvant trastuzumab therapy [23, 24]. In contrast, the combination of adjuvant lapatinib and 
trastuzumab has failed to provide further benefit so far [25]. 
 
The widespread application of trastuzumab in the adjuvant setting has substantially improved 
the outcome for patients with HER2-positive primary breast cancer. For those who despite the 
adjuvant treatment face a relapse, trastuzumab-based regimens are indicated. In this setting of 
advanced disease, patients have been pretreated with trastuzumab. Whether the benefit of 
trastuzumab is similar in this setting, as was seen in the initial publications of trastuzumab in 
the metastatic setting, remains unknown. Furthermore, a few concerns have risen regarding 
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the duration of systemic therapies in MBC and the selection of patients for these treatments. 
Cytotoxic regimens with anthracyclins and taxanes often induce cardiotoxicity, neuropathy 
and myalgia [26-28]. Her2 targeted therapy has extended the overall survival to more than 5 
years in more than 10% of  the patients with Her2 positive MBC [29] but is associated with 
cardiotoxicity and high costs. As patients live longer, the question rises how long anti-Her2 
maintenance therapy should be continued. In addition, resistance to trastuzumab after initial 
response is an increasingly observed phenomenon and the mechanism of resistance is possible 
partly dependent of the sequence of previous treatment lines, thus differs between patients 
[30].  
 
So, the selection of the right patient for the right treatment is essential but remains a 
challenge, especially in older cancer patients, who are more prone to develop treatment-
related toxicities and where assessment of treatment risks can be difficult due to subclinical 
differences in physical reserve [31]. Increasing evidence suggests that treatment selection is 
not solely dependent of tumor biology, but also of patient-related clinical parameters, for 
example low muscle mass.  
 
Body composition analysis as clinical prognostic factor for oncological outcomes.  
 
Recently, low muscle mass has been independently associated with impaired overall survival 
in multiple tumor types [32-34]  and a higher incidence of chemotherapeutic toxicity [35]. 
The use of muscle parameters in treatment decision making in cancer patients is a fast 
developing field of clinical research. Muscle mass deteriorates in all aging people due to age-
related metabolic changes and age-related changes in muscle turnover [36]. It is considered 
the major component of age-related (primary) sarcopenia [37], a geriatric syndrome with 
multifactorial etiology presenting with low muscle mass and low muscle strength or impaired 
physical performance [38, 39]. Disease-related (secondary) sarcopenia, as occurs in cancer 
patients, accelerates muscle wasting and is mostly due to cachexia-related processes [40]. 
The combination of muscle mass, water and bone forms the lean body mass. Total body 
weight consists of the lean body mass (also called the fat-free mass) and the fat mass [41]. 
Recent studies have suggested that increased chemotherapeutic toxicity can occur in patients 
with muscle wasting, as the decrease of the lean body mass causes a lower distribution of 
chemotherapeutic drugs to this compartment and therefore higher systemic drug levels [35, 
42]. However, standard measures of body weight, body mass index and body surface area are 
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insufficient to detect individual alterations of the lean body mass and the fat mass [43-45]. In 
body composition analyses, these compartments are measured separately, which is 
increasingly recognized as a new strategy to investigate the influence of muscle wasting on 
prognosis.  
 
Muscle measurement using CT imaging.   
 
Several imaging diagnostics can be used to obtain skeletal muscle measures, such as 
ultrasound, dual energy x-ray absorptiometry (DEXA), bioelectrical impedance analysis 
(BIA), computed tomography (CT) and magnetic resonance imaging (MRI) [46, 47]. In 
oncological research, CT imaging is often preferred since this is considered the gold standard 
for muscle measurement [48], because the different muscle and adipose tissue depots can 
easily be quantified using only one slice at the L3 level [49] (figure 2) and because CT 
images are widely available in oncological care.  
 
 
Figure 2. Body composition analysis using CT imaging at the L3 level 
Red = Skeletal muscle tissue.  Green = Intramuscular adipose tissue 
Blue = Subcutaneous adipose tissue. Yellow = Visceral adipose tissue. 
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Knowledge regarding muscle strength and physical performance is necessary to diagnose 
sarcopenia [38]. The quality of muscle may be of prognostic value too, measured by the 
density of muscle, which reflects the infiltration of muscle by adipose tissue [50, 51].  
 
Aim and outline of the thesis 
 
The aim of this thesis was to evaluate the impact of several patient- and treatment related 
factors on the outcome of patients with metastatic breast cancer. The efficacy of anti-Her2 
agents in the treatment of Her2 positive MBC is well established across clinical trials. 
However, the field of Her2-targeted therapy in Her2 positive MBC is rapidly evolving and 
sometimes previous cohorts of patients in clinical trials are therefore not representative 
anymore for the current daily clinical practice. In general, most patients in clinical trials were  
trastuzumab-naive before enrollment in the study according to current guidelines. As a result, 
the efficacy of retreatment with anti-Her2 agents after progressive disease on previous Her2-
targeted therapy with the same agents remains unclear. In chapter 2, the efficacy of first line 
Her2-targeted based chemotherapy between patients relapsing after adjuvant trastuzumab and 
patients without adjuvant trastuzumab treatment is evaluated in a large multicenter 
retrospective study in the South Western part of the Netherlands.  
In addition to mechanisms at tumor site level leading to resistance, also body composition 
parameters in metastatic breast cancer might impact outcome. At this moment, the use of 
body composition parameters in oncological care is intensively studied, but the research field 
is hampered by the lack of a standardized muscle mass measurement and no consensus on a 
definition of sarcopenia. In chapter 3, a review of the literature is provided on the importance 
of muscle mass and body composition in cancer patients and the methods of muscle 
measurement. Most knowledge regarding the prognostic impact of body composition and 
muscle quality in cancer patients is generated in patients with abdominal malignancies as 
abdominal CT imaging is necessary for muscle measurement using the technique of analyzing 
a single slice. Studies investigating this in breast cancer are scarce, but might have clinical 
impact by improving clinical outcome, physical performance and quality of life in breast 
cancer in case of interventions targeting low muscle mass [52]. Chapter 4 investigated the 
impact of low muscle mass and low muscle quality on time to next treatment and overall 
survival in patients with MBC undergoing first line palliative chemotherapy. In chapter 5, 
changes in body composition during chemotherapeutic treatment for MBC are described. The 
research field of body composition is especially clinically relevant in patients with higher risk 
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of complications, i.e. in older patients. Muscle parameters might be an additional help during 
risk assessment before the start of therapy. Therefore, in chapter 6, the association between 
different levels of sarcopenia prior to therapy and a decline of physical independence after 
chemotherapy in older cancer patients is studied.  In addition, there is a need of alternative 
ways of evaluating skeletal muscle and body composition in case CT images are not available 
or when less invasive diagnostics are preferable, which is often the case in older people. 
Therefore, the association between muscle parameters and functional measures in elderly 
patients with a wide range of different cancers is reported in chapter 6 as well. The main 
findings of this thesis and future directions for research are discussed in chapter 7.  
 
 
 
 
 
 
 
 
 
 
 
 
18 Chapter 1 
 
 
References 
1. Anonymous http://www.cijfersoverkanker.nl/nkr/index. 
2. Anonymous www.cbs.nl. 
3. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United 
States explained by well-established risk factors. J Natl Cancer Inst. 1995; 87:1681-1685. 
4. van Gemert WA, Lanting CI, Goldbohm RA, van den Brandt PA, Grooters HG, Kampman E, et al. The 
proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors. 
Breast Cancer Res Treat. 2015; 152:155-162; doi: 10.1007/s10549-015-3447-7 [doi]. 
5. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30; 
doi: 10.1093/annonc/mdv298 [doi]. 
6. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes--
dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the 
Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22:1736-1747; doi: 10.1093/annonc/mdr304 
[doi]. 
7. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast 
cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010; 28:92-98; 
doi: 10.1200/JCO.2008.19.9844 [doi]. 
8. Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, et al. Afatinib plus vinorelbine versus trastuzumab 
plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one 
previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016; 
17:357-366; doi: 10.1016/S1470-2045(15)00540-9 [doi]. 
9. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized 
anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer 
cells. Cancer Res. 2001; 61:4744-4749. 
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a 
monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 
344:783-792; doi: 10.1056/NEJM200103153441101 [doi]. 
11. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly 
intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-
overexpressing metastatic breast cancer. J Clin Oncol. 1996; 14:737-744. 
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the 
efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing 
metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 
17:2639-2648. 
13. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of 
trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin 
Oncol. 2002; 20:719-726. 
14. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-
positive breast cancer. N Engl J Med. 2011; 365:1273-1283; doi: 10.1056/NEJMoa0910383 [doi]. 
General introduction and outline of the thesis 
 
19 
 
15. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab 
for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of 
a randomised controlled trial. Lancet Oncol. 2011; 12:236-244; doi: 10.1016/S1470-2045(11)70033-X [doi]. 
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after 
adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-1672; doi: 353/16/1659 
[pii]. 
17. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE,Jr, Davidson NE, et al. Trastuzumab plus adjuvant 
chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673-1684; doi: 353/16/1673 
[pii]. 
18. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or 
vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354:809-820; doi: 354/8/809 
[pii]. 
19. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of 
trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 
2007; 369:29-36; doi: S0140-6736(07)60028-2 [pii]. 
20. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al. Systemic therapy for 
patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of 
Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32:2078-2099; doi: 
10.1200/JCO.2013.54.0948 [doi]. 
21. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and 
docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a 
randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14:461-471; doi: 
10.1016/S1470-2045(13)70130-X [doi]. 
22. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-
positive advanced breast cancer. N Engl J Med. 2012; 367:1783-1791; doi: 10.1056/NEJMoa1209124 [doi]. 
23. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant 
pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive 
breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17:791-800; 
doi: 10.1016/S1470-2045(16)00163-7 [doi]. 
24. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for 
metastatic breast cancer. N Engl J Med. 2012; 366:109-119; doi: 10.1056/NEJMoa1113216 [doi]. 
25. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant Lapatinib and 
Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the 
Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol. 
2016; 34:1034-1042; doi: 10.1200/JCO.2015.62.1797 [doi]. 
26. Ghersi D, Willson ML, Chan MM, Simes J, Donoghue E, Wilcken N. Taxane-containing regimens for 
metastatic breast cancer. Cochrane Database Syst Rev. 2015; 6:CD003366; doi: 
10.1002/14651858.CD003366.pub3 [doi]. 
27. Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M, et al. Taxane-induced arthralgia and myalgia: A 
literature review. J Oncol Pharm Pract. 2016 Jan 24. pii: 1078155215627502; doi: 1078155215627502 [pii]. 
28. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. 
FASEB J. 1997; 11:931-936. 
20 Chapter 1 
 
 
29. Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, et al. Clinicopathological 
and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. 
Breast Cancer Res Treat. 2016; 159:367-374; doi: 10.1007/s10549-016-3933-6 [doi]. 
30. Tagliabue E, Campiglio M, Pupa SM, Menard S, Balsari A. Activity and resistance of trastuzumab according 
to different clinical settings. Cancer Treat Rev. 2012; 38:212-217; doi: 10.1016/j.ctrv.2011.06.002 [doi]. 
31. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a 
haematological malignancy--a systematic review. Leuk Res. 2014; 38:275-283; doi: 
10.1016/j.leukres.2013.12.018 [doi]. 
32. Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Imaging body composition in cancer patients: 
visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015; 
6:489-497; doi: 10.1007/s13244-015-0414-0 [doi]. 
33. Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are 
associated with cancer clinical outcomes. Semin Cell Dev Biol. 2016; 54:2-10; doi: 
10.1016/j.semcdb.2015.09.001 [doi]. 
34. Malietzis G, Johns N, Al-Hassi HO, Knight SC, Kennedy RH, Fearon KC, et al. Low Muscularity and 
Myosteatosis Is Related to the Host Systemic Inflammatory Response in Patients Undergoing Surgery for 
Colorectal Cancer. Ann Surg. 2016; 263:320-325; doi: 10.1097/SLA.0000000000001113 [doi]. 
35. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an 
independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007; 13:3264-3268; 
doi: 13/11/3264 [pii]. 
36. Walrand S, Guillet C, Salles J, Cano N, Boirie Y. Physiopathological mechanism of sarcopenia. Clin Geriatr 
Med. 2011; 27:365-385; doi: 10.1016/j.cger.2011.03.005 [doi]. 
37. Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. Clin Cases Miner Bone 
Metab. 2014; 11:177-180. 
38. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European 
consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. 
Age Ageing. 2010; 39:412-423; doi: 10.1093/ageing/afq034 [doi]. 
39. Rolland Y, Abellan van Kan G, Gillette-Guyonnet S, Vellas B. Cachexia versus sarcopenia. Curr Opin Clin 
Nutr Metab Care. 2011; 14:15-21; doi: 10.1097/MCO.0b013e328340c2c2 [doi]. 
40. Delano MJ, Moldawer LL. The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin 
Pract. 2006; 21:68-81; doi: 21/1/68 [pii]. 
41. Ribeiro SM, Kehayias JJ. Sarcopenia and the analysis of body composition. Adv Nutr. 2014; 5:260-267; doi: 
10.3945/an.113.005256 [doi]. 
42. Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, et al. Lean body mass as an independent 
determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX 
regimens. Cancer Med. 2016; 5:607-616; doi: 10.1002/cam4.621 [doi]. 
43. St-Onge MP, Gallagher D. Body composition changes with aging: the cause or the result of alterations in 
metabolic rate and macronutrient oxidation?. Nutrition. 2010; 26:152-155; doi: 10.1016/j.nut.2009.07.004 [doi]. 
44. Kenny AM, Dawson L, Kleppinger A, Iannuzzi-Sucich M, Judge JO. Prevalence of sarcopenia and 
predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen-replacement therapy. 
J Gerontol A Biol Sci Med Sci. 2003; 58:M436-40. 
General introduction and outline of the thesis 
 
21 
 
45. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-
small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image 
analysis. Am J Clin Nutr. 2010; 91:1133S-1137S; doi: 10.3945/ajcn.2010.28608C [doi]. 
46. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise 
approach to quantification of body composition in cancer patients using computed tomography images acquired 
during routine care. Appl Physiol Nutr Metab. 2008; 33:997-1006; doi: 10.1139/H08-075 [doi]. 
47. Mourtzakis M, Wischmeyer P. Bedside ultrasound measurement of skeletal muscle. Curr Opin Clin Nutr 
Metab Care. 2014; 17:389-395; doi: 10.1097/MCO.0000000000000088 [doi]. 
48. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of 
skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 
(1985). 1998; 85:115-122. 
49. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and 
adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004; 
97:2333-2338; doi: 10.1152/japplphysiol.00744.2004 [doi]. 
50. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal 
muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf). 2014; 210:489-497; doi: 
10.1111/apha.12224 [doi]. 
51. Awad S, Tan BH, Cui H, Bhalla A, Fearon KC, Parsons SL, et al. Marked changes in body composition 
following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2012; 31:74-77; doi: 
10.1016/j.clnu.2011.08.008 [doi]. 
52. Adams SC, Segal RJ, McKenzie DC, Vallerand JR, Morielli AR, Mackey JR, et al. Impact of resistance and 
aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a 
multicenter randomized controlled trial. Breast Cancer Res Treat. 2016; 158:497-507; doi: 10.1007/s10549-016-
3900-2 [doi]. 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2 
 
First-line palliative treatment with trastuzumab in 
Her2 positive metastatic breast cancer is less 
effective after failure of adjuvant trastuzumab. 
 
 
Hánah N. Rier 
Mark-David Levin 
Joost van Rosmalen 
Monique Bos 
Jan C. Drooger 
Paul de Jong 
Johanneke E.A. Portielje 
Lizet Elsten 
Albert-Jan ten Tije 
Stefan Sleijfer 
Agnes Jager 
 
 
 
 
 
 
The Oncologist 2017 Aug;22(8):901-909 
24 
 
Chapter 2 
 
Abstract 
 
Background: Survival of patients with Her2-positive metastatic breast cancer (MBC) has 
improved dramatically since trastuzumab has become available, although the disease 
eventually progresses in most patients. This study investigates the outcome (overall survival 
(OS) and time to next treatment (TNT)) in MBC patients pre-treated with trastuzumab in the 
adjuvant setting (TP-group) compared to trastuzumab-naïve patients (TN-group) in order to 
investigate the possibility of trastuzumab resistance. 
Patients and methods: Patients treated with first-line Her2-targeted-containing 
chemotherapy were eligible for the study. A power analysis was performed to estimate the 
minimum size of the TP-group. OS and TNT were estimated using Kaplan-Meier curves and 
multivariable Cox proportional hazards models.  
Results: Between January 1, 2000 and June 1, 2014, 469 patients were included of whom 82 
in the TP-group and 387 in the TN-group. Median OS and TNT were significantly worse in 
the TP-group compared to the TN-group (17 vs. 30 months, adjusted HR 1.84 (1.15 – 2.96), p 
= 0.01 and 7 vs. 13 months, adjusted HR 1.65 (1.06 – 2.58), p = 0.03)) after adjustment for 
age, year of diagnosis, disease-free interval, hormone receptor status, metastatic site and 
cytotoxic regimens.  
Conclusion: First-line trastuzumab-containing treatment regimens are less effective in 
patients with failure of adjuvant trastuzumab compared to trastuzumab-naïve patients and 
might be due to trastuzumab resistance. The impact of trastuzumab resistance on the response 
on dual Her2-blockade with trastuzumab and pertuzumab and how resistance mechanisms can 
be used in the optimization of Her2-targeted treatment lines needs further investigation. 
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Introduction 
 
Survival of patients with Her2-positive breast cancer has dramatically improved since 
trastuzumab has become available in both the (neo) adjuvant and palliative setting [1-3]. In 
the advanced setting, trastuzumab-based therapy is the cornerstone of antitumor treatment. 
Although significant improvement of survival has been reached with this strategy, most 
metastatic breast cancer (MBC) patients will eventually develop progressive disease. This 
might be due to resistance against chemotherapy, but might also be partly explained by 
resistance against trastuzumab, for example due to previous exposure to trastuzumab in the 
adjuvant setting. Recognizing patients with trastuzumab (acquired) resistance could be of 
value to prevent unnecessary trastuzumab administrations, thus reducing costs, and 
furthermore stress the need for developing new anti-Her2 treatment strategies. 
 
In case acquired resistance to trastuzumab after previous exposure plays a role, it could be 
hypothesized that patients with prior exposure to adjuvant trastuzumab will have less clinical 
benefit from first line palliative trastuzumab-treatment compared with trastuzumab-naïve 
patients. A possible way to study this might be comparing long-term outcome between 
patients pretreated with trastuzumab and patients without previous trastuzumab. However, 
studies investigating this issue have shown conflicting results [4-7], possibly due to small 
numbers of patients [4,5], low numbers of events [6,7], or short duration of follow-up [7]. We 
have therefore performed a retrospective study to compare the efficacy of first-line Her2-
targeted-containing chemotherapy between patients who did or did not undergo adjuvant 
trastuzumab-based treatment in a large number of patients, determined by a power analysis 
calculated prior to the start of the study, thereby guaranteeing a sufficient number of events 
(deaths). Detailed information on previous systemic treatment was collected and the influence 
of clinical prognostic parameters on the efficacy of retreatment with Her2-targeted-containing 
treatment schedules/therapy in palliative setting was determined.  
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Materials and methods 
 
Study design 
 
Consecutive patients who had received at least one dose of first-line Her2-targeted-containing 
chemotherapy because of Her2-positive MBC from January 1, 2000 to June 1, 2014 at seven 
hospitals in the Netherlands were eligible for the present study and retrospectively identified. 
Any first-line Her2-targeted-containing chemotherapy was allowed, irrespective of the anti-
Her2 agent. Patients were excluded in case of pathologically proven Her2 negative MBC, 
incomplete clinical data in the patient record, or a second active malignancy in the five years 
prior to the initial breast cancer diagnosis. Only patients with combined chemotherapy and 
Her2-targeted therapy as first-line regimen were included because of two reasons. First, the 
beneficial effect of trastuzumab addition to first-line chemotherapy has been more 
pronounced than the beneficial effect of trastuzumab addition to palliative endocrine therapy. 
Second, the combination of an anti-Her2 agent with chemotherapy is independent of the 
hormone receptor status, and thus allows a larger population to be investigated.  
 
Patients were divided into two groups: the trastuzumab pretreated (TP)-group, consisting of 
patients who were treated with adjuvant trastuzumab in the past and the trastuzumab-naïve 
(TN)-group, consisting of patients who were not treated with trastuzumab before the diagnosis 
of MBC. Patients in the TN-group had either relapsed after stage I-III primary breast cancer 
or presented with de novo stage IV disease. Because previous studies reported that the 
presentation with primary metastatic disease does not affect long-term outcomes, these 
patients were pooled [4,6]. The retrospective review of electronic patients records for the 
purpose of this study was approved by the central ethical review board (METC 15-046) in 
addition to the permission of omitting written informed consent.  
 
Data collection 
 
Trained investigators searched electronic medical records for patient and tumor 
characteristics, treatment patterns, and location of metastases. The end of follow up was  
January 1, 2015. Her2 receptor status was locally determined using immunohistochemistry 
(IHC) on the primary tumor or on a metastatic lesion if available. Tumors were classified as 
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Her2 positive if there was 3+ staining on IHC or 2+ staining confirmed with gene 
amplification by CISH/FISH in at least 10% of the tumor cells. Hormone receptors were 
locally tested and ER/PR positive MBC was defined as ≥10% of the primary breast tumor 
cells showing positive nuclear staining of estrogen and/or progesterone receptor. In case a 
biopsy had been performed from a metastatic lesion, the hormone receptor status was based 
on this material obtained by the biopsy. Tumor grade was determined on the primary breast 
tumor using the Bloom-Richardson grading system [8]. Tumor stage at initial presentation 
was scored using the 7
th
 edition of the TNM classification for breast cancer [9]. At start of 
first-line Her2-targeted-containing chemotherapy, all radiological detectable sites of distant 
metastases per patient were described, that is bone, visceral (liver, lung and other intestinal 
sites), central nervous system, skin or lymph nodes. 
 
Statistical analyses 
 
A power analysis was performed to determine the required number of patients to detect a 
clinically relevant difference in survival between the TP-group and the TN-group, assuming 
that this difference is present. A hazard ratio (HR) of 1.47 for OS was assumed based on a 
study that reported impaired OS for patients in the TP-group compared with the TN-group [4]. 
This study was chosen for the power analysis because other studies investigating this subject 
were not available at the start of this study. With a power of 80%, a two-sided significance 
level of 5%, a survival rate of 40% at the end of follow up in the TP group (based on the 
median duration of follow up in our study), approximately 100 patients in the TP-group were 
needed to detect a HR of 1.47 for OS in the TP-group compared with the TN group. Based on 
the incidence of metastatic breast cancer, the patients of seven regional hospitals were 
included in this study.  
 
Continuous variables were described using medians and interquartile ranges (IQR). 
Categorical variables were described using percentages. Patient characteristics were compared 
between the TP-group and the TN-group using Mann-Whitney tests for continuous variables 
Fisher’s exact tests for categorical variables with 2 categories and chi-square tests for 
categorical variables with more than 2 categories. The primary study endpoint was OS after 
start of first-line chemotherapy. OS was defined as the time between start of first-line Her2-
targeted-containing chemotherapy and death of any cause. Patients were censored on January 
1, 2015. The secondary study endpoint was time to next treatment (TNT), which was defined 
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as the time between the start of first-line Her2-targeted-containing chemotherapy and the start 
of a second treatment line because of disease progression. A switch to another regimen 
because of toxicity or patient demand was not considered a switch to second-line treatment. In 
case no second treatment line was started, TNT was until the date of documented disease 
progression or death, whichever came first. In all other cases, patients were censored at 
January 1, 2015. In this study, TNT was chosen as marker of progression-free survival to 
indicate the duration of clinical benefit, that is, the time until another treatment was deemed 
necessary by the treating physician to get disease control. The difference between TNT and 
the more commonly used time until documented disease progression (i.e. progression-free 
survival) was minimal, with less than 1 month in 82.5% of the entire study population and 
less than 2 months in 92.5%. OS and TNT were assessed using Kaplan-Meier curves and 
further explored by univariable and multivariable Cox proportional hazard models. To assess 
the effects of selection bias, the survival analyses were repeated with the following 
subgroups: 1. Exclusion of patients treated with lapatinib. 2. Exclusion of the patients 
presenting with brain metastases. 3. Exclusion of the patients treated before 2006. 4. 
Exclusion of the patients without adjuvant treatment with taxanes. The independent variables 
in the Cox proportional hazard models were included based on their prognostic relevance and 
were: age, year of diagnosis, the disease free interval (time between the initial breast cancer 
diagnosis and the occurrence of distant metastases), estrogen/progesterone receptor positivity, 
treatment with lapatinib, previous treatment with taxanes, the presence of brain metastases 
and the presence of visceral metastases. The proportional hazards assumption was assessed by 
including interaction effects of covariates and follow-up time in a Cox proportional hazard 
model with time-dependent covariates. Variance inflation factors were calculated to assess the 
degree of multicollinearity among the independent variables in the Cox proportional hazard 
models. A two-sided p-value of p <0.05 was considered to be statistically significant. All 
analyses were conducted using SPSS version 24 (SPSS Inc.,Chicago, Illinois). 
 
Results 
 
Patient characteristics 
 
Between January 1, 2000 and June 1, 2014, 753 patients with Her2 positive MBC were 
identified. After excluding patients who did not receive first-line Her2-targeted-based 
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chemotherapy (n = 259; see also below) and patients with incomplete clinical data (n = 25), 
469 were included in the final analyses (Figure 1), of which 82 in the TP-group and 387 in 
the TN-group. The median duration of follow-up was 30 months (range 0 – 165 months), 
starting at the diagnosis of distant metastases. The death rate in the entire cohort was 74%. No 
patients were lost to follow up.  
 
Patients in the TP-group were slightly younger than patients in the TN-group (48.3 vs. 51.5 
years, p = 0.02). All patients in the TP-group had received adjuvant chemotherapy (as this 
was combined with trastuzumab) compared with 41.1% of the patients in the TN-group. 
Patients in the TP-group more often had brain metastases at presentation of metastatic disease 
(11.0% vs. 0.5%) and were more often treated with other first-line anti-Her2 agents (i.e. 
lapatinib and pertuzumab) than with trastuzumab monotherapy (19.5% vs. 5.4%, p < 0.001). 
Hormone receptor status, nuclear grade of the primary tumor, and localization of metastatic 
sites were equally distributed over the two groups (table 1). 
 
Selection of patients treated with anti Her2-agents 
 
The omission of first-line anti-Her2-based chemotherapy of the 259 excluded patients was 
mostly due to preferred anthracyclines without trastuzumab as first-line therapy (32.8%), poor 
clinical condition (19.7%), or no indication of chemotherapy yet (9.7%) (Supplemental table 
1). To investigate potential selection bias of the excluded patients, these were also divided 
into (a) patients having received adjuvant trastuzumab or having an indication for adjuvant 
trastuzumab without receiving it and (b) patients without an indication for adjuvant 
trastuzumab. Patient characteristics for both groups were compared with the TP and TN-group 
of the included patients, respectively, showing no selection of patients with prognostic 
negative characteristics in the TP-group and no selection of patients with prognostic positive 
characteristics in the TN-group (Supplemental table 2). 
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Figure 1. Flow chart patient inclusion 
 
Overall survival and time to next treatment 
 
Median OS was 17 months in the TP-group and 30 months in the TN-group (HR 2.00, 95% 
CI 1.51 – 2.63, p <0.001). Median TNT was 7 months in the TP-group and 13 months in the 
TN-group (HR 2.02, 95% CI 1.56 – 2.62, p < 0.001) (Figure 2A and B). Dividing the TN-
group into patients relapsing after stage I-III breast cancer and patients presenting with de 
novo stage IV disease did not affect the results (Supplemental figure 1). Lapatinib instead of 
trastuzumab as first-line anti-Her2 therapy was administered in 19 patients (TP-group: n = 9, 
TN-group: n = 10); exclusion of these patients from the analyses showed similar results 
(Supplemental figure 2), as well as the removal of the patients with brain metastases as first 
metastatic site (11 in the TP-group and 2 in the TN-group) to avoid negative selection bias of 
patients with brain metastases (OS 18 vs. 30 months, log-rank p < 0.001, TNT 7 vs. 13  
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Table 1. Patient characteristics 
 TN-group (n = 387) TP-group (n = 82) P 
Age (range) (y) 51.5 (25 – 84) 48.3 (24 – 72) 0.02 
Diagnosis before 2006 241 (62.3) 21 (25.6) <0.001 
Hormone receptor status 
 Positive 
 Negative 
 Unknown 
 
223 (57.6) 
163 (42.1) 
1 (0.3) 
 
45 (54.9) 
37 (44.6) 
0 
0.72 
Tumor stage 
 I 
 II 
 III 
 IV 
 Unknown 
 
53 (13.7) 
120 (31.0) 
80 (20.7) 
119 (30.7) 
15 (3.9) 
 
3 (3.7) 
40 (48.8) 
39 (47.6) 
0 
0 
 
<0.001 
Nuclear grade 
 I or II 
 III 
 Unknown 
 
95 (24.5) 
160 (41.3) 
132 (34.1) 
 
19 (23.2) 
44 (53.7) 
19 (23.2) 
0.31 
Adjuvant chemotherapy 
 None 
 Anthracyclines only 
 Taxanes only 
 Anthracyclines + taxanes 
 Other 
 
228 (58.9) 
125 (32.3) 
1 (0.3) 
14 (3.6) 
19 (4.9) 
 
0 
10 (12.2) 
3 (3.7) 
69 (84.1) 
0 
 
<0.001 
Previous palliative endocrine therapy 82 (21.2) 17 (20.7) 1.00 
First metastatic site 
 Bone 
 Visceralb 
 CNSc 
 Other 
 Multiple sites 
 
67 (17.3) 
79 (20.4) 
2 (0.5) 
41 (10.6) 
198 (51.2) 
 
17 (20.7) 
11 (13.4) 
9 (11.0) 
10 (12.2) 
35 (42.7) 
<0.001a 
Number of metastatic sites 
 1 
 2 
 3 
 >3 
 
189 (48.8) 
122 (31.5) 
52 (13.4) 
24 (6.2) 
 
47 (57.3) 
20 (24.4) 
9 (11.0) 
6 (7.3) 
 
0.47 
Disease-free interval
d
 (IQR
e
) (months) 42 (20 – 78) 33.5 (21 – 46) 0.03 
First line chemotherapy used in 
combination with Her2 targeted agent 
 Anthracyclines 
 Taxanes 
 Capecitabine 
 Vinorelbine 
 Other 
 Unknown 
 
 
7 (1.8) 
317 (81.9) 
14 (3.6) 
29 (7.5) 
9 (2.3) 
11 (2.8) 
 
 
0 
51 (62.2) 
17 (20.7) 
11 (13.4) 
2 (2.4) 
1 (1.2) 
<0.001 
Overall duration of palliative trastuzumab 
(IQR) (months) 
 Unknown 
16 (8 – 32) 
 
16 
9.4 (4 – 19) 
 
4 
<0.001 
a
When removing the patients with CNS-located metastases from this analysis, the first metastatic site did not 
differ between the groups (p = 0.43). 
bVisceral: Liver, lung, pleural, peritoneal, pericardial, intestinal cCNS: Central nervous system 
dDisease free interval: Time from initial breast cancer diagnosis until the diagnosis of distant metastases. 
eIQR: Interquartile range  
fTime to palliative treatment: Time from the diagnosis of distant metastases until the start of first-line palliative 
chemotherapy.  
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months, p < 0.001). In the multivariable Cox regression, OS and TNT in the TP-group were 
still shorter compared with the TN group (HR 1.84 for OS, 95% CI 1.15 – 2.96, p = 0.01 and 
HR 1.65 for TNT, 95% CI 1.06 – 2.58, p = 0.03, respectively) (table 2-3). After assessing the 
proportional hazards assumption, a significant interaction was found between the 
development of brain metastases and the duration of follow-up. Therefore, brain metastases 
were modeled as a time-dependent covariate in the multivariate Cox regression. No other 
significant violations of the proportional hazards assumption were detected. 
Median OS of ER+ vs. ER- patients in the TP-group was 18 vs. 15 months and in the TN-
group 31 vs. 27 months (p = 0.91 and p = 0.20, respectively). Median TNT of ER+ vs. ER- 
patients in the TP-group was 7 vs. 6 months and in the TN-group 14 vs. 11 months, 
respectively (p = 0.79 and p = 0.42, respectively). However, when calculating OS from the 
first presentation of metastatic disease, median OS of ER- patients was significantly shorter   
than of ER+ patients (30 vs. 38 months, p = 0.01), suggesting that the prognostic advantage of 
ER positivity disappeared once first-line chemotherapy was indicated for disease control. 
 
Since mid-2005, trastuzumab has been available for adjuvant treatment. Therefore, most 
patients in the TP-group were diagnosed with breast cancer after 2006, whereas the TN-group 
was largely exposed to older treatment regimens. Repeating the survival analyses with only 
the patients diagnosed after 2006 (TP-group: n = 61, TN-group: n = 146), in order to assess 
bias by difference in treatment regimens, still showed impaired OS and TNT in the TP-group. 
(16 vs. 29 months and 6 vs. 14 months, respectively (both log-rank p <0.001) (Supplemental 
figure 3).  
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a. 
 
b. 
 
Abbreviations:  
TP: Trastuzumab pretreated, i.e. relapsed after adjuvant trastuzumab-treatment; TN: Trastuzumab-naïve.  
 
Figure 2. Fig. 2 Overall survival (a) and time to next treatment (b) in patients treated 
with first-line palliative anti-Her2 therapy 
Univariable Cox regression: 
HR: 2.00 (95% CI 1.51 – 2.63) 
P < 0.001 
Univariable Cox regression: 
HR: 2.02 (95% CI 1.56 – 2.62) 
P < 0.001 
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Effect of taxanes 
 
Previous adjuvant chemotherapy was administered in 159 patients (41.1%) in the TN-group 
and in all patients in the TP-group. In these patients, previous adjuvant chemotherapy 
consisting of taxanes was administered in 87.8% of the patients (n = 72) in the TP-group 
compared with 3.9% (n=15) in the TN-group. Due to the strong association between previous 
adjuvant taxanes and TP/TN-group, we found relatively high variation inflation factors for 
these two variables (3.1 and 3.2 respectively). To assess the effects of this multicollinearity, 
and to minimize the effect of possible taxane-resistance between both groups, we repeated the 
univariable survival analyses with only the patients relapsing after taxane therapy. We found 
that OS in the TP-group was still significantly shorter compared to the TN-group (17 vs. 29 
months, log rank p = 0.048). The difference in TNT between both groups did not reach 
statistical significance (6 vs. 11 months, log rank p = 0.07) (figure 3). In the univariable Cox 
regression, previous taxane-exposure, which suggests resistance to taxanes, had a large  
association with OS and TNT (HR 1.75, 95%CI 1.34 – 2.28, p < 0.001 and HR 1.93, 95% CI 
1.50 – 2.48, p < 0.001, respectively), but this was no longer statistically significant after 
adjustment for previous trastuzumab exposure in the multivariable Cox regression. 
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a. 
 
b. 
 
Figure 3. Overall survival (a) and time to next treatment (b) among patients with 
previous adjuvant treatment with taxanes 
 
Univariable Cox regression: 
HR: 1.75 (95% CI 1.34 – 2.28) 
P < 0.001 
Univariable Cox regression: 
HR: 1.93 (95% CI 1.50 – 2.48) 
P < 0.001 
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Table 2. Univariable and multivariable Cox proportional hazard models for overall 
survival.  
 
 Univariable Multivariable 
 HR 95% CI p HR 95% CI P 
Age
a
 (range) (y) 
 
1.01 1.00 – 1.02 0.33 1.01 1.00 – 1.02 0.15 
Diagnosis after 01.01.2006 vs. 
before 01.01.2006 
 
1.21 0.97 – 1.51 0.09 0.99 0.75 – 1.30 0.94 
DFI
b 
 
1.00 1.00 – 1.00 0.20 1.00 1.00 – 1.00 0.48 
Hormone receptor status: 
positive vs. negative 
0.86 0.69 – 1.06 0.15 0.88 0.70 – 1.10 0.88 
 
Brain metastases vs. no brain 
metastases
 
 
1.02 
 
1.01 – 1.54 
 
0.04 
 
0.88 
 
0.61 – 1.25 
 
0.88 
 
Interaction between brain 
metastases and follow-up time 
(months) 
 
-- 
 
-- 
 
-- 
 
1.02 
 
1.00 – 1.03 
 
0.01 
 
Visceral metastases vs. no 
visceral metastases 
 
1.25 
 
1.01 – 1.56 
 
0.04 
 
1.36 
 
1.08 – 1.90 
 
0.01 
 
First line lapatinib vs. 
trastzumab 
 
1.62 
 
0.99 – 2.64 
 
0.05 
 
1.36 
 
0.82 – 2.28 
 
0.24 
 
Adjuvant taxane treatment vs. no 
previous taxane treatment 
 
1.75 
 
1.34 – 2.28 
 
<0.001 
 
1.16 
 
0.74 – 1.83 
 
0.52 
 
Adjuvant trastuzumab vs. no 
adjuvant trastuzumab
c 
 
2.00 
 
1.51 – 2.63 
 
<0.001 
 
1.84 
 
1.15 – 2.96 
 
0.01 
aAge at initial breast cancer diagnosis 
bTime from initial breast cancer diagnosis until the first diagnosis of distant metastases.  
cTP-group vs. TN-group 
 
Abbreviations: HR: Hazard ratio; CI: Confidence interval; DFI: Disease-free interval; CNS: Central nervous 
system. 
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Table 3. Univariable and multivariable Cox proportional hazard models for time to next 
treatment. 
 
 Univariable Multivariable 
 HR 95% CI p HR 95% CI p 
Age
a
 (range) (y) 
 
1.00 0.99 – 1.01 0.79 1.01 1.00 – 1.02 0.28 
Diagnosis after 01.01.2006 vs. 
before 01.01.2006 
 
1.08 0.89 – 1.32 0.43 0.86 0.67 – 1.11 0.25 
DFI
b 
 
1.00 1.00 – 1.00 0.13 1.00 1.00– 1.00 0.12 
Hormone receptor status: 
positive vs. negative 
 
0.91 0.74 – 1.11 0.33 0.91 0.73 – 1.12 0.35 
Brain metastases vs. no brain 
metastases 
 
1.33 1.09 – 1.63 0.01 0.78 0.58 – 1.05 0.10 
Interaction between brain 
metastases and follow-up time 
(months) 
 
-- -- -- 1.04 1.03 – 1.06 <0.001 
Visceral metastases vs. no 
visceral metastases 
 
1.10 0.90 – 1.35 0.36 1.23 1.00 – 1.52 0.048 
First line lapatinib vs. 
trastzumab 
 
1.59 0.97 – 2.58 0.06 1.36 0.82 – 2.26 0.23 
Adjuvant taxane treatment vs. no 
previous taxane treatment 
 
1.93 1.50 – 2.48 <0.001 1.41 0.92 – 2.15 0.11 
Adjuvant trastuzumab vs. no 
adjuvant trastuzumab
c 
2.02 1.56 – 2.62 <0.001 1.65 1.06 – 2.58 0.03 
aAge at initial breast cancer diagnosis 
bTime from initial breast cancer diagnosis until the first diagnosis of distant metastases.  
cTP-group vs. TN-group 
 
Abbreviations: HR: Hazard ratio; CI: Confidence interval; DFI: Disease-free interval; CNS: Central nervous 
system. 
 
Discussion 
 
This study shows that patients receiving first line Her2-targeted-containing chemotherapy for 
Her2 positive MBC who were previously exposed to adjuvant trastuzumab had a shorter 
median OS and TNT compared to patients who were never exposed to trastuzumab at the time 
of diagnosing distant metastases. The unfavorable effect of prior trastuzumab exposure was 
independent of clinical and tumor characteristics and seems, at least partly, independent of 
pretreatment with taxanes.  
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Four retrospective studies have previously reported on this issue and showed conflicting 
results [4-7]. In two of these studies, some degree of shorter OS was reported in patients 
previously treated with adjuvant trastuzumab (univariable HRs 1.47 and 1.16) [4,6], although 
these associations were not retained after adjustment for other clinical risk factors. However, 
these could be false-negative observations, as the 95% confidence intervals of the hazard ratio 
of previous adjuvant trastuzumab treatment in these studies showed overlap with our 95% 
confidence interval (0.87 – 1.75 and 0.80 – 1.74  respectively, vs. 1.00 – 2.91 in our study). 
This implicates that no survival difference was detected, despite patients with relatively high 
hazard ratios of death.  In the third study with 96 patients in the TP-group, 2-year overall 
survival was the only study endpoint and was not affected (HR 0.79, 95% CI 0.50 - 1.26) by 
previous adjuvant trastuzumab treatment [7]. A fourth study reported that patients with 
trastuzumab-retreatment also less often obtained long-term clinical benefit from re-
introduction of Her2-targeted-based chemotherapy [5]. Although in line with our study 
results, this study had a short time of follow up after the registration of trastuzumab in 
adjuvant setting, which might have led to a negative selection of patients with relatively rapid 
development of distant metastases in the TP-group. Thus, small numbers of patients, short 
duration of follow-up, small number of events and possible selection bias could have 
influenced these previous study results.  
 
The survival of the patients in our study seemed to be somewhat shorter when compared to 
prospective studies recently done in patients with Her2-positive MBC, including the 
CLEOPATRA- and RHEA-trials [10,11]. The median OS of our entire cohort was 28 months, 
compared with 37.6 months in the control-arm of the CLEOPATRA-trial [11]. The median 
OS of our trastuzumab-pretreated patients (TP-group) was 17 months, compared with 25 
months in the RHEA-trial (which included only trastuzumab-pretreated patients). The median 
TNT in our study (TP-group: 7 months, entire cohort: 11 months) was comparable with the 
PFS of both the RHEA-trial (8 months) and the control-arm of the CLEOPATRA trial (12.4 
months) [12].  
 
Possible explanations for the shorter median OS in our study could be the differences in 
inclusion- and exclusion criteria, favoring the patients in both the CLEOPATRA- and RHEA-
trials. In these studies, patients needed to have  an ECOG performance status of 0 or 1, a 
relapse-free interval after adjuvant treatment of ≥6 months and a life expectancy of ≥3 
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months. These (prognostic positive) restrictions were not applied to our study cohort, which 
might have influenced OS.  
 
We aimed to strengthen the interpretation of the analyses by investigating whether possible 
selection could have biased the current findings. Excluded patients could have caused a 
selection bias of preferentially poor prognosis patients in the TP-group or a selection bias of 
preferentially good prognosis patients in the TN-group, however, this was not observed when 
comparing the included and excluded patients (supplemental table 2).  Furthermore, patients 
in the TP-group more frequently had brain metastases as first presentation of metastatic 
disease than patients in the TN-group, possibly predisposing the TP-group to unfavorable 
outcomes. However, exclusion of these patients from the analyses still showed worse OS and 
TNT in the TP-group. Also possible selection by difference in treatment period was unlikely. 
A larger percentage of the TP-group compared to the TN-group was treated in recent time 
periods, so patients in the TP-group had a shorter disease-free interval (time between the 
initial breast cancer diagnosis and the development of distant metastases), but also could have 
benefited from newer recently developed anti-Her2 agents than the TN-group. Analyzing only 
the patients included after January 1, 2006, in order to compare patients with comparable 
disease-free interval and treated according to the same guidelines, did not alter the results. 
Finally, the TP-group more often received adjuvant taxanes (87.8% vs. 3.9%), possibly 
causing impaired sensitivity to taxanes in advanced setting, which might have contributed to 
the worse outcome in the TP-group. However, selecting only the patients who were treated 
with adjuvant taxanes still showed shorter OS and TNT in the TP-group. Altogether, after 
showing the comparable results in different subgroup analyses, we believe that the lower 
efficacy of first-line palliative trastuzumab in the TP-group is possibly due to less sensitivity 
to trastuzumab or resistance among a subset of MBC patients pretreated with trastuzumab. 
 
This study was not designed to unravel exact mechanisms of resistance among treated 
patients, but nevertheless showed signs of possible clinically relevant unresponsiveness to 
trastuzumab (primary or acquired during previous adjuvant therapy), which could have 
implications for treatment decision making after short progression-free intervals in the 
palliative setting.  
 
It must be noted that the current standard of care of first-line Her2-targeted therapy is dual 
Her2-blockade with trastuzumab and pertuzumab, instead of single trastuzumab, after the 
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results of the CLEOPATRA trial [12]. In this trial, trastuzumab pretreated patients seemed to 
have shorter PFS than trastuzumab-naïve patients, in both the pertuzumab-arm (16.9 vs. 21.6 
months) and the control-arm (10.4 vs. 12.6 months). Although trastuzumab pretreated patients 
seemed to derive similar benefit from the addition of pertuzumab, as compared to 
trastuzumab-naïve patients, the benefit of dual Her2-blockade above trastuzumab 
monotherapy was not statistically significant in trastuzumab pretreated patients, as shown by 
the 95% confidence interval (HR 0.65, 95% CI 0.35 – 1.07). However, the number of patients 
with previous adjuvant trastuzumab was only 11% of the entire cohort, which could explain 
the loss of statistical significance. A future study is needed to determine the impact of 
trastuzumab resistance on first-line dual Her2-blockade in trastuzumab pretreated patients.  
 
Several limitations of this study have to be mentioned. First, fewer patients than the needed 
number of patients determined by the power calculation were included. The main cause for 
this was the well known low incidence (about 10%) of developing distant metastases among 
patients in the TP-group, thus among those who were treated with adjuvant trastuzumab [13]. 
However, more events (deaths) occurred, so the power in our study was not substantially 
limited. Second, patients with lapatinib were included in this study, so the analysis was not 
restricted to only patients with trastuzumab retreatment. However, we chose to include all 
patients with any type of palliative first-line Her2-targeted therapy, in order to include a study 
population as close to the “real world” as possible. Furthermore, we provided a subgroup 
analysis without the patients treated with lapatinib, which showed similar results. Third, the 
loss of Her2 overexpression in distant metastases, which might result in trastuzumab 
unresponsiveness, could not be estimated due to the lack of metastatic biopsies. This has 
however been reported to be only 3-6% of the cases [14-16]. Fourth, first-line Her2-targeted 
therapy nowadays consists of the combination trastuzumab and pertuzumab [11], so cohorts 
treated with first line single Her2 blockade with trastuzumab will dissappear in the near 
future. However, the results of this study might still be useful, as single blockade of the Her2 
receptor is still the standard of care in second line regimens and beyond. Finally, information 
about subsequent treatment lines and decisions was lacking, which also could affect survival. 
Nevertheless, this is not the case for TNT, which was clearly different between TN-and TP-
group and was not affected by subsequent treatment lines.  
 
 
Efficacy of first-line palliative therapy with trastuzumab in Her2 positive MBC 
 
41 
 
Conclusion 
 
First-line trastuzumab containing chemotherapy is less effective in patients treated with 
adjuvant trastuzumab compared to those not treated with adjuvant trastuzumab for primary 
breast cancer. Although resistance against taxane treatment could not be fully excluded, our 
study provides evidence that at least a subset of the patients derives less clinical benefit from 
Her2-targeted therapy, possibly due to trastuzumab resistance. Whether this resistance might 
also influence the response on dual Her2-blockade in first line treatment is currently unknown 
and needs further investigation.   
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Supplemental table 1. Omission of Her2-targeted therapy in the excluded patients (n = 
259). 
 
Patients never treated with anti-Her2 agents (n = 128) 
Reasons for omitting adjuvant Her2-targeted 
therapy 
Reasons for omitting first-line Her2-targeted 
therapy 
 
Stage IV de novo 49 (38.3%) Poor clinical condition 39 (30.5%) 
Not available yet
a
 48 (37.5%) Anthracyclins preferred
b 22 (17.2%) 
Endocrine therapy because of age 10 (7.8%) No indication of chemotherapy yet 
because of limited metastatic burden 
16 (12.5%) 
No indication adjuvant 
chemotherapy 
9 (7.0%) Patient refusal 10 (7.8%) 
Poor clinical condition 3 (2.3%) No chemotherapy because of age 8 (6.3%) 
Patient refusal 3 (2.3%) Metastasis Her2 negative 1 (0.8%) 
Low ejection fraction 2 (1.6%) Low ejection fraction 1 (0.8%) 
Unknown 2 (1.6%) No insurance 1 (0.8%) 
Primary tumor Her2 negative 1 (0.8%) Unknown 30 (23.4%) 
Early development of distant 
metastases 
1 (0.8%)   
 
Patients without first-line anti Her2-based chemotherapy, adjuvant Her2-targeted therapy: yes 
(n = 25) 
Reasons for omitting adjuvant Her2-targeted 
therapy 
Reasons for omitting first-line Her2-targeted 
therapy 
 
NA 
 
NA 
 
Poor clinical condition 
 
7 (28.0%) 
  Solitary brain metastases 5 (20.0%) 
  Limited metastatic burden 4 (16.0%) 
  Rapid progression after adjuvant 
trastuzumab 
2 (8.0%) 
  Metastatic lesion Her2 negative 2 (8.0%) 
  Patient refusal 2 (8.0%) 
  Unknown 1 (4.0%) 
  Anthracyclins preferred 1 (4.0%) 
  Low ejection fraction 1 (4.0%) 
 
Patients without first-line anti-Her2-based chemotherapy, adjuvant Her2-targeted therapy: no (n = 91)
c
 
Reasons for omitting adjuvant Her2-targeted 
therapy 
Reasons for omitting first-line Her2-targeted 
therapy 
 
Not available yet 
 
61 (67.0%) 
 
Anthracyclins preferred 
 
62 (68.1%) 
Stage IV de novo 26 (28.6%) Unknown 18 (19.8%) 
Low ejection fraction 1 (1.1%) Anti-Her2 agents not common 
practiced 
5 (5.5%) 
Primary tumor Her2 negative 1 (1.1%) Metastatic lesion Her2 negative 2 (2.2%) 
No indication adjuvant systemic 
therapy 
1 (1.1%) Low ejection fraction 1 (1.1%) 
  Tumor origin at first unclear 1 (1.1%) 
  First chemotherapy, trastuzumab 
started at disease progressione 
1 (1.1%) 
 
 
Patients with first-line Her2-targeted monotherapy (no chemotherapy) (n = 15)
f 
Reasons for omitting adjuvant Her2-targeted 
therapy 
Reasons for omitting first-line Her2-targeted 
therapy 
 
Not available yet 
 
8 (53.3%) 
 
Poor clinical condition 
 
5 (33.3%) 
Stage IV de novo 3 (20.0%) Limited metastatic burden 5 (33.3%) 
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No indication adjuvant systemic 
therapy 
1 (6.7%) Unknown 4 (26.7%) 
Patient refusal 1 (6.7%) Endocrine therapy because of age 1 (6.7%) 
aUntil July 2005 
bAnthracyclins preferred as first line chemotherapy (between 2000 and 2005) 
cAdjuvant treatment with trastuzumab was omitted in 90 of the 91 patients.  
dUntil July 2002 
eClinical trial 
fAdjuvant treatment with trastuzumab was omitted in 13 of the 15 patients.  
 
Abbreviations: NA: Not applicable 
 
Supplemental table 2. Patient characteristics of the included vs. excluded patients  in the 
TP-group (a) and the TN-group (b). 
 
a. TP-group 
 
 Included (n = 82) Excluded (n = 28) P 
Mean age (range) (y) 48.3 (24 – 72) 51.2 (26 – 78) 0.58 
Diagnosis before 2006 21 (25.6) 6 (21.4%) 0.80 
Hormone receptor status 
 Positive 
 Negative 
 Unknown 
 
45 (54.9) 
37 (44.6) 
0 
 
13 (46.4%) 
15 (53.6%) 
0 
0.51 
Tumor stage 
 I 
 II 
 III 
 IV 
 Unknown 
 
3 (3.7) 
40 (48.8) 
39 (47.6) 
0 
0 
 
 
2 (7.1%) 
3 (10.7%) 
23 (82.1%) 
0 
0 
 
0.002 
Nuclear grade 
 I or II 
 III 
 Unknown 
 
19 (23.2) 
44 (53.7) 
19 (23.2) 
 
4 (14.3%) 
17 (60.7%) 
7 
0.41 
Adjuvant chemotherapy 
 None 
 Anthracyclins only 
 Taxanes only 
 Anthracyclin + taxane 
 Other 
 
0 
10 (12.2) 
3 (3.7) 
69 (84.1) 
0 
 
 
2 (7.1%) 
3 (10.7%) 
0 
23 (82,1) 
0 
 
0.07 
Previous palliative endocrine therapy 17 (20.7) 5 (17.9%) 1.00 
First metastatic site 
 Bone 
 Viscerala 
 CNSb 
 Other 
 Multiple sites 
 
17 (20.7) 
11 (13.4) 
9 (11.0) 
10 (12.2) 
35 (42.7) 
 
 
3 (10.7%) 
3 (10.7%) 
11 (39.3%) 
3 (10.7%) 
8 (28.6%) 
 
0.02 
Number of metastatic sites 
 1 
 2 
 3 
 >3 
 
47 (57.3) 
20 (24.4) 
9 (11.0) 
6 (7.3) 
 
 
20 (71.4%) 
4 (14.3%) 
3 (10.7%) 
1 (3.6%) 
 
0.55 
Brain metastases 31 (37.8) 
 
16 (57.1%) 
 
0.08 
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Disease-free interval
c
 (IQR
d
) (months) 33.5 (21 – 46) 24 (17 – 35) 0.04 
Time to palliative treatment
e
 (IQR) 
(months) 
 Not applicable 
1 (0 – 6.25) 
 
0 
1.5 (1.0 – 7,25) 
 
24 
0.40 
First palliative chemotherapy 
 None 
 Anthracycline 
 Taxane 
 Capecitabine 
 Vinorelbine 
 Other 
 Unknown 
 
0 
0 
51 (62.2) 
17 (20.7) 
11 (13.4) 
2 (2.4) 
1 (1.2) 
 
23 (82.1%) 
3 (10.7%) 
2 (7.1%) 
0 
0 
0 
0 
<0.001 
 
B. TN-group 
 
 Included (n = 387) Excluded (n = 231) P 
Mean age (range) (y) 51.5 (25 – 84) 56.1 (24 –92) 0.002 
Diagnosis before 2006 241 (62.3) 165 (71.4%) 0.02 
Hormone receptor status 
 Positive 
 Negative 
 Unknown 
 
223 (57.6) 
163 (42.1) 
1 (0.3) 
 
150 (64.9%) 
74 (32.0%) 
7 
0.03 
Tumor stage 
 I 
 II 
 III 
 IV 
 Unknown 
 
53 (13.7) 
120 (31.0) 
80 (20.7) 
119 (30.7) 
15 (3.9) 
 
20 (8.7%) 
69 (29.9%) 
57 (24.7%) 
78 (33.8%) 
7 
0.20 
Nuclear grade 
 I or II 
 III 
 Unknown 
 
95 (24.5) 
160 (41.3) 
132 (34.1) 
 
44 (19.0%) 
82 (35.5%) 
105 
0.73 
Adjuvant chemotherapy 
 None 
 Anthracyclins only 
 Taxanes only 
 Anthracyclin + taxane 
 Other 
 
228 (58.9) 
125 (32.3) 
1 (0.3) 
14 (3.6) 
19 (4.9) 
 
150 (64.9%) 
57 (24.7%) 
0 
2 (0.9%) 
12 (5.2%) 
0.08 
Previous palliative endocrine therapy 82 (21.2) 83 (35.9%) <0.001 
First metastatic site 
 Bone 
 Viscerala 
 CNSb 
 Other 
 Multiple sites 
 Unknown 
 
67 (17.3) 
79 (20.4) 
2 (0.5) 
41 (10.6) 
198 (51.2) 
 
53 (22.9%) 
38 (16.5%) 
8 (3.5%) 
18 (7.8%) 
101 (43.7%) 
13 
0.01 
Number of metastatic sites 
 1 
 2 
 3 
 >3 
 Unknown 
 
189 (48.8) 
122 (31.5) 
52 (13.4) 
24 (6.2) 
 
117 (50.6%) 
69 (29.9%) 
23 (10.0%) 
9 (3.9%) 
13 
0.44 
Brain metastases 
 Unknown 
144 (37.2) 
1 (0.3) 
54 (23.4%) 
3 
<0.001 
Disease-free interval
c
 (IQR
d
) (months) 42 (20 – 78) 28.5 (16.8 – 52.3) 0.01 
Time to palliative treatment
e
 (IQR) 
(months) 
1 (0 – 3) 1 (0 – 5) 
 
0.63 
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 Not applicable 100 
First palliative chemotherapy 
 None 
 Anthracycline 
 Taxane 
 Capecitabine 
 Vinorelbine 
 Other 
 Unknown 
 
7 (1.8) 
317 (81.9) 
14 (3.6) 
29 (7.5) 
9 (2.3) 
11 (2.8) 
 
99 (42.9%) 
80 (34.6%) 
23 (10.0%) 
14 (6.1%) 
1 (0.4%) 
9 (3.9%) 
5 
<0.001 
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Supplemental figure 1. Survival of patients treated with first-line palliative anti-Her2 
therapy. 
A. Overall survival 
 
B. Time to next treatment 
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Supplemental figure 2. Survival without the patients treated with first-line lapatinib. 
A. Overall survival 
 
B. Time to next treatment  
 
 
48 
 
Chapter 2 
 
Supplemental figure 3. Survival of patients diagnosed after 1
st
 January 2006 
A. Overall survival 
 
 
 
B. Time to next treatment 
 
 
 
Univariable Cox regression: 
HR: 2.42 (95% CI 1.67 – 3.51) 
P < 0.001 
Univariable Cox regression: 
HR: 2.41 (95% CI 1.72 – 3.37) 
P < 0.001 
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Abstract 
 
In several diseases, a low muscle mass has been revealed as an unfavorable prognostic factor 
for outcome. Whether or not this holds true in patients with solid malignancies as well has 
increasingly been explored in the last years. This research field is however severely hampered 
by a lack of consensus on how to determine muscle mass in cancer patients and on the 
definition of low muscle mass. Consequently, the prevalence of a low muscle mass widely 
varies across the several studies. Nevertheless, most studies show that also in patients with 
solid malignancies a low muscle mass is associated with a poor outcome. In the next years, 
more effort is needed to get a better insight into the best method to determine the muscle 
mass, on the exact prognostic value of a low muscle mass in the diverse tumor types and 
stages, on pathophysiology of a low muscle mass in patients with cancer and on ways to 
intervene and to improve muscle mass in patients. The review addresses the current literature 
of the importance of muscle mass in cancer patients and the methods of muscle 
measurement.     
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Introduction 
 
Muscle mass starts to decline around the age of 40 years, resulting in a mean loss of 8% per 
decade until the age of 70 [1]. Above 70 years of age, this decline accelerates to 25-40% 
muscle mass loss per decade [2,3].  
 
Loss of muscle mass is associated with unfavourable outcomes in chronic diseases such as 
liver-cirrhosis [4] and cardiovascular disease [5], and is frequently present in patients with 
rheumatoid arthritis [6], diabetes [7] and HIV/AIDS [8]. In surgical patients, low muscle mass 
is associated with postoperative complications and can be used to identify risk patients before 
surgery [9]. Recently, the role of low muscle mass has become of interest in patients with 
cancer. In different tumor types and treatment settings, patients with a low muscle mass 
appear to have worse survival compared to patients without a low muscle mass [10-13]. 
Additionally, patients with low muscle mass are more likely to experience more severe 
toxicities from systemic anti-tumor agents [14]. Many chemotherapeutic drugs are distributed 
to the fat-free compartment of the body [15]. Since low muscle mass is associated with a 
decline of the fat-free compartment, low muscle mass is thought to result in relatively higher 
drug concentrations with all accompanying toxicities [16]. Consequently, muscle mass could 
be an important new prognostic factor for survival and treatment tolerability in cancer 
patients.  
 
In patients with cancer, muscle loss is probably the result of both sarcopenia and processes 
closely linked to cachexia. Sarcopenia is a geriatric syndrome with multifactorial etiology and 
consisting of a low muscle mass combined with low muscle strength or impaired physical 
performance [17]. In older adults, sarcopenia is associated with mortality [18,19] and physical 
disability [20]. Cachexia is a severe wasting of both fat- and muscle mass and loss of weight, 
mediated by systemic inflammation in the presence of a severe chronic disease [22]. Several 
names have been used in the literature to describe muscle status, such as sarcopenia, low 
muscle mass and muscle loss. In oncological studies, the term sarcopenia is frequently used 
although most studies do not report impaired muscle function and physical performance, 
while these parameters are crucial to diagnose sarcopenia [17]. 
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Here, we review the current knowledge on diagnosing low muscle mass, its prevalence and its 
prognostic value in cancer patients. To make the nomenclature in this review clear, we use the 
term low muscle mass to describe radiological measured muscle mass (i.e. using radiation 
techniques). We use the term sarcopenia when describing the combination of radiological 
measured muscle mass, impaired muscle function and impaired physical performance. As 
most of the literature on muscle mass and its association with outcome has been generated in 
studies on elderly, special emphasis is put on the methods used in muscle measurement, 
which might be useful for studying the clinical relevance of low muscle mass in patients with 
cancer.     
 
Sarcopenia and aging 
 
The probable mechanism of sarcopenia occurring in elderly is an imbalance in muscle protein 
turnover [23] without the possibility of pointing out a single factor as the main cause (table 1) 
[17]. Muscle protein synthesis decreases during aging, partly because of age-related endocrine 
changes such as a reduction of sex hormones and growth factors [24]. Additionally, muscle 
protein breakdown increases mainly due to age-related low-grade systemic inflammation [25], 
alongside other factors such as physical inactivity and malnutrition [22]. This low-grade 
systemic inflammation, also called inflammaging [26], is characterized by elevated pro-
inflammatory cytokines and is caused by age-related cell damage [26] and mitochondrial 
dysfunction, leading to accumulation of oxidative stress [27].  
 
Middle-aged men (40-50 years) have more muscle mass than women of the same age [1]. 
However, due to faster deterioration of muscle mass and muscle strength in men compared to 
women, at older age, men experience more absolute muscle loss and larger percent losses of 
both muscle mass and muscle strength than women [2,3]. A specific subgroup is patients 
suffering from sarcopenic obesity. Sarcopenic obesity is not just the combination of obesity 
and low muscle mass, but the result of unfavorable metabolic changes leading to both obesity 
and low muscle mass [28]. These patients possibly form a particular worse prognostic group 
for adverse outcomes. 
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Table 1. Etiological factors of sarcopenia. 
 
Etiological factors of sarcopenia
a 
Mechanisms 
Muscle disuse Physical activity ↓ 
Cognition ↓ 
Immobility 
Endocrinal changes Testosterone ↓ 
Growth hormone ↓ 
IGF-1 ↓ 
Insulin resistance ↑ 
Malnutrition Inadequate food intake 
Impaired adaptation to nutrients by skeletal muscles 
Malabsorption 
Low-grade systemic inflammation Interleukin 1 ↑ 
Interleukin 6 ↑ 
TNF-α ↑ 
Based on references [23] and [101] 
aSarcopenia could be age-related (primary) or disease-related (secondary) 
 
Diagnosing sarcopenia in geriatrics 
 
Nowadays, deterioration of muscle mass alone is considered insufficient to establish the 
diagnosis sarcopenia. A prospective cohort study in 2292 community-dwelling elderly 
showed that muscle strength had a higher association with mortality than muscle mass [29], 
while there is no linear correlation between muscle loss and reduced muscle strength [17]. 
Longitudinal studies report dissociations in time between loss of muscle mass and loss of 
muscle strength [30] with muscle strength deteriorating more rapidly than muscle mass [20].  
 
Therefore, it is recommended by the European Working Group on Sarcopenia in older people 
(EWGSOP) to include muscle strength and physical performance besides muscle mass to 
diagnose sarcopenia in the elderly (fig 1) [17,20,22,31]. A crucial shortcoming of this 
recommendation however, is that no advice on how to measure muscle mass and strength has 
been given, neither which cut-off values to define sarcopenia should be used. Consequently, 
consensus about a definition of sarcopenia has not been reached yet and various methods and 
definitions are used [17,32]. Studies comparing the various definitions diagnosing sarcopenia 
which include muscle mass, muscle strength and physical performance, showed a large 
variation of 0% to 20% in the prevalence of sarcopenia in different populations [21,33,34].  
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Cachexia 
 
In contrast to sarcopenia, cachexia is not caused by aging itself, but is a result of metabolic 
changes due to disease [35]. Cachexia is a combination of weight loss, muscle- and adipose 
tissue loss, anorexia [35], hyperglycaemia, hyperlipidaemia and anaemia [36] (the 2 most 
widely used definitions of cachexia are listed in table 2). Factors contributing to these 
metabolic changes and muscle protein degradation are pro-inflammatory cytokines, while in 
cancer patients, tumour metabolism contributes as well [36]. 
 
Both sarcopenia and cachexia are featured by the combined loss of muscle mass and muscle 
function, thus distinguishing these two syndromes in one patient can be difficult or even 
impossible [22,37]. However, certain clinical features are more pathognomic for cachexia, 
such as weight loss in a short time-frame in combination with failure of nutrition support 
[36,38] and abnormal biochemistry. In general, muscle mass measurement only or even the 
combination with muscle function, is not sufficient to differentiate sarcopenia and cachexia; 
knowledge regarding metabolic state is essential [37]. 
 
Determination of muscle mass in non-cancer patients 
 
Muscle mass is part of the fat-free mass (FFM) of the human body. Total body mass consists 
of several compartments; i.e. fat mass (FM), water, protein and bone, with the latter three 
forming the fat-free compartment [39]. Body composition analyses focus on measuring these 
compartments individually rather than simply measuring total body weight. Distinguishing the 
measurement of FM and FFM can be important, as alterations in both compartments do not 
occur synchronically [40]. Furthermore, body mass index [41] and body surface area [42] 
cannot be relied on to detect total lean body mass or muscle mass, which urges the need to 
assess these conditions separately.  
 
In geriatric studies, measurement of muscle mass is mostly done by dual energy X-ray 
absorptiometry (DEXA) and bioelectrical impedance analysis (BIA) [31]. In oncological 
studies, CT-imaging is most often used. Other options are magnetic resonance (MR)-imaging 
[32] and ultrasound [43]. CT- and MR-imaging are regarded as gold standards for muscle 
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mass measurement [31,44]. In a cadaver validation study, muscle measurement was highly 
accurate using CT- and MRI-imaging (r = 0.99). [45]. An alternative is DEXA, as this has 
shown high accuracy (r = 0.94) compared to MRI-images [46], although DEXA loses 
accuracy when assessing body composition in obese patients [47]. Furthermore, a study in 
advanced cancer patients showed that appendicular skeletal muscle mass obtained from 
DEXA and muscle cross-sectional area at the L3 level measured by CT showed a moderate 
correlation (R = 0.70) but with a large difference in agreement after Bland Altman analysis 
[48]. Use of BIA is discouraged because of less accuracy, [31,49,50], often leading to 
overestimation of measured muscle mass [51]. In oncological patients, we recommend CT-
imaging to measure skeletal muscle, because of the high accuracy and availability.  
 
 
 
aLow gait speed: ≤0.8 m/s.   Normal gait speed: >0.8 m/s. 
 
Figure 1. Sarcopenia in older people (EWGSOP) [17]. 
  
Muscle mass measurement using DEXA has been described in two ways, with different cut-
off points to define low muscle mass. In the first method, appendicular skeletal muscle mass 
(ASM), which is the sum of the muscle mass of all limbs [52], is measured and corrected for 
height. In one study, low muscle mass is defined as ASM two standard deviations below 
ASM in young adults, aged 30 years (mean), resulting in cut-offs of 7.26 kg/m
2
 for men and 
5.45 kg/m
2
 for women [53] and these cut-off points are frequently used in studies. In other 
cut-off points commonly used, low muscle mass is defined as the 20
th
 percentile ASM in 
Grip 
strength 
Gait speed
a 
Muscle 
mass 
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community-dwelling elderly, resulting in cut-offs of 7.23 kg/m
2
 for men and 5.67 kg/m
2
 for 
women [54], which shows high similarity. In the second method, ASM is corrected for both 
height and fat mass using linear regression. The residuals of the regression were used to 
identify the difference between expected muscle mass and true muscle mass. Low muscle 
mass was defined as the 20
th
 percentile of the distribution of the residuals [54]. However, 
despite using 20
th
 percentiles as cut-off points in both methods, almost half of the people in a 
population of community-dwelling elderly were identified as having low muscle mass by one 
method, but not by the other [54]. This discrepancy clearly stresses the high need for a 
standardized approach to measure muscle mass.  
 
Table 2. Definitions of cachexia. 
Reference Definition of cachexia 
Fearon K et al 2011 [36] Pre-cachexia 
 Weight loss ≤5% 
 Anorexia (reduced food intake) 
 Metabolic change 
 Cachexia 
 Weight loss >5% the past 6 months in the absence of starvation 
or  
 BMI <20 kg/m2 and any weight loss >2% 
or  
 Low muscle massa and weight loss >2% 
 Refractory cachexia 
 Variable degree of cachexia 
 Cancer disease procatabolic and not responsive to cancer treatment 
 WHO performance score 3 or 4 
 Expected survival <3 months 
 
Evans WJ et al 2008 [38] Cachexia 
 Weight loss ≥5% in the past 12 months 
or 
 BMI <20 kg/m2 
and 3-5 of the following: 
 Decreased muscle strength 
 Fatigue 
 Anorexia 
 Low muscle massa 
 Abnormal biochemistry (elevated inflammation parameters, anaemia, 
hypoalbuminaemia)  
a
Appendicular skeletal muscle index <7.26 kg/m
2
 for males and <5.45 kg/m
2
 for females 
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Determination of low muscle mass in cancer patients 
 
Little is known about the pathophysiology of low muscle mass in cancer patients [55]. 
Etiological factors seen during aging such as physical inactivity and increased levels of pro-
inflammatory cytokines also contribute to cancer-related muscle wasting, however, the main 
cause is probably an increased activity of the ubiquitin-proteasome system (UPS), resulting in 
an increased muscle protein degradation. This can be present without the other determinants 
of cachexia, such as weight loss, metabolic changes and loss of muscle- and adipose tissue. 
Furthermore, cancer treatment frequently lead to, vomiting, inappropriate food intake and lack 
of physical activity which can also result in the loss of both fat and muscle tissue [56]. In 
addition, corticosteroids frequently used in cancer patients, stimulate the UPS and cause 
insulin resistance, both leading to muscle proteolysis [57].  
 
To measure muscle mass in cancer patients, CT-imaging instead of DEXA is mostly used 
because of its high availability given its frequent use to evaluate tumor growth. However, also 
in cancer patients DEXA could be a valuable alternative to measure muscle mass. 
Unfortunately, as holds true for muscle measurement in elderly, consensus for determining 
muscle mass by CT-scanning is lacking.  
 
Muscle mass has been determined by measuring either the total psoas cross-sectional area 
(TPA) at the L3-level [58-61], or the total abdominal muscle area (TAMA) at the L3-level 
[16,42,62,63]. The TAMA measured at the L3-level is highly correlated with the total body 
muscle mass (Pearson correlation coefficient of 0.924) [64]. The TAMA is corrected for 
height, resulting in a skeletal muscle index (SMI) (cm
2
/m
2
). Therefore, muscle mass 
quantification can be performed easily using only one slice, avoiding analyses of multiple 
images and larger surfaces being exposed to radiation.  
Importantly, the first cut-off  points for TAMA measurement using the single slice technique 
were computed in an obese population [16], but the prevalence of obesity in later studies 
using these cut-off points varied from 14% [65] to 57% [66]. Several studies established their 
own cut-off points for both TAMA and TPA, resulting in a large variation of diagnosing low 
muscle mass (table 3). Furthermore, cut-off points for low muscle mass are mostly 
established by optimum stratification to detect the association with mortality but the 
sensitivity to detect survival differences is higher in obese patients [62]. However, few studies 
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report the distribution of muscle loss according to body mass index (BMI)-groups in cancer 
patients. 
 
Table 3. Cut-off points for low muscle mass associated with mortality. 
 
Study Number of 
patients 
Definition of sarcopenia Population 
Method 1: 
Prado CM et al 2008 
[16] 
250 L3a TAMAb/height2 in cm2/m2 
HU: -29 to +150 
Males: <52.4 
Females: <38.6 
 
Cancer of the gastro-
intestinal and respiratory 
tract. BMIc ≥30 
Method 2: 
Baracos VE et al 2010 
[42] 
441 L3 TAMA/height2 in cm2/m2 
HU: -29 to +150 
Males: <55.4 
Females: <38.9 
 
Cancer of the respiratory 
tract (at diagnosis) 
Method 3: 
Vledder van MG et al 
2012 [102] 
196 L3 TAMA/height2 in cm2/m2 
HU: -30 to +110 
Males: <43.75 
Females: <41.1 
 
Colorectal cancer with 
liver metastases (before 
hepatic surgery) 
Method 4: 
Peng P et al 2012 [58] 
557 L3 lowest quartile TPAd/height in 
cm2/m2 
HU: -30 to +110 
Males: <4.92 
Females: <3.62 
 
Pancreatic cancer (before 
curative surgery) 
Method 5: 
Martin L et al 2013 
[62] 
1473 L3 TAMA/height2 in cm2/m2 
HU: -29 to +150 
Males BMI <25: ≤43.0 
Males BMI ≥25: ≤53.0 
Females BMI <25: ≤41.0 
Females BMI ≥25: ≤33.0 
 
Cancer of the gastro-
intestinal and respiratory 
tract 
Method 6: 
Camus V et al 2014 
[73] 
80 L3 TAMA/height2 in cm2/m2 
HU: -29 to +150 
Males: <55.8 
Females: <38.9 
 
Elderly patients (mean 
age 79 years) with 
DLBCLe  
Method 7: 
Smith AB et al 2014 
[61] 
 
224 fL3 TPA/height2 in cm2/m2 
HU: -30 to +110 
Males: <65.3 
Females: <52.3 
 
Bladder cancer 
Method 8: 
Fujiwara N et al 2015 
[68] 
1257 L3 TAMA/height2 in cm2/m2 
HU: -29 to +150 
Males: <36.2 
Females: <29.6 
 
Hepatocellular carcinoma 
in Asian people 
Method 9: 
Iritani S et al 2015 
[77] 
217 L3 TAMA/height2 in cm2/m2 
HU: -29 to +150 
Males: <36.0 
Females: <29.0 
 
Hepatocellular carcinoma 
in Asian people 
Method 10: 
Amini N et al 2015 
[59] 
763 L3 lowest quartile TPA/height in 
cm2/m2 
HU: -30 to +110 
Pancreatic cancer (before 
surgery) 
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Males: <5.64 
Females: <4.15 
 
Method 11: 
Joglekar S et al 
2015[60] 
118 L3 lowest quartile TPA/height in 
cm2/m2 
HU: -30 to +110 
Males: <5.2 
Females: <4.0 
 
Pancreatic cancer (before 
surgery) 
Method 12: 
Nakamura N et al 
2015 [91] 
207 L3 TAMA/height2 in cm2/m2 
HU: -29 to +150 
Males: <47.1 
Females: <34.4 
 
DLBCL 
Asian people 
Method 13: 
Peyton CC et al 2015 
[103] 
128 L3 lowest quartile TPA/height2 in 
cm2/m2 
HU: -20 to +100 
Males: ≤4.27 
Females: ≤3.80 
 
Renal cancer 
Method 14: 
Choi Y et al 2015 
[104] 
484 L3 TAMA/height2 in cm2/m2 
HU: -29 to +150 
Males: <42.2 
Females: <33.0 
 
Pancreatic cancer 
(unresectable or 
metastatic) 
Method 15: 
Harada K et al 2015 
[105] 
325 L3 lowest tertile TAMA/height2 in 
cm2/m2 
HU: -29 to +150 
Males: <44.5 
Females: <36.5 
 
Lung cancer 
Method 16: 
Kimura L et al 2015 
[106] 
134 L3 TAMA/height2 in cm2/m2 
HU: -29 to +100 
Males: <41.0 
Females: <38.0 
 
Lung cancer 
a
 L3: Lumbar vertebra 3 
b TAMA: Total abdominal muscle area (psoas, Para spinal muscles, abdominal wall muscles) 
c BMI: Body mass index 
d TPA: Total psoas area (psoas muscle area only) 
e DLBCL: Diffuse Large B-cell Lymphoma 
f Muscle mass associated with major postoperative complications instead of mortality 
 
Prevalence of low muscle mass in cancer patients 
 
Several large studies have reported on the prevalence of low muscle mass in cancer patients 
[42,62,67,68]. Most studies used TAMA and TPA to describe the prevalence of low muscle 
mass. The prevalence of low muscle mass using TPA seems to be somewhat lower compared 
to the measurement of TAMA (table 4). However, since there is no standard method for the 
quantification of muscle mass by CT-imaging, reported prevalence’s of low muscle mass are 
difficult to compare and are highly dependent of the used definition for muscle measurement. 
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Furthermore, the level of correlation between TPA and TAMA is unknown, which makes it 
hard to compare these results with other studies. Table 4 describes the reported prevalence of 
low muscle mass and the used definition per cancer type. The prevalence of low muscle mass 
was highly variable across cancer types, ranging from 5% to 89%.  
In cancer patients, low muscle mass more often occurs in patients above 65 years, although is 
not restricted to the elderly [16]. In patients with tumors of the respiratory and gastro-
intestinal tract, 68% of the patients with low muscle mass was above 65 years. Among the 
group of patients without low muscle mass, 45% was above 65 years [16]. Knowledge about 
the prognostic value of low muscle mass in different age groups, in the presence of 
malignancy, is lacking. According to gender, there seems no difference in the prevalence of 
low muscle mass [68-71]. Compared to women however, susceptibility for muscle loss and 
adverse outcomes related to low muscle mass in males has been described on multiple 
occasions in patients with [69,72-74], and without cancer [19,75].  
 
In addition to taking into account gender and BMI, it should be considered to stratify cut-off 
points for low muscle mass also by ethnicity. It has been reported that the muscle mass of 
young healthy Chinese men was 17% lower than in Caucasian men [76]. In studies 
investigating Asian populations, lower cut-off points for low muscle mass are applied [68,77] 
(table 3).  
 
 
Adding functional assessments to muscle mass 
measurements in cancer patients 
 
Importantly, likewise of what has been done in studies in elderly and according to the 
previously mentioned EWGSOP guidelines, the prognostic value of determining muscle mass 
can potentially be increased by adding functional tests to muscle mass measurement in cancer 
patients. Physical performance is mostly described using the ECOG performance score in 
cancer patients. Although a high ECOG performance score correlated well with impaired 
physical function according to geriatric assessment, 38% of the patients with low ECOG 
performance scores were limited in instrumental activities of daily living, which possibly 
requires additional parameters to assess functional status [78].  
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However, so far, only two studies among cancer patients combined muscle mass 
determination and functional assessments (gait speed and handgrip strength) according to the 
EWGSOP guidelines, and reported that the combination of radiological muscle mass and 
functional assessments had more predictive power for postoperative complications than 
radiological muscle mass alone in patients with colorectal cancer [12] and in patients with 
gastric cancer [83]. Although the EWGSOP guidelines do not recommend devices to 
determine hand grip strength, the Jamar hand dynamometer (Lafayette Instrument Company, 
USA) is most widely used and is considered the gold standard to measure hand grip strength 
[84].  
 
Functional tests actually reflect muscle quality and several mechanisms of muscle quality are 
reported in the literature, such as decrease in muscle fiber size and number (resulting in 
reduced gait speed), reduction of muscle fiber contractility (resulting in reduced strength), 
mitochondrial dysfunction and micro- or macro fatty infiltration of muscle. Further research is 
warranted to determine whether or not adding functional tests improves the clinical value of 
muscle mass determination in cancer patients, and to establish the most appropriate way to 
determine muscle quality.  
 
Association of low muscle mass with 
chemotherapeutic toxicity and survival 
 
Low muscle mass might be of emerging clinical significance in the oncological field due to its 
association with clinical end points such as toxicity and cancer-related mortality [85]. A 
summary of all studies reporting on the prognostic value of low muscle mass for survival and 
treatment toxicity in cancer patients undergoing chemotherapeutic treatment is listed in table 
5. The studies are characterized by a variation of muscle measurement methods. The 
knowledge regarding prognosis will be described per cancer type.  
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Table 4. Prevalence of low muscle mass in patients with cancer using CT imaging.  
Cancer site Studies Mean age Prevalence (%)  Method
a
 
Respiratory tract Prado CM et al 2008 [16] 64 5 Method 1 
 Baracos VE et al 2010 [42] 67 (male) 
65 (female) 
 
61 
31 
 
Method 2 
 
 Stene GB et al 2015 [74] 67 74 Method 1 
 Kim E et al 2015 [107] 69 79 Method 2 
 
Respiratory tract 
metastatic 
Kitamura L et al 2015 [1] 66 87 (male) 
36 (female) 
Method 16 
 
 
Colorectal Prado CM et al 2008 [16] 64 25 Method 1 
 Lieffers JR et al 2012 [108] 63 39 Method 1 
 Huang DD et al 2015 [12] 62 12 Method 9 + impaired 
hand grip strengthb or 
gait speed
c
 
 Jung HW et al 2015 [92] 61 25 L4 TPA sex-specific 
lowest quartile (not 
specified) 
 Reisinger K et al 2015 
[109] 
51% <70 yrs 48 Method 1 
 Broughman JR et al 2015 
[110] 
77 60 (male) 
56 (female) 
Method 5  
(used different HUs) 
 
Colorectal 
metastatic 
Vledder van, MG et al 
2012 [102] 
65 19 Method 3 
 Thoresen L et al 2012 
[111] 
64 20 Method 1 
 Thoresen L et al 2013 
[112] 
65 39 Method 1 
 Barret M et al 2014 [72] 65 71 Method 2 
 Vugt van, JL et al 2015 
[71] 
61 44 Method 1 
 
Breast Del Fabbro E et al 2012 
[87] 
NAd 14 Method 1 
 
Breast metastatic Prado CM et al 2009 [86] 55 27 Method 1 
 
Pancreas (curative) Dalal S et al 2012[113] 59 37 Method 1 
 Peng P et al 2012[58] 66 25 Method 4 
 Di Sebastiano et al 2013 
[114] 
66 48 Method 2 
 Amini N et al 2015 [59] 67 25 Method 10 
 Cooper AB et al 2015 [99]  63 52 Method 2 
 Joglekar S et al 2015 [60] NA 26 Method 11 
 
Pancreas (palliative) Tan et al 2009 [98] 56 60 Method 1 
 Wesseltoft N et al 2015 
[115]  
72 89 Method 2 
 Choi Y et al 2015 [104] NA 21 Method 14 
 
Kidney Antoun S et al 2010 [116] 59 55 Method 2 
 Peyton CC et al 2015 [103] 63 25 Method 13 
 
Kidney metastatic Huillard O et al 2013 [117] 60 53 Method 2 
 Cushen S et al 2014 [118] 64 33 Method 2 
 Sharma P et al 2015 [119]  61 29 Method 5 
 
Oesophagealf Awad S et al 2012 [94] 63 57 Method 1 
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 Yip C et al 2014 [65] 63 26 Method 1 
 Anandavadivelan et al 
2015 [66] 
67 43 Method 1 
 Tan et al 2015 [70] 66 50 Method 1 
 Tamandl D et al 2015 
[120] 
64 65 Method 2 
 Harada K et al 2015 [105] NA 33 Method 15 
 
Liver Mir O et al 2012 [121] 63 28 Method 2 
 Mir O et al 2012 [100] 64 50 Method 2 
 Harimoto N et al 2013 
[122] 
66 40 Method 3 
 Meza-Junco J et al 2013 
[69] 
58 30 Method 5 
 Voron T et al 2014 [123] 62 54 Method 1 
 Fujiwara N et al 2015 [68] 69 11 Method 8 
 Imai K et al 2015 [124] 67 38 <39.2g 
 Iritani S et al 2015 [77] 72 11 Method 9 
 Nault JC et al 2015 [125] 61 76 hL3 TAMA/height2 in 
cm2/m2 
Males: <55.0 
Females: <39.0 
 
 Kamachi S et al 2015 [126] 72 67 Method 1 
 
Bladder Psutka SP et al 2015 [127] 71 70 hL3 TAMA/height2 in 
cm2/m2 
Males: <55.0 
Females: <39.0 
 
 Smith AB et al 2014 [61] 66 38 Method 7 
 Fukushima H et al 2015 
[128] 
68 60 Method 5 
 
 
Non-Hodgkin 
Lymphoma 
Camus V et al 2014 [73] 79 55 Method 6 
 Nakamura N et al 2015 
[91] 
67 56 Method 12 
 
Gastric Tegels JJ et al 2015 [95] 70 58 Method 5 
a The used sarcopenia-definition refers to the methods mentioned in table 2.  
b Hand grip strength <26 kg for males or 18 kg for females 
c Gait speed <0.8 m/s 
d NA: Not available 
e HU: Hounsfield unit 
f All before start of neo-adjuvant chemotherapy 
g L3 TAMA/height2 in cm2/m2. No specification by gender 
h Based on the definition of a muscle mass of two standard deviations below healthy adults [36]. It must be noted 
that muscle mass in that population was measured using dual-energy X-ray (DXA). Reference populations for 
CT-imaging are currently not available.  
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Breast cancer 
 
After the introduction of muscle mass measurement using CT imaging, the first study that 
reported on the association of low muscle mass and oncological outcome was conducted 
among 55 younger patients with metastatic breast cancer and a mean age of 55 years [86]. All 
patients received a fixed dose of capecitabine and toxicity was determined after one cycle to 
avoid the influence of treatment adjustments. Muscle mass was calculated using TAMA-
measurement. Patients with low muscle mass had a calculated higher capecitabine dose per kg 
lean body mass and had a 3-times greater risk of chemotherapeutic toxicity, such as diarrhoea 
and stomatitis. Moreover, low muscle mass was the only independent predictor of toxicity in a 
model with age, body surface area and ECOG performance score. In the same study, low 
muscle mass was associated with a shorter time to tumor progression (62 days vs.105 days). 
The authors mentioned that chemotherapeutic dose interruption or reduction for toxicity, 
which was more prevalent in patients with low muscle mass, could be responsible for a 
shorter time to tumour progression. Alternatively, the low muscle mass before starting 
treatment itself could be a sign of aggressive or advanced underlying disease [86].  
 
In contrast, patients with localized breast cancer and low muscle mass achieved higher rates 
of pathological complete response after neo-adjuvant chemotherapeutic treatment compared 
to those without low muscle mass [87]. An explanation for this finding is unclear, but it is 
possible that patients with low muscle mass received a higher dose of chemotherapeutic 
agents per kg lean body mass (LBM), resulting in a better chemotherapeutic efficacy on tumor 
eradication [87]. The systemic clearance of hydrophilic chemotherapeutic agents correlates 
well with the LBM [15,88] and in patients with low LBM in relation to their length and 
weight, a low volume of distribution of chemotherapeutic drugs in proportion to the BSA is 
reported [14,89,90].   
 
Non-Hodgkin lymphoma 
 
Three studies described the prognosis of patients with non-Hodgkin lymphoma undergoing 
chemotherapeutic treatment [63,73,91]. Only one study investigated the association between 
low muscle mass and treatment tolerability. Low muscle mass was a predictive factor of 
cancellation of chemotherapy compared to normal muscle mass, although the reasons of 
treatment interruption were not mentioned (40% vs. 16%, p = 0.02) [63]. In all studies, 
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muscle mass was measured before the start of chemotherapy and low muscle mass was 
associated with a worse overall survival compared to patient with normal muscle masses. In 
one study, the unfavorable survival effect was only detected in males [63,73,91].  
 
Gastro-intestinal tumors 
 
In colorectal cancer, low muscle mass was associated with a higher incidence of grade 3-4 
chemotherapeutic toxicity during both adjuvant [92] and palliative treatment [72,93]. 
Furthermore, most studies report impaired overall survival in patients with low muscle mass. 
Two studies showed an association between low muscle mass and mortality due to disease 
progression in patients with stage III colon cancer receiving adjuvant chemotherapy (HR 1.85, 
p=0.022) [92] and in a large cohort of 1473 patients (HR 1.34, p<0.001) [62]. A third study 
showed that muscle loss larger than 5% during chemotherapy resulted in a two times higher 
mortality [93]. Remarkably, no association with recurrence-free survival is reported [92,93].  
 
In patients with oesophageal cancer, the association of low muscle mass with a higher 
incidence of chemotherapeutic toxicity was further confirmed [66,70]. Among obese patients, 
low muscle mass had a five times higher risk of treatment toxicity compared to obese patients 
without low muscle mass prior to neo-adjuvant chemotherapy. Risk of toxicity did not reach 
significance in patients with low muscle mass and normal weight, also indicating that 
especially obese patients with low muscle mass are the worst prognostic group [66]. Another 
study containing 47 patients with esophago-gastric cancer reported that 57% was diagnosed 
with low muscle mass before start of neo-adjuvant chemotherapy and these patients suffered 
further reduction of muscle mass during chemotherapy. There was no association with 
reduced completion of chemotherapy or mortality, although this should be interpreted with 
caution, as the study was not powered to detect differences in clinical outcome [94].  
Only one study determined the association between muscle mass and survival in patients with 
gastric cancer [95]. In this study, involving 152 patients before surgery, low muscle mass was 
not associated with mortality during hospital admission and 6-month mortality, although other 
studies have reported a higher incidence of postoperative complications in patients with low 
muscle mass after gastrectomy [96,97]. 
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Pancreas and hepatocellular cancer 
 
Associations of low muscle mass with treatment toxicity in patients with these types of cancer 
have not been described yet. In patients with pancreas cancer in palliative setting, impaired 
overall survival has been reported in obese patients with low muscle mass. Noteworthy, these 
results mostly could not be extended to patients with low muscle mass and normal weight 
[98,99] (table 5). In patients with hepatocellular carcinoma, low muscle mass was associated 
with both overall- and progression free survival [69,100]. 
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Table 5. Prognostic impact of low muscle mass in patients undergoing chemotherapeutic 
treatment. 
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-2
0
.1
 m
g
/k
g
 
N
A
 
T
o
x
ic
it
y
 a
ft
er
 1
 c
y
cl
e:
 
5
0
%
 v
s.
 2
0
%
 (
p
=
0
.0
3
) 
N
A
 
M
ea
n
 L
B
M
: 
 
5
6
.2
 v
s.
 4
1
.6
 k
g
 (
p
=
0
.0
0
2
) 
N
A
 
P
re
v
a
le
n
ce
 l
o
w
 
m
u
sc
le
 m
a
ss
 (
%
) 
N
A
e  
1
5
.2
 
2
5
.5
 
5
5
.9
 
N
A
 
B
ef
o
re
: 
5
7
.4
 
A
ft
er
: 
7
8
.7
 
M
e
th
o
d
a
 a
n
d
 c
u
t-
o
ff
s 
T
o
ta
l 
L
B
M
d
 =
 T
A
M
A
 
–
 3
.2
4
5
9
 /
 3
.0
5
8
3
 
A
t 
ca
n
ce
r 
d
ia
g
n
o
si
s 
 A
ft
er
 f
ai
lu
re
 o
f 
ta
x
an
es
/a
n
th
ra
cy
cl
in
es
 
 A
t 
d
ia
g
n
o
si
s 
o
f 
d
is
ta
n
t 
m
et
as
ta
se
s 
  
 T
o
ta
l 
L
B
M
 =
 0
.3
0
 x
 
T
A
M
A
 +
 6
.0
6
 
B
ef
o
re
 a
n
d
 a
ft
er
 n
eo
-
ad
ju
v
an
t 
ch
em
o
th
er
ap
y
 
   
T
y
p
e
 o
f 
c
a
n
ce
r 
C
o
lo
n
 
G
If
 +
 
re
sp
ir
at
o
ry
 
M
et
as
ta
ti
c 
b
re
as
t 
ca
n
ce
r 
P
an
cr
ea
s 
B
re
as
t 
ca
n
ce
r 
O
es
o
p
h
ag
o
-
g
as
tr
ic
 
M
e
a
n
  
a
g
e 
6
0
 
6
3
.9
 
5
4
.8
 
5
5
.9
 
5
2
.5
 
6
3
.0
 
N
 
6
2
 
2
5
0
 
5
5
 
1
1
1
 
2
4
 
4
7
 
Y
e
a
r 
2
0
0
7
 
2
0
0
8
 
2
0
0
9
 
2
0
0
9
 
2
0
1
1
 
2
0
1
2
 
R
e
f 
[1
4
] 
[1
6
] 
[8
6
] 
[9
8
] 
[5
6
] 
[9
4
] 
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Table 5. Continued. 
S
u
r
v
iv
a
l 
 M
u
sc
le
 l
o
ss
 <
3
.8
%
 v
s.
 
>
3
.8
%
: 
1
0
.1
 v
s.
 1
6
.3
 
m
o
n
th
s.
 (
p
=
N
S
) 
3
.0
 v
s.
 1
0
.0
 m
o
n
th
s 
(p
<
0
.0
0
1
) 
P
F
S
: 
2
.3
 v
s.
 4
.5
 m
o
n
th
s 
(p
=
0
.0
0
0
8
) 
p
C
R
i : 
7
2
%
 v
s.
 4
9
%
 
(p
=
N
S
) 
  1
3
.0
 v
s.
  
2
0
.1
 m
o
n
th
s 
(p
<
0
.0
0
1
) 
1
6
.6
 v
s.
 2
8
.3
 m
o
n
th
s 
 
(H
R
 2
.2
, 
p
=
0
.0
1
) 
9
0
-d
ay
s 
m
o
rt
al
it
y
: 
9
.3
%
 v
s.
 1
2
.7
%
 (
p
=
N
S
) 
In
c
id
e
n
ce
  
g
r
a
d
e 
3
-4
 t
o
x
ic
it
y
 
 N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
P
re
v
a
le
n
ce
 l
o
w
 
m
u
sc
le
 m
a
ss
 (
%
) 
B
ef
o
re
: 
3
7
.0
 
5
0
 
1
4
 
4
0
.9
 
3
0
 
2
8
 
M
e
th
o
d
 a
n
d
 c
u
t-
o
ff
s 
B
ef
o
re
 a
n
d
 a
ft
er
 c
h
em
o
 
ra
d
ia
ti
o
n
 
   B
ef
o
re
 c
h
em
o
th
er
ap
y
 
L
3
 T
A
M
A
 
M
al
es
: 
≤
5
5
.4
 
F
em
al
es
 ≤
3
8
.9
 
B
ef
o
re
 n
eo
-a
d
ju
v
an
t 
ch
em
o
th
er
ap
y
 
  A
t 
ca
n
ce
r 
d
ia
g
n
o
si
s.
 
S
ex
- 
an
d
 B
M
I 
sp
ec
if
ic
 
cu
t-
o
ff
 p
o
in
ts
j 
A
t 
ca
n
ce
r 
d
ia
g
n
o
si
s.
 
S
ex
- 
an
d
 B
M
I 
sp
ec
if
ic
 
cu
t-
o
ff
 p
o
in
ts
j  
L
3
 T
P
A
 l
o
w
es
t 
q
u
ar
ti
le
 
M
al
es
: 
≤
4
7
7
 m
m
2
/m
2
 
F
em
al
es
: 
≤
3
3
8
 m
m
2
/m
2
 
T
y
p
e
 o
f 
c
a
n
ce
r 
P
an
cr
ea
s 
(i
n
o
p
er
ab
le
) 
L
iv
er
 
B
re
as
t 
ca
n
ce
r 
G
I/
re
sp
ir
at
o
ry
 
L
iv
er
 
L
iv
er
 (
lo
ca
l 
o
r 
d
is
ta
n
t)
 
M
e
a
n
  
a
g
e 
5
8
.9
 
6
4
.0
 
N
A
 
6
4
.7
 
5
8
.0
 
6
0
.0
 
N
 
4
1
 
6
5
 
1
2
9
 
1
4
7
3
 
1
1
6
 
2
1
6
 
Y
e
a
r 
2
0
1
2
 
2
0
1
2
 
2
0
1
2
 
2
0
1
3
 
2
0
1
3
 
2
0
1
3
 
R
e
f 
[1
1
3
] 
[1
2
1
] 
[8
7
] 
[6
2
] 
[6
9
] 
[1
2
9
] 
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Table 5. Continued. 
 
S
u
r
v
iv
a
l 
 N
A
 
L
o
w
 m
u
sc
le
 m
as
s:
  
H
R
 3
.2
3
 (
p
 =
 0
.0
0
0
7
) 
P
F
S
l :
 N
S
 
N
A
 
P
F
S
: 
1
3
.0
 v
s.
 3
2
.8
 m
o
n
th
s 
(H
R
 2
.7
, 
p
 =
 0
.0
0
0
8
) 
2
-y
ea
rs
 O
S
: 
4
6
%
 v
s.
 8
4
%
 
(H
R
 3
.2
, 
p
 =
 0
.0
0
0
2
) 
In
c
id
e
n
ce
  
g
r
a
d
e 
3
-4
 t
o
x
ic
it
y
 
 3
3
.3
%
 v
s.
 1
3
.3
%
 (
p
 =
 0
.0
4
3
) 
N
A
 
M
ea
n
 S
M
Im
 D
L
T
n
/D
IT
o
 v
s.
 n
o
 
D
L
T
/D
IT
: 
 
M
al
es
: 
4
4
.4
 v
s.
 5
3
.6
 (
p
=
 0
.0
1
) 
F
em
al
es
: 
4
0
.0
 v
s.
 4
2
.0
 (
p
=
N
S
) 
  C
an
ce
ll
at
io
n
 o
f 
tr
ea
tm
en
t:
 
4
0
%
 v
s.
 1
6
.2
%
 (
p
 =
 0
.0
2
) 
P
re
v
a
le
n
ce
 l
o
w
 
m
u
sc
le
 m
a
ss
 (
%
) 
7
0
.6
 
5
5
 
N
A
 
5
5
 
M
e
th
o
d
 a
n
d
 c
u
t-
o
ff
s 
B
ef
o
re
 p
al
li
at
iv
e 
ch
em
o
th
er
ap
y
. 
L
3
 T
A
M
A
  
M
al
es
: 
<
5
5
.4
 
F
em
al
es
: 
3
8
.9
 
A
t 
d
ia
g
n
o
si
s 
L
3
 T
A
M
A
 
M
al
es
: 
≤
5
5
.4
 
F
em
al
es
 ≤
3
8
.9
 
<
3
0
 d
ay
s 
b
ef
o
re
 
in
cl
u
si
o
n
. 
L
3
 T
A
M
A
 m
ed
ia
n
 
M
al
es
: 
<
5
2
.1
 
F
em
al
es
: 
<
4
1
.8
 
B
ef
o
re
 c
h
em
o
th
er
ap
y
 
L
3
 T
A
M
A
 
M
al
es
: 
≤
5
5
.4
 
F
em
al
es
 ≤
3
8
.9
 
T
y
p
e
 o
f 
c
a
n
ce
r 
M
et
as
ta
ti
c 
co
lo
re
ct
al
  
D
L
B
C
k
 
V
ar
ie
d
  
(P
h
as
e 
I-
tr
ia
l)
 
D
L
B
C
L
 
M
e
a
n
  
a
g
e 
6
5
.0
 
7
8
.7
 
5
7
.0
 
7
8
.0
 
N
 
5
1
 
8
0
 
9
3
 
8
2
 
Y
e
a
r 
2
0
1
4
 
2
0
1
4
 
2
0
1
4
 
2
0
1
4
 
R
e
f 
[7
2
] 
[7
3
] 
[1
3
0
] 
[6
3
] 
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Table 5. Continued. 
S
u
r
v
iv
a
l 
 T
re
at
m
en
t 
re
sp
o
n
se
: 
N
S
 
O
S
: 
N
S
 
P
F
S
: 
N
S
 
7
.5
 v
s.
 7
.9
 m
o
n
th
s 
 
(H
R
 1
.4
, 
p
=
N
S
) 
  M
ed
ia
n
 n
o
t 
re
ac
h
ed
  
(H
R
 1
.8
5
, 
p
 =
 0
.0
2
2
) 
P
F
S
: 
N
S
 
N
A
 
5
6
9
 v
s.
 1
0
1
3
 d
ay
s 
 
(p
 =
 0
.0
4
) 
In
c
id
e
n
ce
  
g
r
a
d
e 
3
-4
 t
o
x
ic
it
y
 
 D
L
T
: 
N
S
 
N
S
 
L
o
w
es
t 
v
s.
 h
ig
h
es
t 
q
u
ar
ti
le
: 
 
7
5
%
 v
s.
 4
0
%
  
(O
R
 1
.6
7
, 
p
 =
0
.0
0
0
1
) 
L
o
w
 m
u
sc
le
 m
as
s:
  
O
R
 2
.4
7
 (
p
 =
 0
.0
9
) 
L
o
w
 m
u
sc
le
 m
as
s 
+
 o
b
es
e:
 
O
R
 5
.5
4
 (
p
 =
 0
.0
4
) 
D
L
T
: 
5
4
.4
%
 v
s.
 2
8
.9
%
 (
O
R
 
2
.9
5
, 
p
 =
 0
.0
1
5
) 
P
re
v
a
le
n
ce
 l
o
w
 
m
u
sc
le
 m
a
ss
 (
%
) 
B
ef
o
re
: 
2
6
 
A
ft
er
: 
4
3
 
7
4
 
2
5
.3
 
4
3
 
4
9
.4
 
M
e
th
o
d
 a
n
d
 c
u
t-
o
ff
s 
B
ef
o
re
 a
n
d
 a
ft
er
 n
eo
-
ad
ju
v
an
t 
ch
em
o
th
er
ap
y
 
B
ef
o
re
 a
n
d
 a
ft
er
 
p
al
li
at
iv
e 
ch
em
o
th
er
ap
y
 
B
ef
o
re
 a
d
ju
v
an
t 
ch
em
o
th
er
ap
y
 
L
4
 T
P
A
 l
o
w
es
t 
q
u
ar
ti
le
 
B
ef
o
re
 n
eo
-a
d
ju
v
an
t 
ch
em
o
th
er
ap
y
 
B
ef
o
re
 n
eo
-a
d
ju
v
an
t 
ch
em
o
th
er
ap
y
 
T
y
p
e
 o
f 
c
a
n
ce
r 
O
es
o
p
h
ag
ea
l 
N
o
n
-s
m
al
l 
L
u
n
g
 c
an
ce
r 
S
ta
g
e 
II
I 
co
lo
n
 c
an
ce
r 
O
es
o
p
h
ag
ea
l 
O
es
o
p
h
ag
o
-
g
as
tr
ic
 
M
e
a
n
  
a
g
e 
6
3
.0
 
6
7
.0
 
6
1
.0
 
6
7
.0
 
6
5
.8
 
N
 
3
5
 
3
5
 
2
2
9
 
7
2
 
8
9
 
Y
e
a
r 
2
0
1
4
 
2
0
1
5
 
2
0
1
5
 
2
0
1
5
 
2
0
1
5
 
R
e
f 
[6
5
] 
[7
4
] 
[9
2
] 
[6
6
] 
[7
0
] 
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Table 5. Continued. 
S
u
r
v
iv
a
l 
 O
S
: 
N
S
 
P
F
S
: 
N
S
 
≥
5
%
 l
o
ss
 o
f 
m
u
sc
le
 m
as
s:
 
H
R
 1
.9
7
, 
p
 =
 0
.0
1
7
 
1
6
.8
 v
s.
 2
0
.4
 m
o
n
th
s 
 
(p
 =
 N
S
) 
L
o
w
 m
u
sc
le
 m
as
s 
+
 o
b
es
e 
1
2
.9
 v
s.
 2
0
.7
 m
o
n
th
s 
 
(p
 =
 0
.0
4
) 
L
o
w
 m
u
sc
le
 m
as
s:
  
H
R
 1
.5
0
2
 (
p
 =
 0
.0
0
2
) 
In
c
id
e
n
ce
  
g
r
a
d
e 
3
-4
 t
o
x
ic
it
y
 
 N
A
 
N
A
 
N
A
 
P
re
v
a
le
n
ce
 l
o
w
 
m
u
sc
le
 m
a
ss
 (
%
) 
N
A
 
M
u
sc
le
 l
o
ss
 
d
u
ri
n
g
 t
h
er
ap
y
: 
4
.2
%
 
5
5
 
2
1
.3
 
M
e
th
o
d
 a
n
d
 c
u
t-
o
ff
s 
B
ef
o
re
 a
n
d
 a
ft
er
 
ch
em
o
th
er
ap
y
 
L
3
 T
A
M
A
 l
o
w
es
t 
q
u
ar
ti
le
 
L
3
 T
A
M
A
 
M
al
es
: 
≤
5
5
.8
 
F
em
al
es
 ≤
3
8
.9
 
B
ef
o
re
 p
al
li
at
iv
e 
ch
em
o
th
er
ap
y
 
L
3
 T
A
M
A
 
M
al
es
: 
<
4
2
.2
 
F
em
al
es
: 
<
3
3
.9
 
T
y
p
e
 o
f 
c
a
n
ce
r 
C
o
lo
re
ct
al
 
(i
n
o
p
er
ab
le
) 
P
an
cr
ea
s 
P
an
cr
ea
s 
M
e
a
n
  
a
g
e 
N
A
  
(7
3
%
 <
7
0
) 
6
3
.0
 
N
A
 
N
 
1
4
8
 
8
9
 
4
8
4
 
Y
e
a
r 
2
0
1
5
 
2
0
1
5
 
2
0
1
5
 
R
e
f 
[9
3
] 
[9
9
] 
[1
0
4
] 
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Table 5. Continued. 
 
S
u
r
v
iv
a
l 
 U
n
iv
ar
ia
b
le
: 
3
-y
r 
O
S
: 
7
0
%
 v
s.
 8
5
%
  
(p
 =
 0
.0
2
6
) 
3
-y
r 
P
F
S
: 
6
3
%
 v
s.
 7
6
%
  
(p
 =
 N
S
) 
M
u
lt
iv
ar
ia
b
le
: 
p
 =
 N
S
 
 M
u
lt
iv
ar
ia
b
le
: 
p
 =
 N
S
 
 P
 =
 N
S
 
1
0
.5
 v
s.
 1
3
.5
 m
o
n
th
s 
 
(p
 =
 N
S
) 
P
F
S
: 
6
.0
 v
s.
 7
.5
 m
o
n
th
s 
 
(p
 =
 0
.0
0
9
) 
In
c
id
e
n
ce
  
g
r
a
d
e 
3
-4
 t
o
x
ic
it
y
 
 N
A
 
1
6
.7
 v
s.
 2
4
.3
%
 (
p
 =
 N
S
) 
C
o
m
p
le
ti
o
n
 o
f 
tr
ea
tm
en
t:
  
3
2
%
 v
s.
 4
3
%
 (
p
 =
 N
S
) 
N
A
 
P
re
v
a
le
n
ce
 l
o
w
 
m
u
sc
le
 m
a
ss
 (
%
) 
5
6
 
B
ef
o
re
: 
6
1
.2
 
A
ft
er
: 
7
0
.4
 
2
5
 
M
e
th
o
d
 a
n
d
 c
u
t-
o
ff
s 
B
ef
o
re
 c
h
em
o
th
er
ap
y
  
L
3
 T
A
M
A
 
M
al
es
: 
<
4
7
.1
 
F
em
al
es
: 
<
3
4
.4
 
B
ef
o
re
 a
n
d
 a
ft
er
 
ch
em
o
th
er
ap
y
. 
S
ex
- 
an
d
 B
M
I 
sp
ec
if
ic
 
cu
t-
o
ff
 p
o
in
ts
j  
B
ef
o
re
 c
h
em
o
th
er
ap
y
 
P
ec
to
ra
l 
m
u
sc
le
 l
o
w
es
t 
q
u
ar
ti
le
. 
<
4
.3
7
 
T
y
p
e
 o
f 
c
a
n
ce
r 
D
L
B
C
L
 
P
an
cr
ea
s 
+
 
b
il
e 
d
u
ct
s 
L
u
n
g
 
M
e
a
n
  
a
g
e 
6
7
.0
 
6
4
.8
 
N
A
 
N
 
2
0
7
 
9
8
 
1
1
7
 
Y
e
a
r 
2
0
1
5
 
2
0
1
5
 
2
0
1
5
 
R
e
f 
[9
3
] 
[1
3
1
] 
[1
3
2
] 
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Table 5. Continued. 
 
S
u
r
v
iv
a
l 
 O
S
 i
n
 m
o
n
th
s:
 
M
al
es
: 
(p
 =
 0
.0
1
1
9
) 
B
ef
o
re
: 
8
.9
 v
s.
 1
4
.8
  
F
em
al
es
: 
(p
 =
 0
.0
1
5
5
) 
B
ef
o
re
: 
1
9
.2
 v
s.
 3
3
.6
  
 
a M
et
h
o
d
 o
f 
m
u
sc
le
 m
ea
su
re
m
en
t 
is
 a
cc
o
rd
in
g
 t
o
 P
ra
d
o
 C
M
 e
t 
al
 [
1
2
] 
(m
et
h
o
d
 1
, 
ta
b
le
 2
),
 u
n
le
ss
 l
is
te
d
 o
th
er
w
is
e
 
b
L
o
w
 m
u
sc
le
 m
as
s 
v
s.
 n
o
 l
o
w
 m
u
sc
le
 m
as
s,
 u
n
le
ss
 l
is
te
d
 o
th
er
w
is
e.
 
c O
v
er
al
l 
su
rv
iv
al
 l
o
w
 m
u
sc
le
 m
as
s 
v
s.
 n
o
 l
o
w
 m
u
sc
le
 m
as
s,
 u
n
le
ss
 l
is
te
d
 o
th
er
w
is
e.
 
d
L
B
M
: 
L
ea
n
 b
o
d
y
 m
as
s 
e N
A
: 
N
o
t 
av
ai
la
b
le
 
f G
I:
 G
as
tr
o
-i
n
te
st
in
al
 
g
T
T
P
: 
T
im
e 
to
 t
u
m
o
u
r 
p
ro
g
re
ss
io
n
 
h
N
S
: 
N
o
t 
si
g
n
if
ic
an
t 
i p
C
R
: 
P
at
h
o
lo
g
ic
 c
o
m
p
le
te
 r
es
p
o
n
se
 
j M
et
h
o
d
 o
f 
m
u
sc
le
 m
ea
su
re
m
en
t 
is
 a
cc
o
rd
in
g
 t
o
 M
ar
ti
n
 L
 e
t 
al
 [
4
9
] 
(m
et
h
o
d
 5
, 
ta
b
le
 2
) 
k
D
L
B
C
L
: 
D
if
fu
se
 L
ar
g
e 
B
-c
el
l 
L
y
m
p
h
o
m
a 
l P
F
S
: 
P
ro
g
re
ss
io
n
-f
re
e 
su
rv
iv
al
 
m
S
M
I:
 S
k
el
et
al
 m
u
sc
le
 i
n
d
ex
 
n
D
L
T
: 
D
o
se
-l
im
it
in
g
 t
o
x
ic
it
y
 
o
D
IT
: 
D
o
se
-i
n
te
rr
u
p
ti
n
g
 t
o
x
ic
it
y
 
 
In
c
id
e
n
ce
  
g
r
a
d
e 
3
-4
 t
o
x
ic
it
y
 
 N
A
 
P
re
v
a
le
n
ce
 l
o
w
 
m
u
sc
le
 m
a
ss
 (
%
) 
B
ef
o
re
: 
3
8
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Discussion and conclusion 
 
Muscle mass loss occurs during aging and in cancer patients is possibly due to cachexia-
associated processes. Accordingly, in cancer patients, low muscle mass is prevalent across all 
ages, but particularly in the elderly. The number of studies in cancer patients investigating the 
relation between low muscle mass and clinical outcome rapidly increases and promising 
results on the use of muscle mass measurement as a prognostic factor have been reported.  
 
There are, however, a few limitations. There is no consensus of a standard approach to 
measure muscle mass while different cut-off points and devices are used. Furthermore, the 
current terminology of muscle mass in the literature is confusing. Radiological low muscle 
mass is part of the sarcopenia-syndrome and is often named sarcopenia. However, sarcopenia 
is more than low muscle mass alone and consists of a triad of radiological low muscle mass, 
low muscle strength and impaired physical performance [17]. Unfortunately, there is also no 
consensus on a definition of sarcopenia. Although low muscle mass seems a good prognostic 
marker, it is possible that the prognostic value can be improved further by measuring muscle 
function and physical performance. This needs further investigation. Functional measures 
such as gait speed and handgrip strength are easy to perform but are not widely available in 
oncological care yet. Nevertheless, many studies report a prognostic significance on 
measuring muscle mass and establishing low muscle mass as a prognostic factor could be a 
valuable addition in estimating treatment risks and survival effects.  
 
In cancer patients, CT-imaging is mostly used to measure muscle mass, but a reference 
population for this evaluation has never been described. Consequently, the prevalence of low 
muscle mass and/or sarcopenia and their association with clinical outcomes is highly variable 
across the different studies and hard to put into perspective. Studies are needed to construct 
reference populations for muscle mass measurement by CT-imaging, adjusted for age, gender, 
ethnicity and body mass index. Furthermore, the usage of devices to measure muscle mass, 
such as DEXA, which are likewise CT-imaging widely available could be explored in cancer 
patients. DEXA is highly available across cancer patients in particular in postmenopausal 
hormone receptor positive breast cancer patients treated with endocrine therapy and reference 
populations for muscle measurement using this device are well described. 
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To further study the prognostic value of low muscle mass in cancer patients, investigating the 
pathophysiology of muscle loss and the accompanying functional impairments in cancer 
patients is crucial. Studies investigating the impact of other well-known etiological factors of 
low muscle mass, such as low androgen levels, physical inactivity and impaired nutritional 
intake, or on the effects of anti-tumor agents or co-medication frequently used in cancer 
patients, such as corticosteroids, on muscle mass in cancer patients are lacking. Better insight 
into the mechanisms underlying low muscle mass in cancer patients is crucial as this might 
provide strategies to improve muscle mass and function and thereby potentially improving 
outcomes. Current treatment strategies to increase the muscle mass in the elderly mainly 
involve resistance training and stimulation of nutritional intake [101]; another possibility 
might be the investigation if low androgen levels are involved in low muscle mass in cancer 
patients and if this can be used as an intervention strategy. However, whether such strategies 
actually work in cancer patients and if so, what the optimal timing of such strategies should 
be, remains to be established.  
 
In conclusion, low muscle mass among cancer patients seems an important prognostic factor 
for outcomes in terms of treatment-induced toxicity and survival, but consensus about a 
definition of impaired muscle mass and a standardized approach to measure this are urgently 
warranted. Functional tests need to be measured to use the term sarcopenia, but the added 
value of these tests in cancer patients are yet to be established. Until a consensus on these 
items has been reached, reported prevalences of low muscle mass in populations and between 
cancer sites remain difficult to put into perspective. Consensus about a definition of low 
muscle mass and knowledge about its prognostic value and the underlying mechanisms are 
likely to contribute to strategies to come to a more personalized treatment approach and to 
novel interventions improving outcome.  
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Abstract 
 
Background: Low muscle mass (LMM) and low muscle attenuation (LMA) reflect low 
muscle quantity and low muscle quality, respectively. Both are associated with a poor 
outcome in several types of solid malignancies.  This study determined the association of 
skeletal muscle measures with overall survival (OS) and time to next treatment (TNT). 
Patients and methods: A skeletal muscle index (SMI) in cm
2
/m
2 
and muscle attenuation 
(MA) in Hounsfield units (HU) were measured using abdominal CT-images of 166 patients 
before start of first-line chemotherapy for metastatic breast cancer. Low muscle mass (SMI 
<41 cm
2
/m
2), sarcopenic obesity (LMM and BMI ≥30 kg/m2) and low muscle attenuation 
(MA <41 HU and BMI <25 kg/m2 or MA <33 HU and BMI ≥25 kg/m2) were related to OS 
and TNT.  
Results: The prevalence of LMM, sarcopenic obesity and LMA were 66.9%, 7.2% and 59.6% 
respectively. LMM and sarcopenic obesity showed no significant association with OS and 
TNT, whereas LMA was associated with both lower OS (HR 2.04, 95% CI 1.34 – 3.12, p = 
0.001) and shorter TNT (HR 1.72, 95% CI 1.14 – 2.62, p = 0.010). Patients with LMA had a 
median OS and TNT of 15 and 8 months respectively, compared to 23 and 10 months in 
patients with normal MA.  
Conclusion:  LMA is a prognostic factor for OS and TNT in metastatic breast cancer patients 
receiving first-line palliative chemotherapy, whereas LMM and sarcopenic obesity are not. 
Further research is needed to establish what impact LMA should have in daily clinical 
practice. 
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Introduction 
 
Muscle mass decreases from 40 years of age and onwards, with approximately 8% total 
muscle mass loss per decade [1]. In several diseases there is an association between low 
muscle mass and outcome, irrespective of the exact underlying mechanism [2]. Also, the 
quality of muscle, measured by the attenuation (density) of muscle by computed tomography 
(CT) reflecting the accumulation of adipose tissue in muscles, may be of prognostic value [3]. 
Also in cancer patients, there is increasing attention to the potential prognostic role of low 
muscle mass (LMM) and low muscle attenuation (LMA). The association of LMM as well as 
low muscle attenuation (LMA) with impaired survival has been well established in several 
tumor types [4-9]. In addition, in cancer patients, LMM and LMA are associated with worse 
disease-related outcomes in terms of postoperative complications [10] and treatment toxicity 
[5,11].  
 
In most oncological studies muscle mass and attenuation are mostly determined by CT-
scanning, which is considered the gold standard to measure muscle parameters. The CT-based 
method of muscle measurement relies on the assumption that muscle cross-sectional area is 
strongly correlated to total body muscle mass [4,12] and muscle measurement can be easily 
conducted using CT-images acquired during routine care. However, despite increasing 
knowledge on the prognostic impact of skeletal muscle measures in several tumor types, this 
is relatively unexplored in breast cancer patients. Furthermore, due to the lack of a 
standardized method of muscle measurement, results from studies in other tumor types cannot 
be extrapolated to a breast cancer population.    
 
To our knowledge, two studies so far have investigated the association between muscle 
measures and survival in patients with metastatic breast cancer. In the first study involving 55 
metastatic breast cancer patients treated with third line capecitabine after failure of taxanes 
and anthracyclins, LMM resulted in a shorter median time to tumor progression (62 days vs. 
105 days, HR 1.9, 95% CI 1.0 – 3.5, p = 0.05), but its association with the clinically more 
relevant overall survival and the impact of muscle quality on outcome was not assessed [5], 
while in some studies, muscle quality was associated with outcome, while muscle mass was 
not [13,14]. In the second study involving 40 metastatic breast cancer patients treated with 
taxanes as first line chemotherapy, patients with LMM seemed to have shorter overall 
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survival (30 vs. 40.3 months, p = 0.07) and time to treatment failure (6.2 vs. 9.2 months, p = 
0.18), but the difference did not reach statistical significance. In the same study, muscle 
attenuation also did not show a significant association with overall survival and treatment 
failure, but no cut-off was used to identify patients with the lowest muscle quality. Due to the 
small sample size, a type II error to detect possible clinically relevant survival differences 
could not be ruled out, and only patients treated with taxanes were investigated [9]. Given 
this, the prognostic impact of skeletal muscle measures in metastatic breast cancer needs 
further evaluation.  
  
We therefore performed a study to assess the prognostic value of skeletal muscle measures in 
patients with metastatic breast cancer by determining the association of LMM, sarcopenic 
obesity and LMA with overall survival and time to next treatment after first line palliative 
chemotherapy in a real-world population of patients with metastatic breast cancer.  
 
 
Materials and methods 
 
Study design 
 
This single-center retrospective study was performed at a regional hospital in the Netherlands. 
Patients diagnosed with breast cancer were identified using the pathology registry of our 
hospital between January 1, 2000 and June 1, 2014. Patients with distant metastases were 
identified from this database. Patients with abdominal CT-images within three months before 
the start of the first palliative chemotherapeutic treatment were included, regardless of tumor 
characteristics and treatment schedules. Exclusion criteria were: male sex, a second active 
malignancy and no palliative chemotherapy. Medical records were searched for patient 
characteristics, body composition parameters, such as height and weight, and data regarding 
clinical follow up. The primary study endpoint was overall survival (OS) and the secondary 
endpoint was time to next treatment (TNT) after first-line chemotherapy. OS was defined as 
the date of the first cycle of first-line chemotherapy to the date of death or the end of follow-
up (January 1, 2016), whichever occurred first. Survival status was confirmed by reviewing 
the Dutch Cancer Registration (IKNL); patients still alive were censored at January 1, 2016. 
The IKNL publishes figures regarding the incidence and mortality of cancer patients and is 
Low muscle attenuation is a prognostic factor for survival in patients with MBC 
 
93 
 
therefore a reliable institution to confirm survival data. TNT was defined as the date of the 
first cycle of first line chemotherapy to the date of the start of the second-line systemic 
treatment (endocrine therapy or chemotherapy) or, in case of no second line treatment, to the 
date of documented disease progression or death, whichever came first. The switch to another 
regimen because of treatment intolerability or patient demand was not considered a change to 
second line treatment. Patients with none of these events were censored at January 1, 2016. 
The study was approved by our ethical committee. 
 
Muscle measurements 
 
Muscle mass was measured by CT-imaging (slice thickness 3 mm, Brilliance 64 CT or 
Brilliance 40 CT, Philips, Best, the Netherlands). All measurements were performed at one 
transversal CT-image at the L3 level using validated segmentation software (Slice-o-matic, 
Tomovision, Canada) [15]. To estimate muscle mass, total abdominal muscle cross-sectional 
area was measured in cm
2
 and corrected for height, resulting in a lumbar skeletal muscle 
index (SMI) in cm
2
/m
2
. Mean muscle attenuation (MA) of all abdominal muscles at L3 was 
measured in Hounsfield units (HU). The HU-threshold for muscle tissue varied from -29 to 
+150 HU [4], as previously published. Low muscle mass (LMM) was defined as a SMI of 
≤41 cm2/m2 [16]. Low muscle attenuation (LMA) was defined as <41 HU for patients with a 
body mass index (BMI) <25 and <33 HU for patients with a BMI ≥25 [16], using previously 
published cut-off points associated with survival after optimum stratification in patients with 
solid malignancies. Sarcopenic obesity was defined as the combination of LMM and a BMI 
≥30 [4].The inter-observer reliability between three trained investigators, as assessed with an 
intraclass correlation coefficient using a two-way random effects model and an absolute 
agreement definition, was 0.993. Hence, all muscle measurements were performed by one 
investigator.  
 
Statistical analyses 
 
Continuous variables were described as mean and standard deviation or as median and 
interquartile range (IQR). Categorical variables were described using percentages. 
Comparisons between included and excluded patients were performed using Mann-Whitney 
tests for continuous variables, Fisher’s exact tests for dichotomous variables and chi-square 
tests for categorical variables with more than 2 categories. Associations between muscle 
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parameters, age and BMI were evaluated using Spearman’s rank correlation and multivariable 
logistic regressions with age and BMI as independent variables and LMM and LMA as 
dependent variables. The association of LMM, sarcopenic obesity and LMA with OS and 
TNT was determined using Kaplan-Meier curves. In univariable and multivariable Cox 
proportional hazard models for OS and TNT, the following patient characteristics were 
included as independent variables: age, body mass index, hormone receptor positivity, 
Her2Neu receptor positivity, year of diagnosis, time between initial breast cancer diagnosis 
and the occurrence of distant metastases, metastatic locations and number of metastatic sites. 
The multivariable Cox models included all patient characteristics as independent variables, 
and each muscle measurement was added to this model separately. The proportional hazards 
assumption was assessed by including interaction effects of covariates and follow-up time in a 
Cox proportional hazards model with time-dependent covariates. All analyses were performed 
using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA) with a two-sided significance level 
of 0.05.  
 
Results 
 
Patient characteristics 
 
Initially, 380 patients with metastatic breast cancer undergoing first line palliative 
chemotherapy were identified. No CT-scan was available in 184 patients, 29 were excluded 
due to unknown length and weight and 1 patient was excluded because of a second 
malignancy. Eventually, a group of 166 patients was analyzed with a mean age of 58.8 ± 11.3 
years (range 30 – 86), of whom 21% had primary metastatic disease. Median duration of 
follow-up was 22 months. No patient was lost to follow-up. The median time from the initial 
breast cancer diagnosis to the diagnosis of distant metastases was 3 years (IQR 0 – 7). The 
median time from the diagnosis of distant metastases to the start of the first palliative 
chemotherapy was 1 month (IQR 0 – 7). The median time from CT-scanning to the start of 
chemotherapeutic treatment was 20 days. Median muscle mass was 38.4 cm
2
/m
2
 (IQR 34.2 – 
42.7).
 
Mean muscle attenuation (MA) was 34.3 HU (IQR 26.3 – 40.5). Median BMI was 26.4 
kg/m
2
 and 43 patients (25.9%) were classified as obese (BMI ≥30) (table 1) 
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Prevalence of LMM, sarcopenic obesity and LMA. 
 
The prevalence of LMM, sarcopenic obesity and LMA was 66.9%, 7.2% and 59.6%, 
respectively. LMA was especially prevalent in older patients (≥70 years), while age did not 
differ between the patients with and without LMM and patients with and without sarcopenic 
obesity. Patients with a higher BMI had more muscle mass on average, but lower MA 
(Spearman correlation +0.61, p < 0.001 and -0.22, p = 0.009 respectively). Spearman 
correlations for muscle mass and MA with age were +0.02 (p = 0.758) and -0.54 (p < 0.001) 
respectively.  Other patient and tumor characteristics did not significantly influence skeletal 
muscle measures (table 1). In multivariable logistic regression analyses with age and BMI as 
independent variables, the associations of LMM with BMI and LMA with age were also 
statistically significant (OR 0.76, 95% CI 0.69 – 0.84, p < 0.0001 and OR 1.11, 95% CI 1.07 
– 1.15, p < 0.0001) (supplemental table).  
 
Overall survival and time to next treatment (TNT) 
 
Median OS for the entire cohort was 18 months (95% CI 15.1 – 20.9 months). At the end of 
follow-up, 84.3% of the patients had died. Muscle mass on a continuous scale was not 
associated with OS, while muscle attenuation on a continuous scale showed a marginal  
association with OS, although this did not reach statistical significance (HR 0.98, 95% CI 
0.96 – 1.00, p = 0.054) (table 2). When using cut-off points to define patients with LMM, 
sarcopenic obesity and LMA, LMM and sarcopenic obesity were not associated with OS 
(median OS 19 vs. 18 months, p = 0.845 for LMM and 20 vs. 18 months, p = 0.481 for 
sarcopenic obesity). In contrast, patients with LMA had worse OS than patients with normal 
MA (median OS 15 vs. 23 months, p = 0.005) (fig. 1A). Using multivariable Cox-regression, 
the negative association of LMA with OS was maintained after adjusting for other common 
prognostic factors (table 2).  
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Table 1. Differences between patients with LMM and no LMM and with LMA and no 
LMA.  
 
 LMM
a 
N = 111 (%) 
No LMM 
N = 55 (%) 
P LMA
b 
N = 99 (%) 
No LMA 
N = 67 (%) 
P 
Age  
 <50y 
 50 – 69y 
 ≥70y 
 
19 (17.1) 
67 (60.4) 
25 (22.5) 
 
10 (18.2) 
38 (69.1) 
7 (12.7) 
0.317  
7 (7.1) 
63 (63.6) 
29 (29.3) 
 
22 (32.8) 
42 (62.7) 
3 (4.5) 
<0.001 
BMI ≥30 12 (10.8)
c 31 (56.4) <0.001 24 (24.2) 19 (28.4) 0.591 
HR status 
 Positive 
 Negative 
 Unknown 
 
77 (70.0) 
33 (33.0) 
1 
 
42 (76.4) 
13 (23.6) 
0.463  
73 (73.7) 
25 (25.5) 
1 
 
46 (68.7) 
21 (31.3) 
0.480 
Her2 status 
 Positive 
 Negative 
 Unknown 
 
31 (29.5) 
74 (70.5) 
6 
 
9 (17.6) 
42 (23.6) 
4 
0.122  
21 (23.1) 
70 (76.9) 
8 
 
19 (29.2) 
46 (70.8) 
2 
0.458 
Primary stage IV 21 (18.9) 14 (25.5) 0.419 18 (18.2) 17 (25.4) 0.333 
DFI
d
 (years) 3.0 
(1.8 – 8.0) 
4.0 
(2 – 8.5) 
0.488 4 (2.0 – 9.0) 3 (1 – 6.3) 0.077 
TTT
e
 (months) 1 (0 – 6) 1 (0 – 13) 0.826 2 (0 – 12) 1 (0 – 3) 0.015 
Metastatic location 
 Bone 
 Visceral 
 CNS 
 Skin or  
lymph node 
 Multiple 
 
24 (21.6) 
16 (14.4) 
3 (2.7) 
10 (9.0) 
 
58 (52.3) 
 
14 (25.5) 
11 (20.0) 
0 
4 (7.3) 
 
26 (47.3) 
0.602  
26 (26.3) 
15 (15.2) 
2 (2.0) 
8 (8.1) 
 
48 (48.5) 
 
12 (17.9) 
12 (17.9) 
1 (1.5) 
6 (9.0) 
 
36 (53.7) 
0.787 
Number of  
metastatic sites 
 1 
 2 
 3 
 >3 
 
 
49 (44.1) 
41 (36.9) 
15 (13.5) 
6 (5.4) 
 
 
27 (49.1) 
20 (36.4) 
7 (12.7) 
1 (1.8) 
0.720  
 
46 (46.5) 
35 (35.4) 
13 (13.1) 
5 (5.1) 
 
 
30 (44.8) 
26 (38.8) 
9 (13.4) 
2 (3.0) 
0.905 
Previous CTx 55 (49.5) 24 (43.6) 0.512 44 (44.4) 35 (52.2) 0.346 
Previous ETx 55 (49.5) 21 (38.2) 0.188 56 (56.6) 34 (50.7) 0.526 
First line CTx 
 FAC 
 Paclitaxel 
 Capecitabine 
 CMF 
 
27 (24.3) 
74 (66.7) 
9 (8.1) 
1 (0.9) 
 
21 (38.2) 
29 (52.7) 
5 (9.1) 
0 
0.248  
29 (29.3) 
58 (58.6) 
11 (11.1) 
1 (1.0) 
 
19 (28.4) 
45 (67.2) 
3 (4.5) 
0 
0.355 
TAMA (cm
2
) 97.7 
(89.9 – 104) 
119.7 
(113 – 132.4) 
<0.001 93.0  
(101.7 –113) 
110.8 
(97.2 – 125.1) 
0.021 
SMI (cm
2
/m
2
) 35.4 
(32.5 – 38.4) 
44.8 
(42.8 – 48.3) 
<0.001 37.6 
(33.7 – 41.3) 
39.5 
(34.4 – 44.2) 
0.040 
MA (HU) 32.8 
(25.8 – 41.9) 
34.7 
(29.3 – 39.8) 
0.530 27.5  
(24.5 – 32.0) 
42.5 
(37.9 – 46.6) 
<0.001 
Continuous variables are described as median (interquartile range). Categorical variables are described as 
numbers (%).  
aLMM: SMI <41 cm2/m2 
bLMA: Muscle attenuation <41 HU in patients with BMI <25 and <33 HU in patients with BMI ≥25 
cClassified as having sarcopenic obesity 
dDFI: Time between the initial breast cancer diagnosis and the first presentation of distant metastases for the 
patients not primary presenting with stage IV breast cancer 
eTTT: Time between the first presentation of distant metastasis and the start of the first line palliative 
chemotherapy 
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Abbreviations: BMI: Body mass index; HR: Hormone receptor; DFI: Disease free interval; TTT: Time to 
palliative treatment; CTx: Chemotherapy; ETx: Endocrine therapy; CNS: Central nervous system; FAC: 5-
fluororacil, Adriamycin, cyclophosphamide; CMF: Cyclophosphamide, methotrexate, 5-fluororacil; TAMA: 
Total abdominal muscle area; SMI: Skeletal muscle index; MA: Muscle attenuation; HU: Hounsfield units. 
 
Table 2. Cox proportional hazards models assessing the association with OS. 
 Univariable  Multivariable
a 
 HR 95% CI p  HR 95% CI P 
Age 
 <50 years 
 50 – 69 years 
 ≥70 years 
 
Ref 
0.79 
0.78 
 
Ref 
0.51 – 1.24 
0.45 – 1.37 
0.573 
Ref 
0.309 
0.394 
  
Ref 
0.66 
0.62 
 
Ref 
0.41 – 1.09 
0.33 – 1.17 
0.215 
Ref 
0.102 
0.140 
Body mass index 0.98 0.95 – 1.01 0.258  0.99 0.96 – 1.02 0.408 
Hormone receptor positive 0.75 0.52 – 1.09 0.128  0.47 0.31 – 0.71 <0.001 
Her2Neu positive 0.65 0.43 – 0.98 0.037  0.41 0.26 – 0.66 <0.001 
Year of diagnosis 1.04 0.98 – 1.11 0.210  1.08 1.01 – 1.15 0.030 
Disease free interval (years)
b
 0.98 0.95 – 1.01 0.258  0.96 0.92 – 1.00 0.038 
Metastatic location 
 Bone 
 Visceral 
 CNSc 
 Skin or lymph nodes 
 Multiple locations 
 
Ref 
0.85 
1.58 
0.79 
0.88 
 
 
Ref 
0.49 – 1.49 
0.48 – 5.17 
0.40 – 1.56 
0.57 – 1.34 
0.813 
Ref 
0.576 
0.453 
0.496 
0.535 
  
Ref 
0.56 
1.48 
0.57 
0.27 
 
 
Ref 
0.29 – 1.12 
0.44 – 4.94 
0.27 – 1.19 
0.10 – 0.68 
0.054 
Ref 
0.100 
0.527 
0.133 
0.006 
Number of metastatic sites 
 1 
 2 
 3 
 >3 
 
Ref 
1.04 
1.22 
1.85 
 
Ref 
0.72 – 1.51 
0.74 – 2.03 
0.84 – 4.05 
0.437 
Ref 
0.826 
0.441 
0.126 
  
Ref 
2.74 
4.58 
5.59 
 
Ref 
1.21 – 6.20 
1.69 – 12.42 
1.77 – 17.64 
0.012 
Ref 
0.015 
0.003 
0.003 
SMI (cm
2
/m
2
, continuous) 0.99 0.97 – 1.02 0.536  1.00 0.97 – 1.04 0.987 
MA (HU, continuous) 0.99 0.97 – 1.00 0.118  0.98 0.96 – 1.00 0.054 
LMM  0.97 0.68 – 1.37 0.845  0.98 0.60 – 1.58 0.923 
Sarcopenic obesity 0.78 0.40 – 1.54 0.481  0.87 0.40 – 1.88 0.723 
LMA 1.65 1.17 – 2.34 0.005  2.04 1.34 – 3.12 0.001 
aA multivariable Cox model with all patient characteristics was performed, after which each muscle 
measurement (below the line) was added to this model in a separate multivariable Cox model. 
 
Abbreviations: OS: Overall survival; SMI: Skeletal muscle index; MA: Muscle attenuation; HU: Hounsfield 
Units; LMM: Low muscle mass; LMA: Low muscle attenuation 
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a. 
 
b. 
 
Figure 1. Kaplan Meier curves for OS (a) and TNT (b) between patients with LMM and 
patients without LMM. 
Univariable Cox-regression:  
HR 1.65 (95% CI 1.17 – 2.34) 
P = 0.005 
Univariable Cox-regression:  
HR 1.36 (95% CI 0.97 – 1.90) 
P = 0.073 
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Median TNT for the entire cohort was 9 months (95% CI 7.4 – 10.6 months). The impact of 
muscle measures on median TNT was comparable to the impact on OS (10 vs. 8 months, p = 
0.540 for LMM and 10 vs. 9 months, p = 0.481 for sarcopenic obesity) (table 3). Patients with 
LMA had a median TNT of 8 months compared to 10 months for patients with normal MA, 
although this was not statistically significant in the univariable Cox regression (fig 1B). 
However, after adjustment for other factors in the multivariable Cox regression, patients with 
LMA had shorter TNT than patients with normal MA (HR 1.72, 95% CI 1.14 – 2.62, p = 
0.010) (table 3). OS and TNT of the included patients were similar to the excluded patients 
(supplemental figure). No significant violations of the proportional hazards assumption were 
detected.  
 
Table 3. Cox proportional hazards models assessing the association with TNT. 
 Univariable  Multivariable
a 
 HR 95% CI p  HR 95% CI p 
Age 
 <50 years 
 50 – 69 years 
 ≥70 years 
 
Ref 
0.66 
0.68 
 
Ref 
0.43 – 1.02 
0.40 – 1.16 
0.173 
Ref 
0.064 
0.160 
  
Ref 
0.53 
0.56 
 
Ref 
0.33 – 0.86 
0.31 – 1.02 
0.033 
Ref 
0.010 
0.059 
Body mass index 0.98 0.95 – 1.01 0.143  0.98 0.95 – 1.01 0.255 
Hormone receptor positive 0.85 0.59 – 1.22 0.368  0.62 0.40 – 0.95 0.027 
Her2Neu positive 0.63 0.42 – 0.94 0.024  0.46 0.30 – 0.72 <0.001 
Year of diagnosis 0.96 0.91 – 1.02 0.151  0.98 0.92 – 1.04 0.417 
Disease free interval (years)
b
 0.98 0.95 – 1.02 0.308  0.97 0.94 – 1.01 0.166 
Metastatic location 
 Bone 
 Visceral 
 CNSc 
 Skin or lymph nodes 
 Multiple locations 
 
Ref 
0.79 
4.34 
1.15 
0.99 
 
 
Ref 
0.46 – 1.37 
1.30 – 14.52 
0.60 – 2.19 
0.66 – 1.50 
0.109 
Ref 
0.407 
0.017 
0.674 
0.966 
  
Ref 
0.56 
3.70 
0.97 
0.25 
 
 
Ref 
0.29 – 1.06 
1.06 – 12.87 
0.48 – 1.95 
0.10 – 0.62 
0.005 
Ref 
0.074 
0.040 
0.932 
0.003 
Number of metastatic sites 
 1 
 2 
 3 
 >3 
 
Ref 
1.11 
1.47 
2.13 
 
Ref 
0.77 – 1.59 
0.90 – 2.43 
0.97 – 4.66 
0.161 
Ref 
0.570 
0.127 
0.059 
  
Ref 
3.20 
5.99 
6.92 
 
Ref 
1.44 – 7.12 
2.26 – 15.86 
2.25 – 21.34 
0.001 
Ref 
0.004 
<0.001 
0.001 
SMI (cm
2
/m
2
, continuous) 1.00 0.98 – 1.03 0.973  1.01 0.97 – 1.04 0.670 
MA (HU, continuous) 1.00 0.98 – 1.01 0.531  0.98 0.96 – 1.00 0.107 
LMM  0.90 0.64 – 1.27 0.540  0.84 0.52 – 1.37 0.486 
Sarcopenic obesity 0.65 0.33 – 1.28 0.211  0.89 0.40 – 1.97 0.774 
LMA 1.36 0.97 – 1.90 0.073  1.72 1.14 – 2.62 0.010 
aA multivariable Cox model with all patient characteristics was performed, after which each muscle 
measurement (below the line) was added to this model in a separate multivariable Cox model. 
 
Abbreviations: TNT: Time to next treatment; SMI: Skeletal muscle index; MA: Muscle attenuation; HU: 
Hounsfield Units; LMM: Low muscle mass; LMA: Low muscle attenuation 
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Discussion 
 
In this study, LMA was a significant prognostic factor for both OS (HR 2.04, 95% CI 1.34 – 
3.12, p=0.001) and TNT (HR 1.72, 95% CI 1.14 – 2.62, p = 0.010), whereas LMM and 
sarcopenic obesity were not. Due to the lack of standardized muscle measurements, we 
additionally repeated these survival analyses using continuous scales of muscle parameters 
and found no association between muscle mass and OS and TNT. Unlike the association 
between LMA and OS, the association between muscle attenuation on a continuous scale and 
OS was not statistically significant, which suggests a possible non-linear association.  
 
Our study reports on the prognostic value of skeletal muscle measures in the largest cohort of 
patients with metastatic breast cancer described so far. The association of LMA and OS has 
only been studied before once in advanced breast cancer patients [9]. In this study, similar to 
our results, muscle attenuation on a continuous scale was not significantly associated with 
survival or time to treatment failure. However, only 40 patients were evaluated and no cut-off 
point was used to identify the patients with LMA and to relate the impact of LMA on OS. Our 
finding that LMA is a prognostic factor for survival is similar to the results of studies with 
other cancer types [13,14,16-19]. Similar to our study, two of these studies reported that LMA 
was significantly associated with poor OS, while LMM was not [13,14], suggesting that LMA 
is a better prognostic marker for OS than LMM. This is in line with earlier observations in 
geriatric medicine. In elderly patients without cancer, LMA causes muscle weakness 
independent of the loss of muscle mass [20], with muscle strength being a better predictor for 
mortality than muscle mass [21]. This knowledge could be used to determine which muscle 
measures may be useful in clinical oncological practice. 
 
Generally, results in the literature on the prognostic impact of LMM are mixed. In the current 
study, we could not show any association between LMM or sarcopenic obesity and OS or 
TNT, which is in concordance with the most recent study in advanced breast cancer [9] and 
studies in other tumor types [4,6,8,16,22-25].  This is somewhat in contrast with the only 
other study among  metastatic breast cancer patients by Prado et al, which reported a shorter 
time to disease progression in patients with LMM compared to patients without LMM [5] and 
some studies in other tumor types [7,26-29]. Explanations for the discrepancy with our study 
are probably found in several factors, including differences in cancer type and disease 
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aggressiveness, age, and disease stage at the time of muscle measurement. Furthermore, 
different cut-offs to diagnose LMM have been used across studies and these cut-off may not 
be applicable for all cancer populations. Therefore, the difference in reported outcome is hard 
to put into perspective. In our study, patients were younger (mean 58.8 years vs. 64-79 years 
in the studies mentioned above) and all were female. A potential explanation for the different 
results is that the prognostic value of LMM is lower in younger patients, where prognosis is 
more dependent on other factors, and in females, which has been reported by studies in 
patients with [25,28,30] and without cancer [31,32]. In addition, in the study by Prado et al 
[5], patients had already failed multiple palliative chemotherapeutic lines, while our study was 
in a population receiving first line chemotherapy. So LMM might be more related to more 
advanced disease than in patients still responsive to treatment.  
 
Muscle measures have increasingly been recognized over the last years as a prognostic factor 
for oncological outcomes, such as survival and treatment tolerability, and could be easily 
obtained in cancer patients using already available CT images. An increasing number of 
studies investigating interventions targeting low muscle parameters in cancer patients are 
conducted, such as physical exercise to reverse LMM and thereby improve quality of life in 
breast cancer [33]. However, implementation of muscle measures in clinical oncological 
practice to predict outcome and treatment risks is hampered by the lack of a standardized 
method of measurement, including knowledge of which muscle component (quantity or 
quality) is best suited as prognostic marker [11]. This study contributes to the literature by 
comparing different muscle components with outcome and observing that LMA seems a 
better prognostic factor for survival than LMM in breast cancer.  
 
Especially in older people, LMM is frequently present and associated with mortality and 
physical disability [34,35]. Furthermore, muscle loss is worsened in the presence of cancer 
due to cachexia-related processes [36]. However, decreased muscle function (strength) has a 
stronger association with negative outcomes than LMM [37], and it has been reported that 
muscle attenuation is negatively correlated with muscle strength. It is therefore likely that 
muscle quality is more important for muscle function and clinical outcomes than absolute 
muscle mass [20], which was also supported by the results of this study. Given this, special 
emphasis in future research should be put on generating prospective data on the prognostic 
impact of LMM and LMA in elderly patients with advanced breast cancer.   
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Muscle loss is an important part of syndromes such as sarcopenia and cachexia [38]. Initially, 
sarcopenia was defined by the decline of muscle mass with aging [39]. Since sarcopenia is a 
multifactorial syndrome and thus more than solitary LMM [40], the current consensus is to 
define sarcopenia as the combination of LMM and either low muscle strength or impaired 
physical performance [41]. Recent studies have reported that sarcopenia is a better prognostic 
factor for oncological outcomes than solitary LMM [42,43].  Therefore, a distinction should 
be made in the nomenclature when reporting studies investigating radiologically measured 
muscle mass or the syndrome sarcopenia, so we used the terms LMM and LMA to indicate 
the muscle measures in this study.  
 
Several limitations of this study have to be mentioned. Firstly, abdominal CT-images had to 
be available for muscle measurement, resulting in patients not eligible for the present analysis. 
It is not possible to avoid this in a population with breast cancer patients as seen in daily 
practice, as imaging diagnostics such as thoracic X-ray and abdominal ultrasound are 
sometimes preferred over abdominal CT-imaging to diagnose distant metastases. However, a 
comparison of the included and excluded patients revealed no differences in outcome, so it is 
not likely that this had significant impact on our results. A possibility could be the exploration 
of other devices to measure muscle mass in breast cancer patients, such as dual energy X-ray 
absorptiometry (DEXA). However, CT is considered the gold standard of muscle 
measurement, so we feel that this study might provide important information on the 
prognostic value of muscle measurements for survival in advanced breast cancer using this 
device. Secondly, the sample size of the patients with sarcopenic obesity was small. Despite 
the fact that muscle mass was not associated with outcome in this study, patients with 
sarcopenic obesity are considered a prognostic worse group. The impact of sarcopenic obesity 
on outcome in advanced breast cancer needs further investigation.   
 
Conclusion 
 
In this cohort of patients with metastatic breast cancer, LMA was a prognostic factor for 
overall survival and time to clinically relevant disease progression, whereas LMM was not. 
LMA is potentially an easy to establish prognostic marker in patients with advanced breast 
cancer, provided that the impact on OS and TNT can be confirmed in other studies. More 
studies are needed to standardize muscle measurements and to investigate which muscle 
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parameter is best suited as prognostic marker in different populations and treatment settings. 
This may eventually result in knowledge on how skeletal muscle measures could be 
incorporated into treatment decision making, and if possible, to develop strategies to 
intervene, thereby hopefully improving outcome of patients with advanced breast cancer. 
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Supplemental figure. Comparison of OS (A) and TNT (B) between included and 
excluded patients.  
 
a. 
 
b. 
 
Univariable Cox-regression:  
HR 0.93 (95% CI 0.75 – 1.17) 
P = 0.550 
Univariable Cox-regression:  
HR 0.99 (95% CI 0.80 – 1.24) 
P = 0.942 
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Supplemental table. Association of body mass index and age with low muscle mass and 
low muscle attenuation. 
 
 Low muscle mass
a
 Low muscle attenuation
b
 
 OR 95% CI p OR 95% CI p 
Age (years) 1.01 0.97 – 1.04 0.731 1.11 1.07 – 1.15 <0.001 
BMI (kg/m
2
) 0.76 0.69 – 0.84 <0.001 0.97 0.91 – 1.03 0.348 
Results of multiple logistic regression 
aSMI < 41 cm2/m2 
bMuscle attenuation <41 HU in patients with BMI <25 and <33 HU in patients with BMI ≥25 
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Abstract 
 
Background: Body composition parameters including low muscle mass, muscle attenuation 
(which reflects muscle quality), and adipose tissue measurements have emerged as prognostic 
factors in cancer patients. However, knowledge regarding the possibility of excessive muscle 
loss during specific systemic therapies is unknown. We describe the changes in body 
composition and muscle attenuation (MA) during taxane- and anthracyclin-based regimens 
and its association with overall survival (OS) in metastatic breast cancer patients. 
Methods: The lumbar skeletal muscle index (LSMI) was used as marker of muscle mass. 
LSMI, MA, subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) and 
intramuscular adipose tissue (IMAT) were measured before and after first-line treatment with 
paclitaxel (n = 73) or 5-fluorouracil-doxorubicin-cyclophosphamide (FAC) (n = 25) using 
CT-images. Determinants of the change of LSMI and MA were analysed using multiple linear 
regression. OS was assessed using Cox proportional hazard models. 
Results: MA significantly decreased during paclitaxel-treatment (-0.9 HU, p = 0.03). LSMI 
(p = 0.40), SAT (p = 0.75), VAT (p = 0.84) and IMAT (p = 0.10) remained stable. No 
significant alterations in body composition parameters during FAC-treatment were observed. 
Previous (neo-)adjuvant chemotherapy contributed to larger loss of MA during the current 
treatment. Body composition changes during chemotherapy were not associated with OS. 
Conclusions: MA decreased during treatment with paclitaxel, while muscle mass was stable. 
Body composition changes are not associated with survival in the absence of progressive 
disease.  
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Introduction 
 
Low muscle mass (LMM) and low muscle attenuation (LMA) have been associated with 
physical disability and mortality of otherwise healthy older adults [1,2]. Muscle attenuation 
(muscle density) reflects the accumulation of adipose tissue in muscles and is therefore 
considered a marker of muscle quality. Quantitative and qualitative muscle loss are largely 
age-related [3,4], but also occur in the presence of a chronic disease [5]. In cancer patients, 
body composition parameters, including LMM, LMA and adipose tissue loss have 
increasingly been related to unfavourable outcomes [6,7] with LMA being a better prognostic 
marker than LMM [8-10]. It has also been reported that higher loss of muscle mass over time 
is associated with impaired survival in cancer patients [11-14], as well as the loss of visceral 
adipose tissue during chemotherapeutic treatment because in patients with pancreatic cancer 
[11,15] and ovarian cancer [13].  
 
Studies in patients with metastatic breast cancer showed that LMM resulted in more 
chemotherapeutic toxicity and a shorter median time to tumour progression [16,17] and that 
LMA was associated with more hospital admissions [17] and a shorter median overall 
survival [8]. Currently, it is however unknown whether body composition parameters change 
during treatment with different systemic agents and whether body composition measures over 
time have more prognostic power than a single muscle measurement at diagnosis in patients 
with metastatic breast cancer. Furthermore, the impact of different systemic agents on body 
composition is relatively unstudied. Therefore, knowledge regarding the possibility of 
excessive muscle loss during specific systemic therapies and its probable clinical impact is 
lacking.  
 
In metastatic breast cancer, anthracyclin- or taxane-based chemotherapeutic regimens are 
often the treatment of choice as palliative chemotherapy. In this study we aimed to describe 
the changes in body composition and muscle quality during first line palliative anthracyclin- 
or taxane-based chemotherapy in metastatic breast cancer. To our knowledge, studies 
regarding this subject are lacking. We hypothesized that patients treated with taxanes 
experience more muscle loss than patients treated with anthracyclins due to the specific nature 
of toxicities associated with taxanes, such as the occurrence of neuropathy [18] and myalgia 
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[19], which might exacerbate any muscle loss. Secondly, we determined the association of 
muscle- and fat wasting with overall survival.  
 
Methods 
 
Patient inclusion and treatment characteristics 
 
This single-centre, retrospective study involved patients with metastatic breast cancer 
undergoing first line palliative chemotherapy with taxanes or a anthracyclin-based regimen. 
Body composition changes during taxane-based therapy were compared with body 
composition changes during anthracyclin-based therapy. We chose a control group with less 
muscle-related toxicity and used only anthracyclin-based regimens as control-group due to the 
less frequent use and large heterogeneity of other cytotoxic regimens. Due to local practice, 
taxane-based regimens always involved paclitaxel and anthracycline-based regimens 
consisted of  5-fluorouracil, doxorubicin and cyclophosphamide (FAC). Patients diagnosed 
with breast cancer between 1
st
 January 2000 and 1
st 
March 2016 were identified using the 
pathology- and radiology-registry at our hospital, after which patients with distant metastases 
were identified from these databases. Inclusion criteria were first-line palliative chemotherapy 
with paclitaxel or FAC (intention to complete 6 cycles) and abdominal CT images available 
within 3 months prior to the start and after the completion of treatment. Exclusion criteria 
were male gender, a second malignancy (except skin cancer other than melanoma), patients 
who completed less than 3 cycles of FAC- or paclitaxel –treatment, treatment with other 
chemotherapeutic regimens than taxanes or FAC and disease progression during the 6 cycles 
of first line palliative chemotherapy. The latter was done to avoid the impact of progressive 
disease on muscle wasting [20]. Medical records were searched for patient- characteristics and 
treatment details. Paclitaxel was administered weekly (6 cycles of 80 mg/m
2
 day 1, 8, 15 per 3 
weeks) i.e. a total of 18 weeks combined with dexamethasone 8 mg before each dose; addition 
of trastuzumab was allowed in case of HER2 positive breast cancer. The FAC-regimen 
consisted of 6 cycles of 5-fluourouracil 500 mg/m
2
, doxorubicin 50 mg/m
2
 and 
cyclophosphamide 500 mg/m
2
 every 3 weeks; i.e. a total of 18 weeks. The study was 
approved by our local institutional review board.  
 
Changes in body composition and muscle attenuation during taxane-based chemotherapy 
 
115 
 
Body composition measurements 
 
Body composition measurements were performed before and after completion of first line 
palliative chemotherapy and consisted of the measurement of muscle mass and muscle 
attenuation (MA), which is the density of muscle tissue, with lower muscle density indicating 
more microscopic fat infiltration of muscle [3]. Total abdominal muscle area (TAMA) 
corrected for height, resulting in a lumbar skeletal muscle index (LSMI) in cm
2
/m
2
 was used 
as parameter of skeletal muscle mass [21]. Adipose measurements included intramuscular 
adipose tissue (IMAT), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and 
total abdominal tissue (TAT), which was the sum of IMAT, VAT and SAT. Muscle tissue 
was identified between -29 and +150 Hounsfield Units (HU) at the L3-level, VAT was 
identified between -150 and -50 HU and SAT + IMAT between -190 and -90 HU, as 
previously published [22]. Slice-o-matic software (Slice-o-matic, Tomovision, Canada) [23] 
was used for all body composition measurements. All body composition measurements were 
performed by one validated observer after an intraclass correlation coefficient of 0.993 was 
reached between three observers.  
 
Statistical analyses 
 
Continuous variables were described as mean plus standard deviation (SD) or as median + 
interquartile range (IQR). Percentages were used to describe categorical variables. Patient 
characteristics were compared between the paclitaxel-group and FAC-group using the Mann-
Whitney U test for continuous variables and the Fisher’s exact test or chi-square test for 
categorical variables. Body composition parameters were measured on a continuous scale 
before the start of the first chemotherapeutic cycle and after completion of therapy. First, 
cross-sectional analyses were performed using the Mann-Whitney U test to compare all body 
composition measurements (LSMI, MA, IMAT, VAT, SAT and TAT) between the two 
treatment groups before and after treatment. Second, the change of these during chemotherapy 
was evaluated in each group using the Wilcoxon signed rank test. Simple multiple linear 
regression analyses were performed to identify possible factors contributing to muscle change 
during chemotherapy. The change of LSMI and MA during chemotherapy (delta after - 
before) was used as dependent variable in these models. The independent variables were age, 
body mass index (BMI), previous chemotherapy (yes/no), previous endocrine therapy 
(yes/no), paclitaxel treatment and Her2 positivity. The stepwise backward method was 
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performed to select the independent variables in the multiple linear regression models and 
only variables with a p-value <0.20 were retained in the final model. Variables that differed 
significantly between the treatment groups were not considered for removal in the stepwise 
backward method. Multicollinearity in the multiple linear regression models was assessed by 
calculating variance inflation factors. Overall survival (OS) was defined as the time from the 
date of the first chemotherapeutic cycle until the date of death or the end of follow-up (1
st
 
September 2016), and was visualized using the Kaplan Meier method. A loss of muscle or fat 
mass was defined as absolute loss of any degree. Univariable and multivariable Cox 
proportional hazard regression analyses were performed to determine the association of 
variables known for their clinical impact and OS. The variables in the multivariable Cox-
regression were selected using the stepwise backward method. To determine the amount of 
selection bias, we compared the patient characteristics and survival between the included and 
excluded patients. All statistical tests were two-sided and used a significance level of 0.05. 
The analyses were performed using SPSS version 24. 
 
Results 
 
Patient characteristics 
 
Between 1
st
 January 2000 and 1
st
 March 2016, 723 patients with metastatic breast cancer were 
identified at our hospital. Patients were excluded in case of other palliative chemotherapy than 
paclitaxel or FAC (n = 30), no CT-images before (n = 188) or after chemotherapy (n = 62), or 
progressive disease during the 6 cycles of first-line chemotherapy (n = 33) (figure 1). 
Eventually, 98 patients were eligible for analysis, of which 73 were treated with paclitaxel 
and 25 underwent treatment with FAC. The median time between the pre-treatment CT-scan 
and the start of chemotherapy was 19.5 days (IQR 13 – 32.8 days), with 95% of the patients 
having CT-imaging less than 60 days before treatment. The post-treatment CT-scan was  
performed within 30 days after therapy completion. In total, 15 patients (15.3%) received less 
than 6 cycles of chemotherapy, resulting in a median of 6 cycles of chemotherapy in the entire 
cohort. Toxicity was the reason of treatment cancellation before completing 6 cycles in 9 
patients.  
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Figure 1. Flow chart of the patient inclusion 
 
Among the other 6 patients, the reasons of treatment cancellation were patient request (n = 2), 
worsening physical condition without progression or toxicity (n = 1) and a switch to another 
treatment (n = 4). Prior to treatment start, there were no significant differences in body 
composition parameters between the two treatment groups (table 1). 
 
  
  
  
Patients with metastatic breast cancer:  
N = 723 
N = 229 
Excluded: 
305 
No CT abdomen at L3 before  
chemotherapy: 
188  
Excluded:   
Other chemotherapy than paclitaxel/FAC:   30   
No CT images after chemotherapy:     62   
Only a single chemotherapeutic gift:   3   
Switch from FAC to paclitaxel  
during therapy: 
  
2 
  
Progression during therapy: 
      
33 
  
Included patients:    
N = 98   
Patients with paclitaxel treatment:   
N = 73   
    
N = 25   
No palliative chemotherapy: 
Patients with CT-images before the first 
palliative chemotherapy 
Patients with FAC treatment:
Second malignancy: 
 
Less than 3 chemotherapeutic cycles: 
1  
1  
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Compared with the excluded patients undergoing palliative chemotherapy (n = 319, 
supplemental table S1), included patients had a longer time from the initial breast cancer 
diagnosis until diagnosis of distant metastases and the sites of the metastases were more often 
multiple and less likely located solitary in bone. Age, BMI, hormone receptor status, Her2 
receptor status, adjuvant chemotherapy and previous palliative endocrine treatment were 
similar.  
 
Table 1. Patient characteristics. 
 
 FAC (n = 25) Paclitaxel (n = 73) p value
a 
Age (years) 
 Mean (SD) 
 Range 
 
56.8 (10.3) 
39 – 73 
 
54.5 (10.2) 
31 – 77 
0.39 
Year of diagnosis
b 
 Median (IQR) 
 
2009 (2006 – 2012) 
 
2011 (2008 – 2013) 
 
0.06 
Body mass index  
 Median (IQR) 
 
26.8 (23.5 – 30.6) 
 
25.9 (22.9 – 30.6) 
0.70 
Hormone receptor status 
 Positive  
 Negative 
 Unknown  
 
19 (76%) 
6 (24%) 
0 (0%) 
 
54 (74%) 
19 (26%) 
0 (0%) 
1.00 
Her2Neu status  
 Positive 
 Negative 
 Unknown 
 
2 (8%) 
23 (92%) 
0% 
 
27 (37%) 
37 (50.7%) 
9 (12.3%) 
0.002 
Primary stage IV (%) 11 (44%) 16 (21.9%) 0.04 
Disease free interval (years)
c
 
 Median (IQR) 
 
9 (3.5 – 12.5) 
 
4 (2.5 – 10) 
 
0.16 
Time to palliative treatment 
(months)
d 
 Median (IQR) 
 
 
1.0 (0 – 4.5) 
 
 
1.0 (0 – 6.0) 
 
 
0.90 
Metastatic location 
 Bone 
 Visceral 
 Skin or lymph nodes 
 Multiple locations 
 
3 (12%) 
3 (12%) 
3 (12%) 
16 (64%) 
 
 
14 (19.2%) 
12 (16.4%) 
5 (6.8%) 
42 (57.5%) 
0.68 
Number of metastatic sites 
 1 
 2 
 3 
 > 3 
 
9 (36%) 
11 (44%) 
4 (16%) 
1 (4%) 
 
 
29 (39.7%) 
27 (37%) 
14 (19.2%) 
3 (4.1%) 
0.94 
Previous (neo)adjuvant 
chemotherapy 
4 (16%) 36 (49.3%) 0.004 
Previous endocrine therapy 
No endocrine therapy 
(Neo-)adjuvant 
Palliative 
Both adjuvant and palliative 
 
16 (64%) 
3 (12%) 
3 (12%) 
3 (12%) 
 
35 (47.9%) 
18 (24.7%) 
11 (15.1%) 
9 (12.3%) 
0.49 
LSMI baseline
e
 38.4 (34.4 – 45.4) 37.7 (33.3 – 41) 0.11 
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MA baseline 31.1 (25.2 – 38.1) 31 (25.2 – 40.6) 0.69 
SAT baseline (Median + IQR) 
 
181.8 (148.7 – 225.1)f 206.9 (147.3 – 237)g 0.58 
VAT baseline 109 (51.8 – 126) 105.4 (65.1 – 147.2) 0.59 
IMAT baseline 17 (11.7 – 22) 14.7 (10.2 – 23.8) 0.61 
TAT
,h
 baseline 314.1 (211.3 – 364) 308.1 (256.9 – 389.5) 0.68 
aThe Fisher’s exact test was used for categorical variables with 2 categories and the chi-square test was used for 
categorical variables with more than 2 categories. 
bDiagnosis of distant metastases. 
cDFS: Time between the initial breast cancer diagnosis and the first presentation of distant metastases for 
patients with M0 presentation of primary breast cancer.  
dTime to palliative treatment: Time between the first presentation of distant metastasis and the start of the first 
line palliative chemotherapy. 
eBefore chemotherapy 
fMissing: n = 4 
gMissing: n = 11 
hTAT: Sum of SAT, VAT and IMAT.  
 
Abbreviations: FAC: 5-fluororacil, Adriamycin, cyclophosphamide; IQR: Interquartile range; DFS: Disease-free 
survival; LSMI: Lumbar skeletal muscle index; MA: Muscle attenuation; SAT: Subcutaneous adipose tissue; 
VAT: Visceral adipose tissue; IMAT: Intramuscular adipose tissue; TAT: Total adipose tissue 
 
Body composition changes during chemotherapy 
 
In patients treated with 4 or more cycles of paclitaxel, MA significantly decreased during 
treatment (median -0.9 HU, IQR -4.2 - +1.9 HU, p = 0.03), while all other body composition 
parameters remained stable. No significant changes in body composition were observed in the 
patients treated with 4 or more cycles of FAC as well (table 2, figure 2).  
 
Table 2. Changes in body composition during chemotherapy. 
 
Muscle change during chemotherapy, mean (95% CI) 
 FAC P
a  Paclitaxel pg  
LSMI (cm
2
/m
2
) -0.5 (-6.2 - +6.6) 0.28  +0.3 (-3.9 - +6.3) 0.40  
MA (HU) -0.6 (-12.1 - +13.8) 0.44  -1.5 (-12.9 - +6.6) 0.03  
SAT -7.4 (-78.4 - +46.2) 0.31  +0.03 (-48.7 - +52.0) 0.75  
VAT -1.6 (-51.4 - +48.6) 0.82  +0.05 (-46.9 - +49.4) 0.84  
IMAT +1.4 (-5.2 - +9.3) 0.15  -0.5 (-11.2 - +8.0) 0.10  
TAT -2.9 (-91.6 - +79.7) 0.71  -0.3 (-100.6 - +88.4) 0.94  
aThe difference in muscle parameters during chemotherapy (after – before) within each treatment group using the 
Wilcoxon signed rank test.  
 
Abbreviations: FAC: 5-fluororacil, Adriamycin, cyclophosphamide; LSMI: Lumbar skeletal muscle index; MA: 
Muscle attenuation; HU: Hounsfield Unit; SAT: Subcutaneous adipose tissue; VAT: Visceral adipose tissue; 
IMAT: Intramuscular adipose tissue; TAT: Total adipose tissue 
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The results were the same after repeating the analyses with all patients, irrespective of the 
number of completed cycles (supplemental table S2 and S3). Except from the relationship 
between muscle mass and MA before chemotherapy and muscle change during therapy, 
multiple linear regression revealed that prior chemotherapy in the (neo-)adjuvant setting 
significantly contributed to a larger loss of MA during the current treatment, while this was 
not observed for the change of LSMI.  
 
Table 3a. The effect on change of lumbar skeletal index (LSMI) during chemotherapy. 
 
 Simple linear regression Multiple linear regression 
 Coefficient  95% CI p Coefficient 95% CI P 
Age -0.02 -0.09 – 0.05 0.65 -- -- -- 
BMI
 0.002 -0.12 – 0.12 0.98 0.22 0.07 – 0.36 0.004 
Previous Ctx
 -0.26 -1.76 – 1.23 0.73 -- -- -- 
Previous Etx
 0.53 -0.95 – 2.01 0.48 1.20 -0.23 – 2.62 0.10 
LSMI
a -0.14 -0.24 - -0.04 0.009 -0.27 -0.40 - -0.14 <0.001 
Paclitaxel 
treatment 
0.84 -0.84 – 2.52 0.32 -0.32 -1.96 – 1.32 0.70 
Her2 positive -0.06 -1.63 – 1.53 0.95 0.31 -1.28 – 1.89 0.70 
Dependent variable: Change of LSMI during chemotherapy. 
aLSMI: Lumbar skeletal muscle index (cm2/m2) before chemotherapy. 
 
Abbreviations: BMI: Body mass index; Ctx: Chemotherapy; Etx: Palliative endocrine therapy; LSMI: Lumbar 
skeletal index  
aBMI: Body mass index in kg/m2 
bCtx: Previous chemotherapy. 
cHtx: Previous endocrine therapy. 
 
 
Table 3b. The effect on change of muscle attenuation during chemotherapy. 
 
 Simple linear regression Multiple linear regression 
 Coefficient  95% CI p Coefficient 95% CI P 
Age 0.09 -0.02 – 0.19 0.10 -- -- -- 
BMI
 -0.03 -0.21 – 0.15 0.75 -- -- -- 
Previous Ctx
 1.27 -0.98 – 3.51 0.27 2.57 0.23 – 4.90 0.03 
Previous Etx
 -0.17 -2.41 – 2.07 0.88 -- -- -- 
MA
a -0.23 -0.33 – 0.13 <0.001 -0.24 -0.35 - -0.13 <0.001 
Paclitaxel 
treatment 
-0.89 -3.44 – 1.65 0.49 0.93 -1.72 – 3.57 0.49 
Her2 positive -3.04 -5.50 – 0.57 0.02 1.32 -1.20 – 3.83 0.30 
Dependent variable: Change of LSMI during chemotherapy. 
aMA: Muscle attenuation (HU) before chemotherapy. 
 
Abbreviations: BMI: Body mass index; Ctx: Chemotherapy; Etx: Palliative endocrine therapy; MA: Muscle 
attenuation; HU: Hounsfield Unit.  
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Patients with prior chemotherapy on average had a 2.57 HU higher loss of MA compared to 
patients without prior chemotherapy (which is 8.3% of the median MA at baseline). A lower 
BMI was associated with larger loss of muscle mass during chemotherapy, although the 
amount of extra muscle loss was limited. Each decrease in BMI of 1 kg/m
2
 resulted in a 0.22 
cm
2
/m
2
 (<1%) increase of muscle mass loss. Previous endocrine treatment was not associated 
with larger loss of muscle mass or attenuation (table 3A and 3B). No severe collinearity 
between variables was detected with variation inflation factors between 1.1 and 1.9. 
 
Survival 
 
The median OS in the paclitaxel-group was 21 months and in the FAC-group 22 months 
(univariable HR for paclitaxel treatment 1.01, 95% CI 0.59 – 1.74, p = 0.96). At the end of 
follow-up, 68 (69.4%) patients had died. No significant differences in OS were observed 
between patients who lost muscle mass or muscle attenuation and patients not losing muscle 
mass or muscle attenuation (fig 3). In the univariable and multivariable Cox-regression,  age 
and de novo stage IV disease were significant predictors of OS. (table 4). Patients with de 
novo stage IV disease had a longer median OS than patients relapsing after adjuvant treatment 
(multivariable HR 0.30, 95% CI 0.14 – 0.67, p = 0.003) and these patients were more often 
allocated to the FAC-group. However, the chemotherapy regimen itself was not predictive of 
OS (multivariable HR 1.04, 95% CI 0.52 – 2.07, p = 0.92.   OS of the excluded patients was 
worse compared with the included patients (supplemental figure S1). No significant 
violations of the proportional hazards assumption were detected.   
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a. 
 
 
 
b. 
 
X-axis: Muscle attenuation (HU) before treatment. 
Y-axis: Change of muscle attenuation (HU) as percentage of the muscle attenuation before treatment.  
 
Figure 2. Muscle attenuation before and after paclitaxel-treatment (a) and FAC-
treatment (b) per patient.  
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a. 
 
Figure 3a. Kaplan Meier curve for overall survival between patients treated with loss of 
muscle mass and stable or gain of muscle mass. 
 
b. 
 
Figure 3B. Kaplan Meier curve for overall survival between patients with loss of muscle 
attenuation and stable or gain of muscle attenuation. 
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Table 4. Cox proportional hazards model assessing the association with overall survival. 
 
 Univariable Multivariable
a 
 HR 95% CI p HR 95% CI P 
Age 1.05 1.02 – 1.07 0.001 1.04 1.01 – 1.08 0.01 
Year of diagnosis 1.03 0.95 – 1.12 0.43 1.08 0.97 – 1.19 0.17 
DFS
b 0.98 0.94 – 1.03 0.44 0.91 0.84 – 0.98  0.01 
ER/PR positive
c 0.68 0.41 – 1.15 0.15 0.59 0.31 – 1.12 0.11 
Her2 positive
d 0.75 0.44 – 1.30 0.31 0.58  0.29 – 1.17 0.13 
Number of 
metastases 
 1 
 2 
 3 
 >3 
 
 
Ref 
1.77 
2.04 
2.30 
 
 
Ref 
1.00 – 3.14 
1.03 – 4.06 
0.78 – 6.75 
0.11 
 
Ref 
0.05 
0.04 
0.13 
 
 
Ref 
2.16 
2.74 
2.09 
 
 
Ref 
1.11 – 4.21 
1.20 – 6.25  
0.59 – 7.38 
0.07 
 
Ref 
0.02 
0.02 
0.25 
Metastatic location 
 Bone 
 Visceral 
 Skin or 
lymph nodes 
 Multiple 
 
 
Ref 
0.79 
0.75 
 
1.27 
 
Ref 
0.31 – 1.99 
0.26 – 2.16 
 
 
0.62 – 2.61 
0.42 
Ref 
0.61 
0.60 
 
 
0.52 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
 
 
- 
Denovo stage IV 0.74 0.42 – 1.28 0.28 0.30 0.14 – 0.67 0.003 
Paclitaxel treatment 1.01 0.59 – 1.74 0.96 1.04  0.52 – 2.07 0.92 
        
Baseline LSMI 0.99 0.95 – 1.02 0.47 0.98 0.94 – 1.03 0.42 
Baseline MA 0.99 0.96 – 1.01 0.26 1.04 1.00 – 1.09 0.06 
Loss of LSMI
 1.10 0.68 – 1.77  0.70 0.65 0.36 – 1.20 0.17 
Loss of MA
 1.03 0.63 – 1.69 0.91 1.22 0.67 – 2.20  0.52 
Loss of SAT 1.73 1.00 – 3.01 0.05 0.83  0.39 – 1.76 0.62 
Loss of VAT 1.15 0.71 – 1.82 0.56 1.00  0.52 – 1.92 0.99 
Loss of IMAT 0.81 0.41 – 1.35 0.42 0.53 0.27 – 1.03 0.06 
Loss of TAT 1.15 0.68 – 1.96 0.60 0.58 0.31 – 1.10  0.10 
aA multivariable Cox model with all patient characteristics was performed, after which each body composition 
parameter (below the line) was added to this model in a separate multivariable Cox model. 
bDFS: Time between initial breast cancer diagnosis and diagnosis of distant metastases). 
cReference category: ER/PR negative patients (either Her2 positive or Her2 negative) 
dReference category: Her2 negative patients (either ER/PR positive or ER/PR negative) 
 
Abbreviations: HR: Hazard ratio; CI: Confidence interval; DFS: Disease-free survival; ER: Estrogen receptor; 
PR: Progesterone receptor; LSMI: Lumbar skeletal muscle index; MA: Muscle attenuation; SAT: Subcutaneous 
adipose tissue; VAT: Visceral adipose tissue; IMAT: Intramuscular adipose tissue; TAT: Total adipose tissue  
 
Discussion 
 
This study shows that median muscle attenuation significantly decreased during treatment 
with paclitaxel (-0.9 HU, p = 0.03). In contrast, in patients treated with anthracyclin-based 
chemotherapy, the change of median MA was not statistically significant. The amount of 
Changes in body composition and muscle attenuation during taxane-based chemotherapy 
 
125 
 
muscle mass and adipose tissue remained stable during treatment in both groups. Previous 
chemotherapy in the (neo-) adjuvant setting was positively correlated with an 8% increase of 
the loss of muscle attenuation during the current treatment. In this patient cohort, OS was not 
affected by body composition changes during chemotherapy.  
 
Only three studies so far have reported results regarding longitudinal changes of MA during 
chemotherapy. Similar to our study, an absolute loss of MA in these studies was observed of -
1.1, -2.4 HU [14,24] and -8.1 HU [25], although the smaller losses of MA did not reach 
statistical significance. In the study with a mean decrease of -8.1 HU involving pancreatic 
cancer patients treated with 5-fluorouracil and gemcitabine, patients with larger loss of MA 
during treatment had shorter OS than patients with small alterations in MA (19.3 vs. 35.3 
months, p = 0.03), irrespective of MA at baseline [25]. We did not observe an association 
between decrease in MA and OS in our study, possibly suggesting that a mean decrease of 1.5 
HU is too small to be clinically relevant. However, it must be noted that we excluded patients 
with progressive disease during the current treatment to avoid the impact of progressive 
cancer on body composition, as we aimed to study possible treatment-specific effects on body 
composition. Nevertheless, other clinical factors might be of influence as well, such as 
decreased physical activity and nutritional intake. The true impact of specific systemic 
therapies on muscle remains difficult without reference populations for muscle measurements 
in healthy people using CT-imaging, so studies on this are urgently warranted.  
 
MA is a marker of microscopic fatty infiltration of muscle, and associated with systemic 
inflammation and poor functional status, similar to cancer cachexia [24]. Therefore, patients 
with MA decrease during treatment could possibly represent frail patients with higher risk of 
treatment complications and chemotherapeutic toxicity during successive chemotherapeutic 
regimens [25]. This is supported by the observation in our study that previous chemotherapy 
in the adjuvant setting was associated with larger decrease of MA during the current 
treatment. Explanations for the loss of MA during paclitaxel remain speculative, but might be 
found in several factors, including less physical activity, alterations in muscle composition 
due to taxane-related myalgia and neuropathy, exposure to (adjuvant) chemotherapy in the 
past and the impact of routine administration of co-medication, such as corticosteroids. In our 
study, dexamethasone was administered in all paclitaxel-regimens.  However, it has been 
reported that short-term administration of corticosteroids does not result in corticosteroid-
induced myopathy [26,27]. As a result, it is not likely that the dexamethasone administration 
126 
 
Chapter 5 
 
in the patients treated with paclitaxel have caused the decrease of median MA. Several studies 
have reported that low MA is a negative prognostic factor for overall survival [9,10,25,28-30], 
including a previous study in metastatic breast cancer [8], clearly indicating that having a low 
MA to start with has different prognostic consequences than diminishing MA during 
treatment with normal MA at baseline.  
 
Mixed results are reported about the association between the loss of muscle mass during 
therapy and overall survival [7,13,31]. Overall, studies are hard to compare due to the use of 
different cut-off points of muscle loss to categorize patients. An association between muscle 
mass loss and an impaired OS has been reported in patients with colorectal cancer (≥5% loss 
HR 1.97, p = 0.017 [12] and ≥9% loss HR 4.47, p < 0.01 [14]) and pancreatic cancer (loss 
≥3.8% HR 2.08, p = 0.027) [11]. We did not detect any survival differences when comparing 
patients with loss of muscle mass versus those without. However, these results are hard to 
compare to the abovementioned studies, as no other studies have been conducted investigating 
the course and prognostic impact of muscle mass change during chemotherapy in patients 
with (metastatic) breast cancer.  
 
In this study, the loss of adipose tissue was not associated with OS, which is in concordance 
with a study in oesophageal cancer [32]. In contrast, studies in ovarian cancer [13] and 
pancreatic cancer [7,11] reported a negative association between the loss of VAT and OS. 
However, these results are difficult to compare with our study as half of the patients had 
ascites [13], which complicates VAT measurement. Higher VAT measurements due to 
diminished ascites as a result of a chemotherapeutic response might have influenced the 
survival analyses. The prognostic impact of adipose tissue measurements, especially VAT, 
needs further investigation in patients with metastatic breast cancer.  
 
To our knowledge, this is the first study investigating longitudinal body composition changes 
during chemotherapy, in patients with metastatic breast cancer. Knowledge regarding changes 
in body composition during chemotherapy might be important for clinical decision-making 
because of several reasons. Since increased fat infiltration of muscle represent negative 
metabolic changes, comparable with the metabolic changes occurring in cancer cachexia 
[3,33], patients with loss of MA might be at increased risk for negative clinical outcomes and 
might have lower quality of life due to worse physical function. Furthermore, it has been 
reported that muscle and adipose tissue measurements show higher association with 
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chemotherapeutic pharmacokinetics than body surface area [34]. It could be hypothesized that 
patients with decreasing fat mass might experience more chemotherapeutic toxicity from the 
lipophilic paclitaxel, as a lower volume of distribution to adipose tissue occurs, resulting in 
higher systemic drug levels.  
 
This study has several limitations. Firstly, this was a single-centre retrospective study. 
Secondly, CT-imaging of the abdomen at L3 level was required for muscle measurement, 
which led to the exclusion of a large number of patients without available CT-images. The 
lack of CT-images was mostly due to other imaging diagnostics preferred at our centre, such 
as thoracic X-ray and ultrasound, to diagnose the presence of distant metastases, which is 
common in clinical breast cancer care. Another frequent reason to omit abdominal CT-
imaging is that metastatic lesions are not located in the abdomen. To avoid this, other devices 
and/or other locations to measure muscle mass in breast cancer patients should be explored. 
Nevertheless, as studies investigating muscle parameters in breast cancer are scarce, we chose 
to measure muscle at the L3-level using CT-imaging, as this is regarded the gold standard. To 
determine the amount of selection bias, we compared the results of the included and excluded 
patients. OS of the excluded patients was worse, but this is likely due to the fact that patients 
not able to complete all cycles of first-choice palliative chemotherapy (i.e. regimens involving 
anthracyclins and/or taxanes) have a worse prognosis, as well as patients treated with other 
agents than anthracyclins or taxanes. Therefore, results cannot be generalized to the entire 
population. Furthermore, this might have affected the observation that changes in body 
composition were not associated with survival. However, the aim of this study was to evaluate 
the possibility of excessive muscle wasting during chemotherapy in the absence of 
progressive disease and we were able to investigate this in a group of patients receiving the 
same type of cytotoxic agents and the same number of cycles. Thirdly, the number of the 
patients in the FAC-group was small and a type II statistical error could not be ruled out. 
However, our main interest was the change of muscle mass and muscle attenuation during a 
treatment with muscle-affecting toxicity compared to a treatment regimen without muscle-
affecting toxicity. We assumed that this would provide a better comparison of body 
composition changes due to systemic therapy than choosing a reference group without 
treatment at all.   
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Conclusion 
 
In conclusion, the quality of the muscle significantly decreased during treatment with 
paclitaxel in our patient cohort, while the amount of muscle mass and adipose tissue remained 
stable. In addition, muscle changes in the absence of progressive disease in metastatic breast 
cancer seem not clinically relevant, which could be useful knowledge when exploring future 
possibilities of selecting patients for interventions optimizing muscle mass and attenuation. 
Prospective studies with a larger number of patients are required to confirm the results of this 
study and to investigate the correlation between body composition alterations over time and 
survival. 
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Supplemental Table 1. Comparison patient characteristics of included and excluded 
patients.  
 
 Included (n = 98) Excluded (n = 319) p value 
Age (years) 
 Median (IQR) 
 Unknown 
 
56 (48 – 63) 
0 
 
52 (45 – 61) 
6 
0.07 
Year of diagnosis
b 
 Median (IQR) 
 Unknown 
 
2011 (2008 – 2013) 
0 
 
2007 (2005 – 2011) 
4 
 
<0.001 
Body mass index  
 Median (IQR)c 
 Unknown 
 
26.9 (23.2 – 30.5) 
0 
 
25.7 (22.8 – 29.6) 
90 
0.40 
Hormone receptor status 
 Positive  
 Negative 
 Unknown  
 
73 (74.5%) 
25 (25.5%) 
0  
 
190 (63.8%) 
108 (36.2%) 
21 
0.06 
Her2Neu status  
 Positive 
 Negative 
 Unknown 
 
26 (40.6%) 
38 (59.4%) 
7 
 
90 (31.7%) 
194 (68.3%) 
35 
0.90 
Primary stage IV (%) 
 Unknown 
20 (28.2%) 
0 
83 (26.1%) 
1 
0.79 
Disease free interval (years)
d
 
 Median (IQR) 
 
5.0 (3 - 10) 
 
2.0 (1 – 6) 
 
<0.001 
Time to palliative treatment 
(months)
e 
 Median (IQR) 
 
 
1.0 (0 – 6) 
 
 
1.0 (0 – 7) 
0.38 
Metastatic location 
 Bone 
 Visceral 
 CNS 
 Skin or lymph nodes 
 Multiple locations 
 Unknown 
 
10 (14.1%) 
11 (15.5%) 
0 
8 (11.3%) 
42 (59.2%) 
0 
 
99 (31.5%) 
44 (14.0%) 
10 (31.8) 
36 (11.5%) 
125 (39.8%) 
5 
0.004 
Number of metastatic sites 
 1 
 2 
 3 
 > 3 
 Unknown 
 
28 (39.4%) 
30 (42.3%) 
10 (14.1%) 
3 (4.2%) 
0 
 
184 (58.6%) 
85 (27.1%) 
32 (10.2%) 
13 (4.1%) 
5 
0.005 
Previous chemotherapy 
 Unknown 
26 (36.6%) 
0 
152 (47.9%) 
2 
0.20 
Previous palliative endocrine 
therapy 
 Unknown 
33 (46.5%) 
 
0 
42 (36.5%) 
 
204 
0.22 
aFAC: 5-fluororacil, Adriamycin, cyclophosphamide. 
bDiagnosis of distant metastases. 
cIQR: Interquartile range. 
dDFS: Time between the initial breast cancer diagnosis and the first presentation of distant metastases for 
patients with M0 presentation of primary breast cancer.  
eTime to palliative treatment: Time between the first presentation of distant metastasis and the start of the first 
line palliative chemotherapy 
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Supplemental Table 2. Patient characteristics of all patients. 
 
 FAC (n = 35) Paclitaxel (n = 100) p value 
Age (years) 
 Median (IQR) 
 
55 (46 – 62) 
 
53 (45 – 61) 
 
0.25 
Year of diagnosis
a 
 Median (IQR) 
 
2009 (2007 – 2012) 
 
2011 (2008 – 2013) 
 
0.03 
Body mass index  
 Median (IQR) 
 
26.7 (23.6 – 30.9) 
 
25.9 (22.5 – 29.8) 
 
0.59 
Hormone receptor status 
 Positive  
 Negative 
 Unknown  
 
25 (71.4%) 
10 (28.6%) 
0 
 
71 (71%) 
29 (29%) 
0 
1.00 
Her2Neu status  
 Positive 
 Negative 
 Unknown 
 
2 (5.7%) 
32 (91.4%) 
1 (2.9%) 
 
33 (33%) 
57 (57%) 
10 (10%) 
0.001 
Primary stage IV (%) 13 (37.1%) 20 (20%) 0.07 
Disease free interval (years)
b
 
 Median (IQR) 
 
7.5 (2 – 10.5) 
 
3 (2 – 8.8) 
 
0.11 
Time to palliative treatment 
(months)
c 
 Median (IQR) 
 
 
1 (0-6) 
 
 
1 (0 – 7) 
 
 
0.66 
Metastatic location 
 Bone 
 Visceral 
 Brain 
 Skin or lymph nodes 
 Multiple locations 
 
6 (17.1%) 
6 (17.1%) 
0 (0%) 
4 (11.4%) 
19 (54.3%) 
 
21 (21%) 
17 (17%) 
1 (1%) 
6 (6%) 
55 (55%) 
 
0.73 
Number of metastatic sites 
 1 
 2 
 3 
 > 3 
 
14 (40%) 
14 (40%) 
6 (17.1%) 
1 (2.9%) 
 
43 (43%) 
35 (35%) 
16 (16%) 
6 (6%) 
0.86 
Previous (neo)adjuvant 
chemotherapy 
9 (25.7%) 56 (56%) 0.003 
Previous endocrine therapy 
No endocrine therapy 
(Neo-)adjuvant 
Palliative 
Both adjuvant and palliative 
Unknown 
 
19 (54.3%) 
7 (20.0%) 
5 (14.3%) 
4 (11.4%) 
0 
 
42 (42%) 
25 (25%) 
13 (13%) 
17 (17%) 
3 (3%) 
0.31 
LSMI baseline
d
 38.4 (35.2 – 44.2) 37.8 (32.8 – 41.0) 0.06 
MA baseline 31.5 (26.6 – 38.2) 31.0 (25.2 – 41.0) 0.81 
SAT baseline (Median + IQR) 
 
191.4 (150.5 – 230.3) 203.5 (150.6 – 250.2) 0.69 
VAT baseline 109 (53.9 – 126.2) 101.0 (61.2 – 144.1) 0.89 
IMAT baseline 16.6 (10.0 – 21.8) 14.6 (9.6 – 22.2) 0.83 
TAT
,g
 baseline 317.9 (211.4 – 364.9) 308.1 (249.3 – 393.1) 0.75 
aDiagnosis of distant metastases. 
bDFS: Time between the initial breast cancer diagnosis and the first presentation of distant metastases for 
patients with M0 presentation of primary breast cancer.  
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cTime to palliative treatment: Time between the first presentation of distant metastasis and the start of the first 
line palliative chemotherapy. 
dBefore chemotherapy 
eMissing: n = 4 
fMissing: n = 11 
gTAT: Sum of SAT, VAT and IMAT.  
 
Abbreviations: FAC: 5-fluororacil, Adriamycin, cyclophosphamide; IQR: Interquartile range; DFS: Disease-free 
survival; LSMI: Lumbar skeletal muscle index; MA: Muscle attenuation; SAT: Subcutaneous adipose tissue; 
VAT: Visceral adipose tissue; IMAT: Intramuscular adipose tissue; TAT: Total adipose tissue 
 
Supplemental table 3. Changes in body composition during chemotherapy of all 
patients. 
 
Muscle change during chemotherapy, median (IQR) 
 FAC p
a  Paclitaxel pa  
LSMI (cm
2
/m
2
) -1.1 (-2.9 - +0.9) 0.05  -0.4 (-2.3 – +1.4) 0.49  
MA (HU) -0.5 (5.1 – +2.5) 0.56  -0.8 (-4.6 - +2.3) 0.02  
SAT -17.3 (-35.5 - +5.1) 0.02  -8.2 (-26.6 - +16.2) 0.29  
VAT -1.0 (-18.0 - +10.3) 0.41  -0.6 (-19.3 - +11.1) 0.52  
IMAT +0.2 (-2.3 - +3.3) 0.34  +0.9 (-2.0 - +3.2) 0.04  
TAT -20.0 (-43.0 - +23.9) 0.12  -3.9 (-41.3 - +28.6) 0.57  
aThe difference in muscle parameters during chemotherapy (after – before) within each treatment group using the 
Wilcoxon signed rank test.  
 
Abbreviations: FAC: 5-fluororacil, Adriamycin, cyclophosphamide; IQR: Interquartile range; LSMI: Lumbar 
skeletal muscle index; MA: Muscle attenuation; HU: Hounsfield Unit; SAT: Subcutaneous adipose tissue; VAT: 
Visceral adipose tissue; IMAT: Intramuscular adipose tissue; TAT: Total adipose tissue 
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Supplemental figure. Kaplan Meier curve for overall survival between included and 
excluded patients. 
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Abstract 
 
Background: Assessing physical reserve in older cancer patients before treatment-decision 
making remains challenging. The maintenance of physical independence during therapy is 
sometimes just as important for these patients as oncological outcomes. Recently, sarcopenia 
has been recognized as a possible important prognostic factor for outcome in cancer patients. 
We  investigated the association between different levels of sarcopenia and the decline of 
physical independence during chemotherapy in older cancer patients (≥ 65 years). 
Methods: Sarcopenia was divided into presarcopenia, sarcopenia and severe sarcopenia 
according to an international consensus and were related to physical independence determined 
by measuring instrumental activities of daily living (IADL), using binary logistic regression 
models. CT-based muscle mass is necessary to diagnose sarcopenia and was related to 5 
functional tests, in order to investigate whether these easy to perform tests could replace the 
more invasive CT-based muscle measurement. 
Results: A total of 131 patients were included (median age 72 years). The prevalence of 
presarcopenia, sarcopenia and severe sarcopenia was 47.7%, 18.5% and 7.7%, respectively. 
Compared to no sarcopenia, only severe sarcopenia seemed associated with a decline of 
physical independence after chemotherapy (OR 5.95, 95% CI 0.76 – 46.48). Muscle mass was 
only significantly associated with muscle strength, but not with tests measuring physical 
function. 
Conclusion: The level of sarcopenia might be a useful tool in addition to routine oncological 
assessment to identify older cancer patients with increased risk of physical decline after 
chemotherapy.  
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Introduction 
 
Sarcopenia, initially defined as a low muscle mass (less than 2 standard deviations below the 
mean of a young reference group) according to the definition of Baumgartner et al [1], has 
been related to physical disability [2, 3] and mortality [4] in older adults. In the presence of 
cancer, low skeletal muscle mass has emerged as a novel negative prognostic factor for 
survival as well as for treatment tolerability [5, 6]. In oncological research, increased attention 
is paid to the prognostic value of CT-based low muscle mass, which on some occasions is 
easy to perform using already available routine staging CT-scans. 
 
However, evidence in the literature suggests that there is no linear correlation between the 
loss of muscle mass and the loss of the clinically more relevant muscle strength [2, 7, 8], with 
muscle strength being more prognostic for mortality than muscle mass [9], and suggesting 
that the geriatric syndrome sarcopenia is more than muscle loss alone. Studies in elderly 
people have revealed that changes in muscle mass only explained 5% of the variability of 
muscle strength decline [10, 11]. Therefore, it is currently recommended to redefine 
sarcopenia as the loss of muscle mass in combination with the loss of muscle strength and/or 
impaired physical performance [7]. In the European consensus on the definition of sarcopenia, 
several levels of sarcopenia are identified, i.e. presarcopenia (solitary low muscle mass), 
sarcopenia (low muscle mass + low muscle strength or slow walking speed) and severe 
sarcopenia (low muscle mass + both low muscle strength and slow walking speed) [7].  
 
Irrespective of oncological outcomes, the physical status of an individual patient and 
maintaining the level of physical independence remains one of the key challenges in the 
treatment of the older cancer patient. Currently, the most commonly used parameters in 
oncological care to assess physical function of patients are the ECOG or WHO performance 
scores. These scores, however, have a low sensitivity to detect the heterogeneous distribution 
of physical reserve that characterizes older cancer patients [12, 13].  
 
Therefore, the purpose of this study was to determine the association between the different 
levels of sarcopenia before chemotherapeutic treatment and the maintenance of physical 
independence after chemotherapy. Muscle mass measurement is the common component 
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between all levels of sarcopenia, but requires imaging diagnostics (CT-imaging in this study), 
and furthermore, there is no uniform definition of low muscle mass yet, which hampers 
muscle mass measurement in routine clinical care. The second aim of this study was 
therefore, to correlate CT-based muscle mass to easy to perform functional tests, in order to 
investigate the possibility of replacing CT-based muscle mass with tests requiring lower costs 
and less patient burden.   
 
Methods 
 
Study design  
 
In this single center prospective cohort study, patients diagnosed with cancer above 65 years 
of age underwent individual tests assessing physical status (as part of a comprehensive 
geriatric assessment) before, halfway and after completion of chemotherapeutic treatment 
between October 2013 and May 2016. Exclusion criteria were chemotherapeutic treatment 
less than 3 months prior to inclusion and the absence of abdominal CT-images. Muscle 
measurements were obtained using abdominal CT-images acquired during routine care and 
correlated to the functional tests, which included walking speed, the five-times-sit-to-stand 
test (FTSTS), handgrip strength, the steep ramp test and the Timed Up and Go (TUG). The 
time between CT-imaging and geriatric assessment had to be less than 3 months. The levels of 
sarcopenia were categorized into presarcopenia, sarcopenia and severe sarcopenia, according 
to the recommendation of the European Working Group on Sarcopenia in Older People [7] 
and were related to diminished physical independence after completion of therapy. Physical 
independence was determined by the measurement of instrumental activities of daily living 
(IADLs) according to the scale of Lawton and Brody [14] (Appendix A). IADLs included 
grocery shopping, meal preparation, telephone use, household and independence in travelling, 
medication management and financial management. A score of 0 points on the IADL-scale of 
Lawton and Brody was considered being fully IADL-dependent and a score of 8 points was 
considered full IADL-independence. A clinically significant decline in IADL-independence 
was defined as either a decline of ≥3 points immediately after completion of chemotherapy or 
a decline of ≥2 points 1 year after the completion of chemotherapy, compared to baseline. The 
study was approved by the central review board (METC 2015_08, NL47633.101.15). All 
patients provided written informed consent prior to inclusion.  
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Muscle measurements and definitions 
 
All muscle measurements were performed at one transversal CT-image (slice thickness 3 mm, 
Brilliance 64 CT or Brilliance 40 CT, Philips, Best, the Netherlands) at the L3-level using 
slice-o-matic software (Slice-o-matic, Tomovision, Canada) [15]. Total abdominal muscle 
area (TAMA) in cm
2
 was used as parameter for muscle mass, as TAMA at L3 is 
representative of total body muscle mass [16]. TAMA was corrected for height according to 
the formula TAMA/height
2
, resulting in a skeletal muscle index (SMI) in cm
2
/m
2
. 
Presarcopenia was defined as solitary low muscle mass (LMM) according to previously 
published cut-off points [17]. In patients with a body mass index (BMI) <25 kg/m
2
, LMM 
was defined as a SMI <43 cm
2
/m
2 
(males) or a SMI <41 cm
2
/m
2 
(females). In patients with a 
BMI ≥25 kg/m2, LMM was defined as a SMI <53 cm2/m2 (males) or a SMI <41 cm2/m2 
(females).  Sarcopenia was defined as LMM plus either a walking speed ≤0.80 m/s or a low 
handgrip strength (<26 kg for males and <16 kg for females, which was based on a pooled 
sample of 9 studies involving 26,625 community-dwelling elderly) [18]. Severe sarcopenia 
was defined as LMM and both slow walking speed and low handgrip strength. HU-thresholds 
to identify muscle tissue were set between -29 and +150 HU, as previously published [19]. 
 
Functional tests assessing physical status 
 
Functional tests reflecting muscle strength (FTSTS, grip strength and the steep ramp test) and 
physical function (walking speed and TUG) were obtained from the geriatric assessment and 
related to CT-based muscle mass on a continuous scale.  
1. FTSTS: The five-times-sit-to-stand test (FTSTS) [20] was used as assessment for lower 
extremity strength [21]. Patients were instructed to sit on a chair standing against the wall 
with their arms crossed over their chest. The performance of the test was demonstrated, after 
which the patient had to rise five times from the chair to a full stand as fast as possible.  The 
time to complete this from the moment that the investigator stated “go” until the return to 
seated position for the fifth time was recorded in seconds.  
2. Grip strength: Hand grip strength was measured using a Jamar hand dynamometer 
(Lafayette Instrument Co., Lafayette, IN, http://www.lafayetteinstrument.com), which 
measures handgrip force in kilograms (kg) per square inch. Measurements were performed 
alternately two times for both hands, after which average grip strength for each hand was 
calculated. The highest average was used for the analysis.  
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3. Steep ramp test: A steep ramp test was performed to determine short maximal exercise 
capacity [22]. Patients were instructed to cycle on a cycle ergometer with a pedal frequency 
between 70 and 90 rounds per minute (rpm), starting at 0 watt (W). After 10 seconds of 
cycling at 0W, the workload was increased by 25W every 10 seconds until exhaustion or 
when the pedal frequency dropped below 60 rpm. The maximal workload in W per kg body 
weight was recorded alongside the cycle time and heart rate at the end of the test.  
4. Walking speed: Walking speed in meters per second (m/s) was determined over an 8 m-
course at usual pace.  
5. TUG: The timed up and go (TUG) was used as assessment for functional mobility [23]. 
The patient was instructed to rise from a seating position (approximately 46 cm height), walk 
over a 3 m-course at usual pace, turn around, walk back and sit down again. The time to 
complete this assessment differs according to age.  
 
Statistical analyses 
 
Continuous variables were described as median + interquartile range (IQR) and categorical 
variables as percentages. Comparisons between males and females were performed using 
Mann-Whitney U tests for continuous variables, Fisher exact tests for categorical variables 
with 2 categories and chi-square tests for categorical variables with more than 2 categories. 
To assess the impact of the heterogeneity in tumor type and disease stage in this cohort on the 
results of our analysis, the following parameters were compared between the patients with 
severe sarcopenia and all other patients: age, body mass index (BMI), gender, WHO score, 
tumor type, disease stage, treatment purpose (curative or palliative), IADL limitations before 
chemotherapy, ADL limitations before chemotherapy, nutritional status, cognition and 
response to chemotherapy. We divided “tumor type” into the following categories: aggressive 
hematological malignancies, indolent hematological malignancies, non-metastatic solid 
malignancies and metastatic solid malignancies. Univariable and multivariable binary logistic 
regression models were used to determine associations between levels of sarcopenia and the 
decline of physical independence after chemotherapy. The dependent variable in these models 
was the decline of physical independence (yes/no). The independent variables were age, 
gender, impaired cognition (Mini Mental State Evaluation ≤24 vs. >24), tumor type, treatment 
purpose, response to chemotherapy, IADL at baseline and the level of sarcopenia before 
treatment. It must be noted that the prognostic impact of disease stage differs considerably 
between solid and hematological malignancies. Therefore, the prognostic impact of disease 
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stage might be better addressed using the purpose of treatment (curative or palliative) as 
variable, than the actual disease stage itself. The level of sarcopenia was categorized into no 
sarcopenia, presarcopenia, sarcopenia and severe sarcopenia. Interaction effects between 
sarcopenia levels/tumor type and sarcopenia/disease stage were assessed by adding these 
interaction terms separately to the multivariable logistic regression model, and testing their 
significance with a likelihood-ratio test. A Hosmer-Lemeshow test was performed to evaluate 
the goodness-of-fit of the multivariate binary logistic regression model. 
Spearman’s rank correlation was used to determine univariate associations between functional 
tests and muscle parameters on a continuous scale in the entire cohort; for this analysis the 
first available measurement of functional tests was used for each patient. Linear mixed 
models were used to determine multivariate associations between the repeated measurements 
of functional tests and muscle parameters on a continuous scale. This statistical method 
accounts for missing observations in the dependent variable. The dependent variables in the 
linear mixed models were the functional tests, with a separate linear mixed model for each 
functional test. The independent variables were age, gender, body mass index (BMI), the time 
of assessment, treatment purpose (palliative vs. curative intent), tumor type (non-
hematological vs. hematological) and muscle mass (SMI in cm
2
/m
2
). The time of assessment 
was categorized into assessment before, during, after and 1 year after chemotherapeutic 
treatment. A random intercept was included in the linear mixed models to account for the 
within-subject correlations. All analyses were performed using SPSS version 24.0 (SPSS Inc., 
Chicago, IL, USA) with a two-sided significance level of 0.05. 
 
Results 
 
Patient characteristics 
 
In total, 142 patients underwent geriatric assessment between October 2013 and May 2016 
with a total of 247 abdominal CT-images available for muscle measurements. Of these, 36 
CT-images were excluded because of no accompanying geriatric assessment and 5 because of 
technical reasons regarding the Slice-o-matic preventing the assessment of muscle mass and 
attenuation. Eventually, 206 combinations of CT-imaging and functional measures, derived 
from 131 individual patients were included in the analysis. The median time between the CT 
scan and the measurement of geriatric parameters was 21.5 days (range 0 – 90, IQR 8 – 44). 
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The median age in the entire cohort was 72 years (IQR 69 – 78) and 73 (55.7%) were male 
(table 1). Compared to females, males had significantly more muscle mass (median 45.3 
cm
2
/m
2
 
vs
. 36.7 cm
2
/m
2
, p < 0.001) and greater grip strength (median 32.0 vs. 18.5 kg, p < 
0.001). Other functional measures were similar between males and females (table 2).  
 
Table 1. Patient characteristics (n = 131) 
 
Variable N (%) 
Age 
 <75 years 
 ≥75 years 
 
78 (59.5) 
53 (40.5) 
Gender 
 Male 
 Female 
 
73 (55.7) 
58 (44.3) 
BMI, median (IQR) 26.3 (23.4 – 29.0) 
WHO performance score 
 0 
 1 
 2 
 3 
 Unknown 
 
29 (29.0) 
59 (59.0) 
11 (11.0) 
1 (1.0) 
31  
 
Tumor type
a 
 Aggressive haematological malignancies 
 Indolent haematological malignancies 
 Non-metastatic solid malignancies 
 Metastatic solid malignancies 
 
29 (22.1%) 
 
34 (26.0%) 
41 (31.3%) 
27 (20.6%) 
Disease stage 
 Stage I 
 Stage II 
 Stage III 
 Stage IV 
 Unknown 
 
6 (4.6) 
19 (14.6) 
46 (35.3) 
59 (45.4) 
1  
Treatment purpose 
 Curative 
 Palliative 
 
69 (52.7) 
62 (47.3) 
IADL limitations
b
 
 Yes 
 No 
 Unknown 
 
44 (36.1) 
78 (63.9) 
9 
ADL limitations
b 
 Yes 
 No 
 
40 (30.5) 
91 (69.5) 
Nutritional status 
 Malnourished (MNA <17) 
 
6 (4.6) 
Cognition 
 Impaired (MMSE ≤ 24) 
 
15 (11.5) 
Abbreviations: BMI: Body mass index; WHO: World Health Organization; IADL: Instrumental activities of 
daily living; ADL: Activities of daily living; MNA: Minimal nutritional assessment; MMSE: Mini mental state 
examination  
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Association between sarcopenia levels and decline of physical independence 
 
The prevalence of presarcopenia, sarcopenia and severe sarcopenia were 47.7% (n = 62), 
18.5% (n = 24) and 7.7% (n = 10), respectively.  Compared to men, slightly more women had 
severe sarcopenia, but this difference was not statistically significant (p = 0.34). The patients 
with severe sarcopenia were older and more often malnourished (MNA <17). Strikingly, 9 of 
the 10 patients with severe sarcopenia were diagnosed with a hematological malignancy, 
equally distributed between aggressive and indolent tumors. Of the 27 patients with 
metastases of solid tumors, no patients were classified as severely sarcopenic (table 3). 
 
Table 2. Muscle parameters and functional measures according to gender. 
 
 Male (n = 73) Female (n = 58) p 
Muscle mass (cm
2
/m
2
) 45.3 (41.6 – 50.4) 36.7 (33.4 – 41.9) <0.001 
Sarcopenia level 
 Normal 
 Presarcopenia 
 Sarcopenia 
 Severe sarcopenia 
 
19 (26.0) 
36 (49.3) 
15 (20.5) 
3 (4.1) 
 
15 (26.3) 
26 (45.6) 
9 (15.8) 
7 (12.3) 
0.35 
 
Walking speed (m/s) 1.0 (0.8 – 1.2) 1.0 (0.8 – 1.2) 0.63 
FTSTS (seconds) 13.3 (11.2 – 16.6) 13.9 (11.1 – 19.3) 0.63 
Hand grip strength (kg) 32.0 (27.5 – 38) 18.5 (13.5 – 21.0) <0.001 
Steep ramp test (W/kg) 2.2 (1.7 – 2.6) 2.0 (1.2 – 2.3) 0.04 
Timed up and go (seconds) 8.8 (7.8 – 10.6) 9.5 (8.2 – 11.4) 0.25 
aThe levels of sarcopenia are described as numbers (%), the other measures as median + interquartile range 
 
Abbreviations: m/s: Meters per second; FTSTS: Five-times-sit-to-stand test; W/kg: Watt per kilogram 
 
Before chemotherapeutic treatment, 63.9% of the patients were fully physically independent 
(IADL-score of 8), which decreased to 56.3% after completion of chemotherapy. A clinically 
significant decline of physical independence (i.e. an IADL-decline of ≤2 points immediately 
after chemotherapy or ≤3 points 1 year after chemotherapy) was observed in 15 patients 
(11.5%). The course of physical independence during therapy could not be observed in a fair 
number of patients (n = 38, 29%) because these patients did not return for follow-up geriatric 
assessment (GA). The main reasons for this were physical decline, causing follow-up GA to 
be a too large burden (23.7%) and progressive disease, resulting in another line of 
chemotherapeutic treatment, death or best supportive care (28.9%). In the analysis, these 
patients were therefore incorporated into the group of patients having clinically significant 
decline of physical independence.  
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Table 3. Characteristics of patients with severe sarcopenia. 
 
 Severe sarcopenia 
(n = 10) 
Normal muscle mass or 
non-severe sarcopenia  
(n = 121) 
P 
Age, median (IQR) 80.5 (72.5 – 82.3) 72 (69 – 77) 0.02 
BMI, median (IQR) 26.3 (20.8 – 30.5) 26.3 (23.4 – 28.8) 0.82 
Gender 
 Male 
 Female 
 
3 (30.0) 
7 (70.0) 
 
70 (57.9) 
51 (42.1) 
<0.001 
WHO performance score 
 0 
 1 
 2 
 3 
 
2 (20.0) 
2 (20.0) 
6 (60.0) 
0 
 
29 (24.0) 
57 (47.1) 
6 (5.0) 
1 (0.8) 
<0.001 
Tumor type 
 Aggressive haematological 
malignancies 
 Indolent haematological 
malignancies 
 Non-metastatic solid 
malignancies 
 Metastatic solid malignancies 
 
5 (50.0) 
 
4 (40.0) 
 
1 (10.0) 
 
0 
 
24 (19.8) 
 
30 (24.8) 
 
40 (33.1) 
 
27 (22.3) 
0.02 
Disease stage 
 I 
 II 
 III 
 IV 
 Unknown 
 
1 (10.0) 
1 (10.0) 
3 (30.0) 
5 (50.0) 
0 
 
5 (4.2) 
18 (15.0) 
43 (35.8) 
54 (45.0) 
1 
0.98 
Treatment purpose 
 Curative 
 Palliative 
 
6 (60.0) 
4 (40.0) 
 
63 (52.1) 
58 (47.9) 
0.75 
Disease response 
 Complete remission 
 Partial remission or stable 
disease 
 Refractory or progressive 
disease 
 Deceaseda  
 Unconfirmed complete 
remission
b
 
 Unknown 
 
0 
5 (50.0) 
 
4 (40.0) 
 
0 
0 
 
1 
 
33 (27.5) 
42 (35.0) 
 
15 (12.5) 
 
3 (2.5) 
27 (22.5) 
 
1 
0.02 
IADL limitations 6 (60.0) 38 (33.6) 0.14 
ADL limitations 9 (90.0) 31 (25.6) <0.001 
MNA <17 2 (20.0) 4 (3.3) 0.02 
MMSE ≤24 2 (22.2) 13 (10.7) 0.28 
aDeceased during chemotherapy, no response monitoring 
bComplete remission not confirmed after adjuvant chemotherapy for a solid malignancy, but no evidence of 
disease. After such treatments, imaging diagnostics to confirm response are not regularly conducted in our 
centre.  
 
 
Abbreviations: ADL: Activities of daily living; BMI: Body mass index; IADL: Instrumental activities of daily 
living; IQR: Interquartile range; MMSE: Mini mental state examination; MNA: Minimal nutritional assessment 
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In the univariable logistic regression models, with decline of physical independence as 
dependent variable, the only parameter associated with decline of physical independence  
during chemotherapy was refractory or progressive disease after completion of treatment 
(univariable OR 7.54, 95% CI 1.95 – 29.14, p = 0.003) with complete remission used as 
reference category. Complete or partial disease response, tumor type, palliative treatment 
purpose, and physical function at baseline and the presence of distant metastases of a solid 
malignancy were not significantly associated with a decline of physical independence after 
chemotherapy.  
 
Table 4. Associations between sarcopenia and decline of physical independence. 
 
 Univariable Multivariable
a 
 OR 95% CI p OR 95% CI p 
Age 1.07 1.00 – 1.15 0.05 1.07 0.99 – 1.16 0.10 
Impaired cognition
b
 3.36 0.99 – 11.43 0.05 3.67 0.84 – 15.96 0.08 
IADL baseline
c 0.88 0.67 – 1.16 0.37 - - - 
Tumor type 
 Solid metastatic 
 Solid non-
metastatic 
 Haematological 
aggressive 
 Haematological 
indolent 
 
Ref 
1.71 
 
1.26 
 
1.65 
 
Ref 
0.54 – 5.50 
 
0.37 – 4.36 
 
0.51 – 5.38 
0.79 
Ref 
0.36 
 
0.71 
 
0.42 
- - - 
Palliative treatment
d 1.00 0.46 – 2.18 0.99 - - - 
Response
 
 Complete remission 
 Partial remission 
 Refractory or 
progression 
 Deceased 
 Unconfirmed 
complete remission
e
 
 
Ref 
 
2.15 
7.54 
 
9.60 
1.80 
 
Ref 
 
0.67 – 6.90 
1.95 – 29.14 
 
0.72 – 153.15 
0.47 – 6.91 
0.03 
Ref 
 
0.20 
0.003 
 
0.09 
0.39 
- - - 
Sarcopenia level 
 Normal 
 Presarcopenia 
 Sarcopenia 
 Severe sarcopenia 
 
Ref 
1.82 
2.56 
4.79 
 
Ref 
0.63 – 5.24 
0.72 – 9.08 
0.98 – 23.56 
 
0.23 
Ref 
0.27 
0.15 
0.05 
 
Ref 
2.90 
2.59 
5.95 
 
Ref 
0.82 – 10.18 
0.53 – 12.52 
0.76 – 46.48 
0.28 
Ref 
0.10 
0.24 
0.09 
 
       
aThe multivariable logistic regression analysis was performed with age, impaired cognition, and sarcopenia level 
as independent variables.  
bMMSE ≤24 
cAccording to the scale of Lawton and Brody (score 0-8, with 8 fully physically independent) 
d
Versus curative treatment (curative = reference category) 
eComplete remission not confirmed after adjuvant chemotherapy for a solid malignancy. After such treatments, 
imaging diagnostics to confirm response are not regularly conducted in our centre.  
 
Abbreviations: BMI: body mass index; MMSE: Mini mental state examination; IADL: Instrumental activities of 
daily living 
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Presarcopenia (solitary low muscle mass) and sarcopenia before chemotherapeutic treatment 
did not result in a clinically significant decline of physical independence after chemotherapy, 
compared to patients without sarcopenia (OR 1.82, 95% CI 0.63 – 5.24, p = 0.27 and OR 
2.56, 95% CI 0.72 – 9.08, p = 0.15, respectively) (table 4). Severe sarcopenia seemed to be 
predictive of a decline of physical independence, with high ORs in both the univariable and 
multivariable regression models, although statistical significance was not reached (OR 4.79, 
95% CI 0.98 – 23.56, p = 0.05 and OR 5.95, 95% CI 0.76 – 46.48, p = 0.09, respectively) 
(table 4). The interaction effects between sarcopenia level and tumor type and between 
sarcopenia level and disease stage were both statistically not significant (p = 0.26 and p = 
0.08, respectively), suggesting that the association between sarcopenia levels and the decline 
of physical independence was not influenced by tumor type or disease stage. 
 
Table 5. Associations between CT-based muscle mass and functional tests.
a
  
 
 Muscle mass (continuous scale) 
 Coefficient 95% CI p 
Walking speed
b -0.001 -0.01 – 0.01 0.74 
FTSTS
b -0.31 -0.51 - -0.11 0.002 
Hand grip strength
b 0.04 -0.10 – 0.19 0.56 
Steep ramp test
b 0.02 0.002 – 0.04 0.03 
Timed up and go
b 0.002 -0.17 – 0.18 0.98 
aA total of 206 measurements were analyzed, derived from 131 individual patients: before chemotherapy: 124; 
halfway chemotherapy: 41; after chemotherapy: 35; 1 year after the start of chemotherapy: 6. 
bLinear mixed models corrected for age, BMI, gender, tumor type (non-haematological vs. haematological), 
treatment purpose (palliative vs. curative) time of assessment and muscle mass, with the functional tests as 
dependent variables.  
 
Correlation between CT-based muscle mass and physical function (walking speed and 
TUG). 
 
Overall, the amount of muscle mass on CT-images showed no correlation with the functional 
tests reflecting physical function (i.e. walking speed and the TUG) using Spearman’s rank 
correlation (walking speed rho = +0.05, p = 0.48, TUG rho = -0.04, p = 0.55). In the linear 
mixed models, the associations between both walking speed and the TUG and muscle mass 
were not statistically significant (table 5). 
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Correlation between CT-based muscle mass and muscle strength (FTSTS, handgrip 
strength and steep ramp test). 
 
In contrast, muscle mass on a continuous scale was significantly associated with functional 
tests reflecting muscle strength, demonstrated by Spearman’s rank correlation coefficients of -
0.20 (p = 0.004), +0.51 (p < 0.001) and +0.19 (p = 0.01) for the FTSTS, grip strength and the 
steep ramp test, respectively.  After correction for age, BMI, gender, tumor type and treatment 
purpose, and the time of assessment using linear mixed models, the FTSTS and the steep 
ramp test in Watt/kg were still significantly associated with the amount of muscle mass on CT 
(coefficient -0.31, 95% CI -0.51 - -0.11, p = 0.002 and coefficient +0.02, 95% CI 0.002 – 
0.04, p = 0.03 respectively). (table 5).  
 
Discussion 
 
In this study, the level of sarcopenia seemed positively correlated with the level of physical 
dependence according to the IADL-scale of Lawton and Brody. High ORs for the decline of 
physical independence were observed in the relatively small group of patients with severe 
sarcopenia (n = 10), indicating that these patients were at risk for a clinically significant 
decline of physical independence after treatment, irrespective of the etiology of this decline. 
These results need to be confirmed in a larger study cohort since statistical significance was 
not reached yet. The only statistically significant predictor of physical decline in this study 
was refractory or progressive disease during chemotherapy. However, treatment response is 
not available at the start of treatment, so cannot be used to estimate the risk of decline of 
physical independence prior to the start of therapy. Therefore, we believe that other 
parameters, including pre-treatment sarcopenia levels, deserve further research as prognostic 
markers for physical decline. Notably, 40% of the patients with severe sarcopenia were 
classified as having a WHO performance score of 0 or 1 by their treating physician (data not 
shown), i.e. were considered physically fit for chemotherapeutic treatment. This indicates that 
assessing the level of sarcopenia might be a useful tool to identify patients at risk of physical 
dysfunction after chemotherapy in older cancer patients in addition to the routine oncological 
assessment. 
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In oncological research, CT-based muscle measurements as prognostic markers for clinical 
outcomes are a field of increasing interest. Low muscle mass (LMM), i.e. presarcopenia, has 
been related to poor oncological outcomes in terms of survival [5] and chemotherapeutic 
toxicity [24]. Studies investigating the association of CT-based muscle measurements with 
patient reported outcomes, such as physical dependence, are scarce while these outcomes are 
particularly important in older cancer patients. Furthermore, in most oncological studies, no 
distinction is made between solitary LMM (presarcopenia) and the syndrome sarcopenia. The 
necessity of this in oncological research is intensively debated. Solitary LMM is frequently 
called sarcopenia in the oncological literature, which in fact is a misnomer. Our study 
revealed that the majority of patients with LMM on CT (n = 97) did not meet the diagnostic 
criteria for sarcopenia (only n = 34) and that patients with presarcopenia only did not have an 
increased risk of physical decline during treatment. This is supported by recent studies in 
colorectal and gastric cancer, reporting that sarcopenia has a stronger prognostic impact than 
LMM alone [6, 25], further underlining the importance to distinguish LMM from sarcopenia. 
 
Muscle mass measurement is the key component in diagnosing sarcopenia, but the method of 
muscle measurement is contentious and there is no consensus on how to define muscle mass. 
Furthermore, CT-based muscle measurement might not always be available. Therefore, we 
related CT-based muscle mass on a continuous scale with easy to perform functional tests. 
CT-based muscle mass showed a significant correlation with functional tests measuring 
muscle strength (the FTSTS and the steep ramp test), but not with functional tests measuring 
physical function (walking speed and the TUG). The associations were not linear, indicating 
that low muscle mass (presarcopenia) and decreased physical reserve are two different 
entities. The observation that CT-based muscle mass did not show a linear association with 
muscle strength and physical function is in line with other observations in the literature. 
Studies in community-dwelling elderly revealed that changes in muscle mass only explained 
5% of the variability of muscle strength decline and that muscle quality seemed to have a 
slightly stronger correlation with physical function than muscle mass [10, 26, 27].  
 
In this study, severe sarcopenia was almost exclusively present in the patients with 
hematological malignancies. The higher incidence of severe sarcopenia in patients with 
hematological tumors might be explained by the fact that a) untreated hematological 
malignancies often cause rapid deterioration of physical performance with possible excessive 
muscle loss and b) patients with few physical reserve more often nevertheless proceed to 
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intensive cytotoxic treatment when compared to patients with solid tumors due to the 
aggressiveness and nature of hematological malignancies. The number of patients with 
metastatic solid tumors was too small to draw robust conclusions about the impact of severe 
sarcopenia on the physical independence of these patients. Further research is needed to 
determine the incidence of (severe) sarcopenia in advanced cancer patients and a possible 
association with clinical outcomes.  
Our study has several limitations. First, both abdominal CT-images combined with functional 
tests had to be available for the analysis, which resulted into the exclusion of 36 
measurements with available CT but without functional tests, mainly because of a poor 
clinical condition preventing further treatment or patients refusing undergoing functional tests 
because of a poor clinical condition. Therefore, a positive selection for patients with good 
physical performance could have occurred. Second, we included a diverse group of patients 
with various tumor types and cytotoxic regimens, which had substantial heterogeneity. 
Therefore, it was not possible to relate the CT-based muscle measurements and functional 
tests to treatment endpoints, such as dose-limiting or dose-interrupting chemotherapeutic 
toxicity, and progression free survival. However, this is the first study investigating the 
association of all levels of sarcopenia according to the current international consensus with a 
clinical endpoint specifically important in older cancer patients and to describe the overlap 
between solitary LMM and the syndrome sarcopenia. Our aim was to investigate a possible 
association between sarcopenia and physical independence in a broad population without 
excluding specific tumor or treatment groups, in order to provide information about a 
population as seen as in the general oncological practice. The results should be interpreted in 
that way, with this  study providing a platform for further studies investigating the exact 
prognostic impact of sarcopenia levels on physical function in well-defined tumor types and 
treatment settings.  Third, we found high ORs for the association between severe sarcopenia 
and the decline of physical independence, suggesting that severe sarcopenia is a negative 
prognostic marker for outcome. However, the results were not statistically significant, 
possibly because of limited power to detect significant outcomes. Furthermore, due to small 
patient numbers, we were not able to conduct a subgroup analysis of the patients with 
hematological malignancies only. Therefore, definitive conclusions about the prognostic 
impact of sarcopenia, especially in hematological malignancies, cannot be drawn, but need to 
be reassessed in further studies with larger patient numbers. When confirmed in further 
studies, it is an easy to evaluate marker, which can be used during treatment decision making 
and patient counseling  before treatment.     
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Conclusion 
 
This study showed that severe sarcopenia seems a promising new marker to identify patients 
at risk for physical decline after chemotherapy, although further studies with larger patient 
numbers are needed to definitely confirm this. Furthermore, functional tests measuring muscle 
strength show some correlation with CT-based muscle mass, but not with tests measuring 
physical function, indicating that low muscle mass and decreased physical reserve are two 
different entities. In future oncological studies on this subject, more attention could be paid to 
the syndrome sarcopenia (impaired muscle function alongside low muscle mass), rather than 
measuring muscle mass only.  
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General discussion and summary 
 
This thesis reported on potential clinical factors influencing treatment decision-making and 
clinical outcomes in cancer patients, with special emphasis on patients with metastatic breast 
cancer (MBC). In patients with Her2 positive MBC, an important prognostic factor is the 
response to Her2-targeted therapy. The current standard of care of first-line Her2-targeted 
therapy in Her2 positive MBC involves dual Her2 blockade with trastuzumab and pertuzumab 
in combination with a taxane [1], while single Her2 blockade is still conducted in further 
treatment lines and in many countries where pertuzumab is not available. Generally, Her2-
targeted therapy is administered until unacceptable toxicity or disease progression [2], 
although there is no evidence on the optimal treatment duration [3]. Furthermore, it is unclear 
whether all patients derive reasonable benefit from Her2-targeted therapies. An attempt to 
provide a possible answer to this question is provided in chapter 2. The remainder of the 
thesis focused on the utility of body composition parameters in oncological care. General 
overviews of the current state of the art regarding body composition measurements in 
oncological care and the evidence on its prognostic impact in solid malignancies is provided 
in chapter 3. In chapter 4 and 5, this was specifically addressed in MBC-patients. The 
position of body composition measurements among other tests assessing physical fitness 
before systemic treatment is studied in chapter 6.  
 
Response to Her2-targeted therapy in metastatic breast cancer.  
 
In chapter 2, we revealed that first-line trastuzumab-containing treatment regimens are less 
effective in patients who have been pretreated with adjuvant trastuzumab, with a median 
overall survival (OS) almost twice as short (17 vs. 30 months, adjusted HR 1.84, p = 0.01). 
Similar results were observed for time to next treatment (7 vs. 13 months, adjusted HR 1.65, p 
= 0.03). Subgroup analyses addressing potential selection bias and multivariate analyses 
addressing possible confounders, including age, disease-free interval, brain- and visceral 
metastases, hormone receptor status and response to taxanes, revealed that this survival 
difference was most likely due to trastuzumab resistance in the patients with failure of 
adjuvant trastuzumab.  
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In the studies performed on HER2-positive MBC, which form the basis of the current 
standard treatment approaches, this group of patients was underrepresented, as these studies 
were mostly done in patients without previous Her2-targeted therapy. A recent study 
reviewing survival data of randomized trials revealed that the number of patients treated with 
adjuvant trastuzumab in these trials was less than 5% [5]. Median progression-free survival 
(PFS) (10.9 months) and OS (33.3 months) of these trial-patients are comparable with PFS 
and OS of our patients without previous trastuzumab treatment  [5]. Clearly, the current 
population of Her2-positive MBC-patients, most treated with trastuzumab in the adjuvant 
setting, might represent a selection of patients with resistance against Her2-targeted therapy, 
either primary or acquired during adjuvant treatment. These results are concerning, as patient 
cohorts with trastuzumab-naïve patients in the first-line setting have been largely disappeared 
in the current daily practice.  
 
Recognizing patients with trastuzumab resistance in advance is an unsolved clinical 
challenge. Trastuzumab has multiple mechanisms of action and therefore also multiple 
mechanisms of resistance, including restored Her2-mediated DNA repair, bypass of the Her2 
signaling pathway and less antibody dependent cell cytotoxicity (ADCC) activity [6]. The 
driving resistance mechanism seems at least partly dependent of the choice of previous 
systemic therapy and is therefore most likely different between patients and time periods. 
Accordingly, it has been reported that trastuzumab resistance after (neo)adjuvant trastuzumab 
treatment, concomitantly administered with chemotherapy, is mostly due to the inhibition of 
Her2-mediated DNA repair [6], while enhancement of ADCC, which is a different resistance 
mechanism, has been reported after dual Her2-blockade in vitro and in mice [7]. This might 
be of particular clinical relevance, since the current standard first-line therapy for Her2 
positive MBC is dual Her2-blockade with trastuzumab and pertuzumab in combination with a 
taxane. In summary, our study revealed possible trastuzumab resistance in Her2 positive 
MBC patients receiving first-line single Her2-blockade with trastuzumab. Further research is 
warranted on the influence of trastuzumab resistance on first-line dual Her2-blockade, which 
is applicable to the future population of Her2 positive MBC patients.  
 
Body composition measurements as prognostic markers in metastatic breast cancer 
 
Body composition analyses include measurements of fat mass and fat-free mass (including 
skeletal muscle), thereby differentiating total body weight into individual compartments. This 
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seems clinically relevant since metabolic activity differs between compartments and 
alterations in individual compartments do not occur synchronically [8, 9]. The use of body 
composition analyses is increasingly studied in cancer patients with muscle mass being the 
most studied body composition parameter. In chapter 3, the literature on low muscle mass 
(LMM) as a prognostic marker for survival and chemotherapeutic toxicity in various solid and 
hematological malignancies is reviewed, confirming LMM as a potentially important 
prognostic maker.  
 
Evidence on the clinical relevance of body composition parameters in breast cancer patients 
is, however, extremely limited. This gap in the literature was addressed in chapter 4 and 5 of 
this thesis. In chapter 4, LMM prior to first-line chemotherapy in MBC patients was not 
associated with overall survival (OS) and time to next treatment (TNT). Strikingly, however, 
the quality of muscle proved to be a better predictor of outcome than quantitative muscle 
mass. Muscle quality can be determined by measuring muscle attenuation (density) using CT-
imaging, with low muscle attenuation (LMA) reflecting the accumulation of microscopic 
adipose tissue in muscle [10]. Our study showed that LMA was associated with both OS 
(adjusted HR 2.04, p = 0.001) and TNT (adjusted HR 1.72, p = 0.01), independently of age, 
tumor biology and metastatic locations.  
 
In concordance with the literature, LMA being a better prognostic marker than LMM is 
reported in patients with other tumor types [11, 12] and in older people without cancer [13, 
14]. The decrease of muscle mass and muscle quality, especially present in older people [15, 
16], is mainly due to age-related endocrine changes, age-related systemic inflammation, 
physical inactivity and malnutrition [17]. Furthermore, muscle quality deteriorates more 
rapidly than muscle mass [18] and is associated with older age and obesity (chapter 3). In the 
presence of cancer, muscle wasting is even further accelerated due to cachexia-related 
processes [19]. In conclusion, LMA is a potentially easy to establish radiological prognostic 
marker in MBC patients undergoing chemotherapy. Future research is needed to investigate 
the impact of LMA on survival a) across different disease stages, b) in older patients with 
MBC, c) during the exploration of other imaging diagnostics measuring muscle than CT and 
d) when conducting interventions optimizing muscle status.  
 
A study in patients with ovarian cancer showed that body composition measures over time 
have more prognostic power than a single measurement at diagnosis [20]. Furthermore, the 
Discussion and summary 161 
 
 
 
possibility of excessive muscle loss during specific systemic treatments and its possible 
clinical impact is unknown. These issues were addressed in chapter 5, in order to further 
explore the prognostic value of LMM and LMA in MBC patients. In this chapter, other 
known body composition parameters (subcutaneous adipose tissue (SAT), visceral adipose 
tissue (VAT) and macroscopic intramuscular adipose tissue (IMAT)) were evaluated as well. 
Changes in body composition during first-line chemotherapy with FAC and paclitaxel were 
determined and related to OS. 
 
The main finding of chapter 5 was that muscle attenuation (MA) significantly decreased 
during treatment with paclitaxel, while muscle mass and adipose tissue remained stable. The 
decrease of MA was associated with previous chemotherapy in the adjuvant setting. No 
changes in body composition were observed during FAC-treatment. OS was not affected by 
the decrease of MA. Importantly, patients with progressive disease during chemotherapy were 
excluded to avoid its impact on muscle wasting, so the results are only applicable in patients 
with controlled disease.  
 
Since OS was not affected by muscle wasting during chemotherapy in our study, our 
observations are contradicted to the study in patients with ovarian cancer. Possible 
explanations for this include the difference in tumor type and the fact that the patients in our 
study were younger, which can cause less prognostic impact of muscle parameters. 
Nevertheless, the results should be interpreted with caution. Firstly, the number of patients 
treated with FAC was small, so the power to detect body composition changes during FAC is 
limited. Further research is warranted to establish body composition alterations during FAC. 
Secondly, we attempted to investigate the impact of specific cytotoxic agents on body 
composition parameters, but this remains difficult since other clinical factors are also 
influencing body composition, such as decreased physical activity and nutritional intake. To 
determine the true impact of specific systemic treatment regimens on body composition, 
reference populations without cancer are needed. 
 
However, chapter 5 shows some results valuable for hypothesis generation on this subject. 
Paclitaxel could possibly induce more muscle wasting (mass or attenuation) due to the 
specific nature of taxane-toxicity, such as neuropathy and myalgia and as a consequence: less 
physical activity and hypothetically, microscopic changes in muscle. Chemotherapy in the 
past was associated with the decrease of MA after adjustment of other clinical factors, 
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including MA at baseline. Almost all these previous regimens were taxane-based, supporting 
the hypothesis that MA is influenced by paclitaxel treatment. This is particularly relevant as 
decreases in MA are associated with systemic inflammation (comparable with the metabolic 
changes observed in cancer cachexia) and poor functional status [21]. Therefore, patients with 
MA decrease might represent frail patients with higher risk of treatment complications during 
successive chemotherapeutic regimens [22]. Longitudinal prospective studies are needed to 
investigate a) the impact of individual cytotoxic agents on body composition and b) the 
correlation of body composition changes during chemotherapy with survival and toxicity.  
 
The road to the implementation of body composition measurements in oncological care 
 
Increasing evidence suggests that body composition measurements should be considered in 
routine clinical care [23, 24]. However, this is hampered by several problems in the research 
field of body composition analyses. Besides describing the prognostic impact of low muscle 
mass in cancer, chapter 3 further describes potential flaws in the methods of muscle 
measurement and is summarized below.  
 
Firstly, there is a lack of consensus on the definition of low muscle mass and on a standard 
approach to measure muscle mass in cancer patients. In almost all oncological studies on this 
subject, sarcopenia is the used term to describe radiological low muscle mass, a term derived 
from the literature on geriatric medicine and which is in concordance with the first proposed 
definition of sarcopenia [25]. However, the relationship between solitary muscle mass loss 
and physical decline and adverse outcomes is inconsistent in older people, i.e. sarcopenia is a 
complex geriatric syndrome with multifactorial etiology [26]. The syndrome “sarcopenia” has 
therefore been redefined to the combination of low muscle mass and either low muscle 
strength, or impaired physical performance [27]. The distinguishement of low muscle mass 
and sarcopenia proved also to be relevant in oncological care, as the prognostic impact of 
sarcopenia on survival was higher than the prognostic impact of solitary LMM in both 
colorectal and gastric cancer [28, 29]. Functional tests measuring muscle strength and 
physical performance are not widely available in oncological care, so more research is needed 
on the relevance of adding functional tests to muscle measurement in cancer patients. 
Recognized tests for determining muscle strength and physical performance respectively are 
hand grip strength measured by a Jamar hand dynamometer (Lafayette Instrument Co. 
Lafayette, IN, http://www.lafayetteinstrument.com) and walking speed at usual pace in meters 
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per second [27]. Recommended cut-offs for low handgrip strength and low walking speed are 
<26 kg in males and <16 kg in females [30] and a walking speed ≤0.80 m/s [27]. However, 
the first step in oncological care is getting the nomenclature of muscle wasting right and 
recognizing that radiological LMM and sarcopenia are two different entitities.   
 
Secondly, the definition of LMM is unclear in terms of reference values to diagnose LMM. In 
geriatric medicine, a widely used definition of LMM is muscle mass below two standard 
deviations below muscle mass in young adults [25], which is usually measured using other 
imaging diagnostics than in oncological care. CT-imaging is considered the gold standard of 
muscle measurement after cadaver validation and most widely used in oncological care due to 
high availability but no such reference populations are described for muscle measurement 
using CT-imaging. These populations are needed to put the reported prevalence and 
prognostic impact of LMM across different oncological studies into perspective and to 
unravel the impact of individual cytotoxic drugs, targeted therapies, and impairments because 
of treatment toxicity on muscle. Future studies constructing reference populations for CT-
based muscle measurements should also adjust these populations for age, gender, race and 
body mass index, as all these parameters influence muscle. Lower muscle mass is particular 
described in older patients [31], patients with lower BMI [32], males [33] and Asian patients 
(compared to caucasian ethnicity) [34]. In the absence of proper reference populations, 
current widely used cut-off points for LMM and LMA are corrected for height and weight and 
proposed by a large study in patients with different solid malignancies after optimum 
stratification for overall survival (table 1)[32].  
 
Table 1. Reference values for muscle parameters.  
 Low muscle mass Low muscle attenuation 
Body mass index <30 kg/m
2 Males: <53 cm2/m2 
Females: <41 cm2/m2 
 
<41 Hounsfield Units 
Body mass index ≥30 kg/m2 Males: <43 cm
2/m2 
Females: <41 cm2/m2 
<33 Hounsfield Units 
 
Thirdly, other body composition parameters than muscle mass are understudied in the 
oncological research field. Studies on muscle quality (attenuation), subcutenaous adipose 
tissue and visceral adipose tissue are scarce. These parameters are, however, also of clinical 
importance because of the possible association between muscle quality and physical function 
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[35, 36] and the possible association of body composition alterations and chemotherapeutic 
pharmacokinetics. It has been described that the systemic clearance of hydrophilic 
chemotherapeutic drugs correlate well with the fat-free mass [37, 38], so in patients with 
LMM in relation to their length and weight, a lower volume of distribution of 
chemotherapeutic drugs is observed, resulting in higher systemic drug levels and 
consequently, more chemotherapeutic toxicity [39-41]. Vice versa, it could be hypothesized 
that low visceral/subcuteneous adipose tissue might be associated with toxicity of lipophilic 
drugs, such as paclitaxel.  
 
A first step towards recognizing which muscle parameters and functional tests could be of 
clinical utility is provided in chapter 6. In this chapter, the association between different 
levels of sarcopenia and a decline of physical independence and the concordance between 
muscle parameters and functional tests were studied in elderly patients with different cancer 
types. Elderly patients were specifically included as these patients might derive the most 
clinical benefit of body composition-based treatment decisions and because adequate 
parameters to assess physical function are warranted in this population. Severe sarcopenia 
seemed positively correlated with the level of physical independence according to the scale of 
Lawton and Brody, while 40% of these patients were classified as having a WHO-
performance score of 0 or 1 according to their treating physician. This indicates that 
sarcopenia levels might serve as an additional clinical marker to assess treatment risks in 
older cancer patients. Further research is needed on the clinical consequences of pre-treatment 
severe sarcopenia in individual tumor types. Functional tests measuring muscle strength 
showed a significant correlation with CT-based muscle mass, while functional tests measuring 
physical performance did not. In contrast, all functional tests showed significant correlations 
with muscle attenuation, supporting the hypothesis that muscle quality is more representative 
for physical function than muscle quantity. The statement that sarcopenia and low muscle 
mass are two different entities was also confirmed in this study, as 75% of the patients were 
considered as having LMM, while only half of the patients fulfilled the diagnostic criteria of 
sarcopenia. However, functional tests were insufficiently able to detect patients with LMM or 
LMA and could therefore not substitute CT-based muscle measurements. 
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Conclusion 
 
Body composition analyses are potential prognostic factors for survival in cancer patients, 
with muscle quality better than muscle quantity. The studies in this thesis are among the first 
confirming this in metastatic breast cancer as well. More specifically for metastatic breast 
cancer, patients with Her2 positive disease derive less clinical benefit from first-line 
trastuzumab-based therapy after failure of trastuzumab in the adjuvant setting. General 
recommendations derived from this thesis for further research on both topics include:  
1. The influence of trastuzumab resistance on first-line dual Her2-blockade.  
2. The exploration of other body composition parameters than muscle mass, i.e. muscle 
attenuation, subcutaneous adipose tissue, visceral adipose tissue and intramuscular adipose 
tissue in cancer patients.  
3. The additional prognostic value of functional tests besides muscle measurements.  
4. The impact of individual cytotoxic agents on body composition.  
5. Possible pharmacokinetic effects of cytotoxic agents due to body composition changes and 
their relation with treatment toxicity.  
 
To work towards the possible use of body composition parameters in oncological care, studies 
are needed to investigate the association of abnormal CT-based body composition 
measurements, derived from reference populations, and clinical endpoints including survival 
and treatment toxicity. In older cancer patients, geriatric endpoints such as the maintenance of 
physical independence or the ability to complete the treatment as planned are often just as 
important as oncological endpoints. From there, intervention trials are needed to study the 
clinical impact of optimizing muscle status.  
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Inleiding 
 
Er is een grote verscheidenheid aan klinische factoren die de behandeling en prognose van 
patiënten met kanker beïnvloedt. Dit proefschrift onderzoekt enkele van deze factoren, 
waarbij het focus ligt op patiënten met uitgezaaide borstkanker. Bij patiënten met Her2 
positieve uitgezaaide borstkanker, is de respons op anti-Her2 therapie een belangrijke 
voorspeller voor een langere overleving. De huidige standaard eerstelijns behandeling bestaat 
uit blokkade van de Her2-receptor, met twee verschillende middelen (trastuzumab en 
pertuzumab) in combinatie met chemotherapie (meestal een taxaan-bevattend schema). In 
vervolgbehandelingslijnen en in veel landen waar pertuzumab (nog) niet beschikbaar is, 
berust de Her2-doelgerichte behandeling nog steeds op blokkade van de Her2-receptor door 
maar één middel, namelijk trastuzumab. Het is echter niet bekend of iedereen wel evenveel 
baat heeft bij deze therapie. In hoofdstuk 2 wordt getracht een antwoord te geven op deze 
vraag. De rest van het proefschrift gaat over de toepasbaarheid van het bepalen van 
lichaamssamenstelling in de oncologische zorg, aangezien steeds duidelijker wordt dat de 
lichaamssamenstelling een belangrijke invloed heeft op de prognose van patiënten met kanker 
en het optreden van bijwerkingen tijdens chemotherapie. De huidige stand van zaken met 
betrekking tot het gebruik van deze parameters in de oncologie en de invloed op de prognose 
wordt beschreven in hoofdstuk 3. In hoofdstuk 4 en 5 wordt dit specifiek verder onderzocht 
bij patiënten met uitgezaaide borstkanker. Verder zou de prognostische waarde van 
veranderingen in lichaamssamenstelling vooral groot kunnen zijn bij patiënten op leeftijd. Dit 
wordt onderzocht in hoofdstuk 6. Het gekozen eindpunt in dit hoofdstuk is vooral voor de 
oudere patiënt van belang, namelijk het behoud van zelfstandig functioneren. Verder wordt in 
hoofdstuk 6 bekeken hoe goed metingen van lichaamssamenstelling overeenkomen met 
testen die veel gebruikt worden om het lichamelijk functioneren van een patiënt in kaart te 
brengen.  
 
Respons op Her2 doelgerichte therapie vanwege uitgezaaide borstkanker. 
 
Uit hoofdstuk 2 blijkt dat eerstelijns behandelingsschema’s met trastuzumab minder effectief 
zijn bij patiënten die in het verleden al eerder met trastuzumab zijn behandeld (in dit geval als 
onderdeel van de adjuvante therapie). Deze patiënten hadden een bijna tweemaal zo korte 
overleving vergeleken met patiënten die nog nooit eerder behandeld waren met trastuzumab 
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(17 vs. 30 maanden). Vergelijkbare resultaten werden gezien voor de tijd tot het nodig was 
om een vervolgbehandeling te starten (7 vs. 13 maanden). Subgroep analyses en correcties 
voor andere klinische factoren lieten zien dat dit overlevingsverschil onafhankelijk bleek van 
leeftijd, de tijd tussen de primaire diagnose en het ontstaan van uitzaaiingen, de locatie van de 
uitzaaiingen, de oestrogeenexpressie en de respons op chemotherapie. De verminderde 
effectiviteit van eerstelijns trastuzumab is het meest waarschijnlijk het gevolg van resistentie 
tegen trastuzumab. 
 
Patiënten met een uitgezaaid mammacarcinoom die eerder trastuzumab hebben gehad als 
adjuvante behandeling hebben een slechtere uitkomst op trastuzumab-bevattende 
chemotherapie. Dit is erg belangrijk omdat deze patiënten ondervertegenwoordigd zijn (maar 
5% van het totaal) in oorspronkelijke klinische studies die de effectiviteit van palliatieve 
Her2-doelgerichte therapie onderzochten. De belangrijkste reden hiervoor is dat veel van deze 
onderzoeken zijn uitgevoerd bij patiënten die nog nooit eerder Her2 doelgerichte therapie 
hebben gehad. De mediane progressie-vrije en totale overleving van deze patiënten is 
vergelijkbaar met die van de patiënten uit onze studie die nog nooit eerder trastuzumab 
hebben gehad. De huidige populatie patiënten met uitgezaaide borstkanker heeft echter 
meestal in de adjuvante setting trastuzumab gehad, en daardoor kan er hier sprake zijn van 
een selectie van patiënten met resistentie tegen trastuzumab, zoals onze studie suggereert.  
 
Het vooraf herkennen van patiënten met trastuzumab resistentie is een onopgelost probleem. 
Trastuzumab heeft verschillende werkingsmechanismen en daardoor zijn er ook verschillende 
mechanismen van resistentie beschreven, zoals: een herstel van Her2-gemedieerde DNA-
reparatie, omzeiling van de Her2-signaalroute en een verminderd celdodend vermogen van 
antilichamen. Het resistentiemechanisme lijkt gedeeltelijk afhankelijk van de voorgaande 
systemische therapie en kan dus verschillend zijn tussen patiënten en tijdsperiodes. In vitro en 
in muizen is aangetoond dat het resistentiemechanisme na Her2-blokkade met één middel 
verschilt van het resistentiemechanisme na Her2-blokkade met twee middelen. Dit kan 
klinisch relevant zijn, aangezien de huidige eerstelijns Her2-doelgerichte therapie met twee 
middelen wordt uitgevoerd en dus weer anders is dan voorheen. Samenvattend liet onze studie 
mogelijke trastuzumabresistentie zien in patiënten met eerstelijns Her2-doelgerichte therapie. 
Er is meer onderzoek nodig om de invloed van trastzumabresistentie op duale Her2-blokkade 
in kaart te brengen, wat belangrijk zal zijn voor de toekomstige populatie patiënten met Her2-
positieve uitgezaaide borstkanker. 
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De prognostische relevantie van lichaamssamenstelling bij uitgezaaide borstkanker. 
 
Het bepalen van de lichaamssamenstelling bevat het meten van de hoeveelheid vetmassa en 
vetvrije massa (skeletspierweefsel valt ook onder dit laatste), waardoor het totale 
lichaamsgewicht onderverdeeld kan worden in verschillende lichaamscompartimenten. Dit 
lijkt klinisch relevant, aangezien de metabolische activiteit verschilt tussen deze 
compartimenten en veranderingen in de hoeveelheid vet- en vetvrije massa niet synchroon 
optreden. Het gebruik van parameters voor lichaamssamenstelling wordt steeds meer 
onderzocht in patiënten met kanker, waarbij de hoeveelheid spiermassa de meest onderzochte 
parameter is. Hoofdstuk 3 bevat een overzicht van alle literatuur over de prognostische 
waarde van een lage spiermassa voor overleving en chemotherapeutische toxiciteit in 
verschillende solide en hematologische maligniteiten. Hierbij werd bevestigd dat een lage 
spiermassa invloed heeft op de prognose van deze patiënten.  
 
Anderzijds is er zeer weinig bewijs voor de klinische relevantie van de lichaamssamenstelling 
bij patiënten met borstkanker. Dit hiaat in de literatuur wordt beschreven in hoofdstuk 4 en 5 
van dit proefschrift. In hoofdstuk 4 wordt getoond dat een lage spiermassa voorafgaand aan 
eerstelijns palliatieve chemotherapie niet geassocieerd is met de totale overleving en de tijd 
tot aan de volgende systemische behandeling bij patiënten met uitgezaaide borstkanker. 
Echter was de spierkwaliteit wel van belang en deze blijkt een duidelijkere relatie te hebben 
met prognose dan spierkwantiteit. De spierkwaliteit kan bepaald worden door het meten van 
de spierdichtheid met behulp van CT-beelden, waarbij een lage spierdensiteit een toename 
van intramusculair microscopisch vet vertegenwoordigt. De studie in hoofdstuk 4 laat zien 
dat een lage spierdensiteit geassocieerd was met zowel totale overleving (HR 2.04, p = 0.001) 
als de tijd tot aan de volgende noodzakelijke systemische behandeling (HR 1.72, p = 0.01). 
Dit was onafhankelijk van leeftijd, tumorbiologie en locaties van uitzaaiingen.  
 
De observatie dat een lage spierkwaliteit een betere prognostische marker is dan een lage 
spiermassa is in overeenstemming met de literatuur over patiënten met andere soorten kanker 
en oudere mensen zonder kanker. De afname van de spiermassa en spierkwaliteit is vooral 
aanwezig in ouderen, en is vooral het gevolg van leeftijd gerelateerde endocrinologische 
veranderingen, leeftijd gerelateerde systemische inflammatie, verminderde fysieke activiteit 
en ondervoeding. Daarnaast neemt de spierkwaliteit sneller af dan de spiermassa en is de 
spierkwaliteit lager in obese patiënten. In de aanwezigheid van een maligniteit wordt het 
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spierverlies zelfs versneld door cachexie-gerelateerde processen. Concluderend is een lage 
spierdensiteit een makkelijk te meten radiologische marker, die belangrijk kan zijn voor de 
prognose van patiënten met uitgezaaide borstkanker die chemotherapie krijgen. Er zijn meer 
studies nodig om de impact van een lage spierdensiteit op de overleving te bepalen: 
- In verschillende ziektestadia 
- In oudere patiënten met borstkanker 
- Als de metingen met andere beeldvormende diagnostiek dan CT wordt gedaan  
- Als er interventies worden gedaan om de spierstatus te optimaliseren. 
 
Een studie in patiënten met eierstokkanker toonde aan dat longitudinale 
lichaamssamenstellings-metingen mogelijk meer prognostische waarde hebben dan een 
enkele meting bij diagnose. Daarnaast is het onbekend of er fors spierverlies als gevolg van 
individuele chemotherapeutica optreedt en wat de klinische impact hiervan is. Deze vragen 
werden bestudeerd in hoofdstuk 5. In deze studie werden er behalve spiermassa en 
spierkwaliteit ook andere lichaamscompartimenten bepaald, te weten: subcutaan vet, visceraal 
vet en macroscopisch intramusculair vet. De veranderingen in lichaamssamenstelling tijdens 
eerstelijns behandeling met 5-fluorouracil/adriamycine/cyclofosfamide (FAC) en paclitaxel 
vanwege uitgezaaide borstkanker werden retrospectief bepaald en gerelateerd aan de totale 
overleving.  
 
De belangrijkste bevinding van de studie in hoofdstuk 5 was dat spierdensiteit significant 
afnam tijdens behandeling met paclitaxel, terwijl de spiermassa en de vetmassa stabiel bleven. 
De afname van de spierkwaliteit was geassocieerd met chemotherapie in het verleden 
(adjuvant). Er werden geen veranderingen in lichaamssamenstelling waargenomen tijdens 
behandeling met FAC. De afname van de spierkwaliteit had deze keer geen invloed op de 
totale overleving. Het is daarbij belangrijk om te noemen dat patiënten met progressieve 
ziekte tijdens de behandeling zijn geëxcludeerd om de impact van progressieve kanker op 
spierverlies te vermijden in de analyses. De resultaten zijn dus alleen van toepassing op 
patiënten waarbij de ziekte tijdens chemotherapie onder controle is.  
 
In onze studie werd gezien dat de totale overleving niet werd beïnvloed door spierverlies 
tijdens chemotherapie. Dit is niet in overeenstemming met de studie bij de patiënten met 
eierstokkanker. Mogelijke verklaringen hiervoor zijn het verschil in tumortype en het feit dat 
de patiënten in onze studie jonger waren, wat kan resulteren in een minder prognostisch effect 
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van spierparameters. Desondanks moeten onze resultaten voorzichtig worden geïnterpreteerd. 
Ten eerste was het aantal patiënten dat behandeld werd met een FAC-schema klein, dus de 
power om verschillen in lichaamssamenstelling tijdens FAC te detecteren was beperkt. Meer 
onderzoek is hiervoor nodig. Ten tweede was ons doel om de impact van specifieke 
cytostatica op de lichaamssamenstelling in kaart te brengen, maar dit blijft lastig als er ook 
andere factoren zijn die de lichaamssamenstelling beïnvloeden en die we niet meten, zoals 
verminderde fysieke activiteit door chemotherapie en voedselintake. Er zijn goede 
controlegroepen nodig met patiënten zonder kanker om de echte impact van cytostatica op de 
lichaamssamenstelling te bepalen. 
 
Toch laat hoofdstuk 5 enkele waardevolle resultaten zien die hypothese-genererend zijn. Er 
kan mogelijk meer spierverlies (zowel kwantiteit als kwaliteit) tijdens behandeling met 
paclitaxel optreden, omdat dit middel specifieke spier-beïnvloedende toxiciteit geeft, zoals 
neuropathie en spierpijnen, met als gevolg minder fysieke activiteit en theoretisch gezien, 
microscopische veranderingen in de spier zelf. Chemotherapie in het verleden was 
geassocieerd met de afname van de spierkwaliteit na correctie voor andere factoren. Deze 
voorgaande chemotherapie was meestal een taxaan-schema, wat de theorie dat de 
spierkwaliteit wordt beïnvloed door paclitaxel versterkt. Dit is vooral klinisch relevant 
aangezien een afname van de spierkwaliteit geassocieerd is met systemische inflammatie 
(vergelijkbaar met de systemische inflammatie bij kanker cachexie) en slechte lichamelijke 
functie. Daarom kan een dalende spierkwaliteit een teken zijn van kwetsbaarheid bij patiënten 
met een hoger risico op complicaties tijdens opeenvolgende lijnen chemotherapie. Er zijn 
longitudinale prospectieve studies nodig om:  
- De impact van individuele cytostatische middelen op de lichaamssamenstelling te bepalen. 
- De correlatie tussen veranderingen in lichaamssamenstelling en overleving of toxiciteit te 
bepalen. 
 
De weg naar het opnemen van de bepaling van lichaamssamenstelling in de oncologische 
zorg 
 
Er is toenemend bewijs dat het bepalen van de lichaamssamenstelling mogelijk opgenomen 
zou moeten worden in de standaard zorg. Dit wordt echter bemoeilijkt door verschillende 
problemen bij het wetenschappelijk onderzoek in dit veld. Naast het beschrijven van de 
prognostische waarde van een lage spiermassa bij patiënten met kanker laat hoofdstuk 3 
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verder zien wat de knelpunten zijn in het huidige onderzoek naar het meten van 
lichaamscompartimenten. 
 
Ten eerste is er geen consensus over een definitie van een lage spiermassa en er is ook geen 
standaardmethode om dit te meten bij patiënten met kanker. In bijna alle oncologische studies 
wordt de term “sarcopenie” gebruikt om een lage spiermassa aan te geven. Deze term is 
afkomstig uit de geriatrische literatuur en de eerste definitie van sarcopenie was inderdaad 
enkel een lage spiermassa. Er is echter bij ouderen geen lineaire relatie tussen een lage 
spiermassa en een verminderd lichamelijk functioneren. Daarom wordt sarcopenie beschouwd 
als een complex geriatrisch syndroom met verschillende oorzaken. Er is om die reden nu een 
nieuwe definitie van sarcopenie, te weten: een lage spiermassa in combinatie met een lage 
spierkracht en/of verminderd lichamelijk functioneren. Het onderscheid tussen een lage 
spiermassa en sarcopenie is ook klinisch van belang in de oncologie, aangezien studies 
hebben aangetoond dat de prognostische impact van sarcopenie veel groter was dan de 
prognostische impact van enkel een lage spiermassa. Veelgebruikte geriatrische testen om een 
verminderd lichamelijk functioneren in kaart te brengen zijn echter niet veel voorhanden in de 
oncologische zorg, dus er zijn meer studies nodig om het toevoegen van deze testen aan de 
standaard oncologische zorg te onderzoeken. Erkende testen voor een lage spierkracht en een 
verminderd lichamelijk functioneren zijn respectievelijk: de spierkracht van de hand meten 
met een Jamar hand dynamometer en het bepalen van de loopsnelheid in meter per seconde. 
Maar de eerste stap in de oncologie zou moeten zijn de nomenclatuur van spierverlies-
fenomenen helder te hebben en te herkennen dat sarcopenie en spierverlies twee verschillende 
entiteiten zijn, die slechts deels met elkaar overlappen. 
 
Ten tweede is de definitie van een lage spiermassa ook onduidelijk, aangezien goede 
referentiewaardes voor een lage spiermassa niet beschikbaar zijn. Een veelgebruikte definitie 
in de geriatrische literatuur is een spiermassa die meer dan twee standaarddeviaties ligt onder 
de gemiddelde spiermassa van een jongvolwassene. Meestal zijn deze metingen met andere 
apparatuur gedaan dan CT. CT-beeldvorming wordt echter gezien als de gouden standaard 
voor spiermetingen, vanwege validatie in kadavers en wordt het meest gebruikt in de 
oncologie. Er zijn echter geen referentiepopulaties beschikbaar voor deze methode. Deze 
referentiepopulaties zijn wel nodig om de prevalentie van een lage spiermassa en de 
prognostische waarde in verschillende oncologische studies te interpreteren en om de impact 
van cytostatica, doelgerichte therapie en de klinische gevolgen van spierverlies in kaart te 
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brengen. Toekomstige studies moeten zich richten op het beschrijven van referentiepopulaties 
voor spiermetingen met behulp van CT-beeldvorming. Deze spiermetingen moeten in 
verschillende leeftijds- en BMI-groepen en per ras en geslacht bepaald worden, aangezien al 
deze parameters de hoeveelheid spiermassa bepalen. Zolang zulke referentiepopulaties nog 
niet beschikbaar zijn, zijn eerder bepaalde afkappunten voor een lage spiermassa een goed 
alternatief, zoals de afkappunten die bepaald zijn in een studie met meer dan 1000 patiënten 
met solide maligniteiten. 
 
Ten derde is er nog relatief weinig aandacht in de oncologische literatuur voor andere 
metingen van lichaamssamenstelling dan spiermassa. Er zijn weinig studies naar de kwaliteit 
van de spier en naar de metingen van diverse vetcompartimenten (subcutaan, visceraal en 
intramusculair). Deze parameters zijn echter ook belangrijk vanwege hun mogelijke associatie 
met lichamelijk functioneren en de mogelijke interacties met de farmacokinetiek van 
chemotherapeutische middelen. In de literatuur is herhaaldelijk beschreven dat de systemische 
klaring van hydrofiele cytostatica een sterke correlatie heeft met de hoeveelheid vetvrije 
massa. Daarom hebben patiënten met een relatief lage spiermassa een lager distributievolume 
van deze middelen, resulterend in hogere plasmaspiegels en daardoor mogelijk meer 
toxiciteit. Andersom zou dit ook kunnen gelden voor een mogelijke relatie tussen een relatief 
lage vetmassa en plasmaspiegels van lipofiele cytostatica, zoals paclitaxel. 
 
Een eerste stap in de richting van de implementatie van lichaamssamenstellingsmetingen in de 
oncologische zorg zou een inventarisatie kunnen zijn van welke spiermetingen en functionele 
testen gebruikt kunnen worden in de praktijk. Dit wordt beschreven in hoofdstuk 6. In dit 
hoofdstuk worden de overeenkomsten tussen spiermassa en spierkwaliteit en functionele 
testen in oudere patiënten met kanker onderzocht. Ook wordt de relatie tussen verschillende 
gradaties van sarcopenie en verlies van zelfstandigheid bestudeerd. Ouderen zijn specifiek 
geïncludeerd omdat deze patiënten waarschijnlijk het meeste voordeel hebben van 
beslissingen op basis van de lichaamssamenstelling. Een tweede reden is dat er meer 
duidelijkheid nodig is over testen die nauwkeurig het lichamelijk functioneren van ouderen 
met kanker kunnen beschrijven. Testen die de spierkracht meten lieten een significante 
correlatie zien met de spiermassa, terwijl dit niet gold voor testen die de mobiliteit in kaart 
brengen. Daarentegen lieten alle functionele testen een significante correlatie zien met de 
spierkwaliteit. Dit steunt opnieuw de theorie dat de spierkwaliteit meer zegt over het 
lichamelijk functioneren dan de spierkwantiteit. De stelling dat sarcopenie en een lage 
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spiermassa niet hetzelfde zijn werd opnieuw bevestigd in deze studie, aangezien 75% van de 
patiënten een lage spiermassa had volgens de afkappunten in de literatuur, maar minder dan 
de helft ook echt sarcopenie had volgens de meest recente criteria. Toch waren functionele 
testen niet goed in staat om patiënten met een lage spiermassa of kwaliteit te identificeren en 
daarom kunnen zij CT-gebaseerde spiermetingen niet vervangen. Patiënten met ernstige 
sarcopenie leken na chemotherapie vaker zo lichamelijk achteruit te zijn gegaan dat er 
langdurig meer zorg voor de dagelijkse activiteiten nodig was. Van belang is dat 40% van 
deze patiënten met ernstige sarcopenie “fit” genoeg werd beschouwd voor chemotherapie 
door de behandelend arts. In toekomstige studies moet daarom eerder aandacht besteed 
worden aan het (geriatrische) syndroom sarcopenie dan aan individuele spiermetingen. 
 
Conclusie 
 
De metingen van de verschillende lichaamscompartimenten (vet en vetvrij) zijn mogelijk 
belangrijke prognostische factoren voor de overleving van patiënten met kanker, waarbij de 
spierkwaliteit beter is dan de spierkwantiteit. De studies in dit proefschrift behoren tot de 
eerste studies wereldwijd die dit ook bevestigen bij patiënten met uitgezaaide borstkanker. 
Specifiek voor deze patiënten is het ook belangrijk dat er minder profijt van Her2-
doelgerichte therapie is na blootstelling aan trastuzumab in de adjuvante setting. Aan de hand 
van dit proefschrift zijn de aanbevelingen voor toekomstig onderzoek naar beide onderwerpen 
als volgt: 
- Onderzoek naar de invloed van trastuzumab resistentie op de effectiviteit van duale Her2-
blokkade. 
- Verder oncologisch onderzoek naar andere lichaamssamenstellingsparameters dan enkel 
spiermassa, te weten: spierkwaliteit (spierdensiteit), subcutaan vet, visceraal vet en 
intramusculair vet. 
- Onderzoek naar de toegevoegde waarde van functionele testen naast spiermetingen. 
- Onderzoek naar de impact van individuele chemotherapeutische middelen op de 
lichaamssamenstelling. 
- Onderzoek naar mogelijke farmacokinetische effecten door veranderingen van 
lichaamssamenstelling en de relatie met chemotherapeutische toxiciteit.  
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Om verder te werken naar een mogelijke toekomst voor het bepalen van de 
lichaamssamenstelling bij patiënten met kanker, zijn er studies nodig die de associatie van een 
abnormale lichaamssamenstelling (bepaald met behulp van referentiepopulaties) en 
oncologische uitkomsten onderzoeken. Vervolgens zijn er interventiestudies nodig die de 
spierstatus optimaliseren, en onderzoeken of de overleving en kwaliteit van leven van 
patiënten met kanker hierdoor verbeterd kan worden. Het is daarbij van essentieel belang op 
te merken dat geriatrische studie-eindpunten zoals het behoud van zelfstandigheid of het 
kunnen doorstaan van een behandeling met acceptabele toxiciteit soms belangrijker zijn voor 
oudere patiënten met kanker dan de oncologische uitkomsten.  
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Dankwoord 
 
Promoveren, dat was iets wat vrij onverwacht op mijn pad kwam. Ik was werkzaam als arts-
assistent niet in opleiding interne geneeskunde in het Albert Schweitzer ziekenhuis en ik was 
nietsvermoedend visite aan het lopen op de locatie Zwijndrecht toen ik een telefoontje kreeg 
van Mark-David Levin met direct de vraag: “Wil jij onderzoek doen, met als doel 
promoveren?” 
 
Na ampel beraad was ik ineens uit de kliniek en vond ik mijzelf terug achter een 
computerscherm. Nu aan het eind van deze rit ben ik een aantal mensen dank verschuldigd, 
aangezien dit proefschrift niet tot stand zou zijn gekomen zonder hen.  
 
Als eerste wil ik mijn promotor noemen, prof. dr. Stefan Sleijfer. Beste Stefan, jij was meteen 
welwillend om mijn promotor te zijn toen ik in 2014 voor het eerst de Daniël den Hoed kwam 
binnenzeilen met mijn onderzoek vanuit de periferie. Wat heb je mij ontzettend geholpen met 
het schrijven van de artikelen en met het brainstormen over de inhoud van het onderzoek. 
Jouw feedback kwam vaak dezelfde dag of de volgende dag, hoe je het doet is mij een 
raadsel. Bedankt dat je zoveel tijd voor mij hebt genomen en mij zoveel hebt geleerd over het 
uitvoeren van wetenschappelijk onderzoek.  
 
Daarnaast mijn copromotor, dr. Agnes Jager. Lieve Agnes, bedankt voor je enorme hulp de 
afgelopen jaren. Ik heb bewondering voor jouw kennis van de oncologie en de wijze waarop 
je mij hebt begeleid. Ik heb veel van je geleerd over de klinische overwegingen van een 
oncoloog en de behandeling van borstkanker. Één van de dingen die ik leuk vond aan jou was 
dat je vaak een stuk of 20 opmerkingen in mijn artikel zette die aangepakt moesten worden en 
dan even later vroeg of ik niet van streek was door zoveel kritiek. Zoals ik vaak heb 
geantwoord: “Nee, in het geheel niet, want je bracht het altijd op een uitzonderlijk 
vriendelijke manier.” Bedankt voor alles en hopelijk meer samenwerking in de toekomst.  
 
Mark-David, jou ben ik ook veel dank verschuldigd als 2
e
 copromotor en vanwege het feit dat 
jij degene was die het überhaupt mogelijk heeft gemaakt om mijn onderzoek uit te voeren. 
Niets was te gek, ik mocht naar alle congressen en cursussen die ik nodig achtte. Jij bent 
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degene met wie ik het meest te maken had op de werkvloer, bedankt voor alle tijd die je 
daarin hebt gestoken en de kansen die ik daardoor heb gehad. 
 
Leden van de kleine commissie, prof. dr. J.N.M. IJzermans, prof. dr. J.L.C.M. van Saase en 
prof. dr. H.M.W. Verheul, hartelijk dank voor jullie bereidheid om mijn proefschrift te 
beoordelen.  
 
Bij dit onderzoek zijn diverse mensen uit het Albert Schweitzer ziekenhuis nauw betrokken 
geweest. Marc en Joost, bedankt voor jullie respectievelijk radiologische en statistische 
ondersteuning van dit onderzoek. Marc, door jou heb ik het genoegen gehad het één en ander 
op te steken van CT-beeldvorming, iets wat ik niet in mijn eigen klinische omgeving zou 
hebben geleerd. Joost, jij bent als statisticus verbonden aan het Erasmus MC, maar werkt als 
statistisch consulent in Dordrecht. Dit schept ontelbare mogelijkheden voor wetenschappelijk 
onderzoek in het Albert Schweitzer ziekenhuis en jij hebt mij met eindeloos geduld van alles 
bijgebracht over data-analyse. Deze kennis kan ik mijn leven lang gebruiken.  
 
De afdeling geriatrie wil ik bijzonder bedanken voor hun gastvrijheid en flexibiliteit. Dit geldt 
zowel voor de geriaters zelf, als voor de verpleegkundigen en poli-assistentes. Jullie hebben al 
die jaren spreekkamers op jullie polikliniek, verpleegkundigen en tijd beschikbaar gesteld aan 
mijn onderzoek. Als kersverse onderzoeker was het een warme omgeving om in terecht te 
komen, bedankt. Marianne en Patricia, jullie komt speciale lof toe voor het includeren van alle 
patiënten.  
 
Tijdens dit promotie-onderzoek heb ik mooie vriendschappen gemaakt die ik anders niet had 
gehad. Marieke, als internist-ouderengeneeskunde met interesse voor de oncologie was jij 
nauw betrokken bij het mogelijk maken en de uitvoer van mijn onderzoek. Maar daarnaast 
was je ook een maatje. We hebben het ontzettend gezellig gehad op congressen, tijdens het 
lunchen en aan de telefoon. Bedankt dat je altijd voor me klaar stond en mij telkens jouw 
motto voorhield: “De aanhouder wint.” 
 
Karlijn, mijn collega-promovendus uit het Albert Schweitzer ziekenhuis. Niet alleen 
voorkwam jij dat ik tegen mezelf ging praten uit eenzaamheid als onderzoeker, maar ook 
hebben we zo ontzettend veel lol gehad. Zowel in het ziekenhuis als daarbuiten. We hebben 
2.5 jaar lang een kamer gedeeld, 40 uur per week, dat is nogal wat. Ja, dan moet je wel 
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vrienden worden. Bedankt voor de vele onderzoeks-gerelateerde hilarische momenten die we 
hebben gehad, onder andere het delen van plaatjes met PhD-comics. 
 
Delal, mijn collega-promovendus uit de Daniel den Hoed kliniek. Wij hebben elkaar leren 
kennen vanwege het feit dat we dezelfde promotor hebben. Door de jaren heen is dat 
uitgegroeid tot een vriendschap waarbij we om de paar weken uiteten gaan om even bij te 
kletsen. En om alle (soms hilarische) verhalen over submissies en reviewers te delen. Echt 
heel gezellig en motiverend om weer door te gaan. Ook na mijn promotie houden we dat 
natuurlijk zo, en uiteraard kijk ik uit naar jouw boekje.  
 
Etienne, jou heb ik leren kennen door de vele uren die ik op de polikliniek geriatrie heb 
doorgebracht. Bedankt voor de gezellige koffie-momenten die mij vooral herinnerden aan het 
feit dat er ook andere zaken zijn dan onderzoek. Jij kon eventuele onderzoek-stress altijd goed 
relativeren en dat houdt me bij de les. 
 
Ook andere collega’s wil ik bedanken voor hun interesse en medewerking aan mijn 
onderzoek. Dit kon zowel op inhoudelijk als persoonlijk gebied zijn. Inge, Peter en Crista, 
jullie zijn gedurende 3 jaar lang een luisterend oor geweest voor mij en ik kon op jullie input 
rekenen indien nodig. Claire, jij was er iets korter dan 3 jaar, maar zeker niet minder 
waardevol. Dank hiervoor. 
 
Diverse vrienden in de privésfeer zijn op de achtergrond continu aanwezig en hebben 
daardoor een speciale plaats in mijn hart. Anne, Romeo, Timothy, Regina en Floor, jullie 
hebben mij altijd door dik en dun gesteund. Ik mocht praatjes komen oefenen, bordspelletjes 
komen spelen, komen logeren en alles wat verder nog nodig is om goed te gedijen als 
promovendus. Lisa, je bent de beste nicht die ik me kan wensen en ookal woon jij in 
Suriname en ik hier, toch was jij er altijd als het moest. Zoals dat gedurende mijn hele leven is 
geweest. 
 
Lieve Mike, als mijn bijna-even-oude broer(tje) en cardioloog in opleiding had jij altijd een 
frisse tegenzin om ook maar iets van mijn artikelen te lezen. Want de oncologie, nee, dat is 
niet jouw vak. Ookal bleef ik, dat wetende, mijn artikelen met goede moed in jouw mailbox 
deponeren, om een uur later te appen: “Heb je het al gelezen?”. Maar juist dat kan ik alleen bij 
een broer doen. Wij blijven een team, bedankt dat je er bent.  
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Lieve mama en papa, jullie zijn de belangrijkste mensen in mijn leven. Zonder jullie was ik 
nergens. Ik kan niet uitdrukken hoeveel ik van jullie hou en hoe belangrijk jullie zijn geweest 
voor het goed afronden van mijn promotie-onderzoek. En overigens voor alles wat ik tot nu 
toe heb mogen bereiken in mijn carrière als arts. Ik zal altijd voor jullie klaarstaan, bedankt 
voor jullie liefde.  
 
Aan het eind gekomen van mijn dankwoord rest mij te zeggen dat ik hoofdstuk 2 van dit 
proefschrift opdraag aan mijn lieve zuster Hanna, die tijdens dit promotie-onderzoek veel te 
jong is gestorven aan het probleem dat ik in dat hoofdstuk heb onderzocht. U wilde erbij zijn 
als dit boek af was, maar dat kon helaas niet. Tijdens het schrijven van dat hoofdstuk kwam ik 
erachter wat elke patiënt in die studie en haar familie heeft doorgemaakt. Ik had het liever niet 
willen weten, en het maakte het soms moeilijk om het hoofdstuk op te schrijven, maar net als 
u laat ik me niet uit het veld slaan. Tijdens het onderzoek niet en in de toekomst ook niet.  
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Curriculum vitae 
 
Hánah Nicole Rier was born on 13th April 1987 in Amsterdam. She graduated from  
secondary school in 2005. Thereafter, she started her study Biomedical Sciences at the  
University of Amsterdam. After 1 year, she quitted this study and attended the study Medicine  
at the Erasmus University in Rotterdam. She obtained her medical degree in 2013, after which  
she worked as a resident internal medicine at the Albert Schweitzer hospital in Dordrecht. She  
started working on this PhD thesis in January 2014 in collaboration with the Erasmus MC  
Cancer Institute under the supervision of Dr. M-D. Levin, dr. A Jager en prof. Dr. S. Sleijfer.  
From January 2017 and onwards, she attended a residence programme at the Albert  
Schweitzer hospital, in order to specialize in the oncological field. 
 
Hánah Nicole Rier werd geboren op 13 april 1987 te Amsterdam. In 2005 voltooide zij het  
Voortgezet Wetenschappelijk Onderwijs aan de Purmerendse Scholengemeenschap, locatie  
Jan van Egmond. Zij startte vervolgens met de studie biomedische wetenschappen aan de  
universiteit van Amsterdam. Na één jaar staakte zij deze opleiding en startte in 2006 met de  
studie geneeskunde aan de Erasmus universiteit, waarbij zij het artsexamen aflegde in januari  
2013. Aansluitend werkte zij als arts-assistent niet in opleiding tot specialist op de afdeling  
Interne geneeskunde in het Albert Schweitzer ziekenhuis te Dordrecht. Vanaf januari 2014  
werkte zij aan het wetenschappelijk onderzoek, wat heeft geresulteerd in dit proefschrift. Het  
onderzoek is uitgevoerd vanuit het Albert Schweitzer ziekenhuis in samenwerking met de  
Daniël den Hoed kliniek onder supervisie van dr. M-D. Levin, dr. A. Jager en prof. dr. S.  
Sleijfer. Vanaf 1 januari 2017 is zij in opleiding tot internist in het Albert Schweitzer  
ziekenhuis. Zij hoopt zich te zijner tijd te specialiseren in de oncologie. 
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PhD Portfolio 
Name PhD student:  Hánah Nicole Rier 
Institution:  Albert Schweitzer hospital and Erasmus MC Cancer Institute 
Period:  January 2014 – December 2016 
Promotor:  prof. dr. S. Sleijfer 
Copromotores: dr. A. Jager 
   dr. M-D. Levin 
 
 Workload 
 Year Hours ECTS 
1. PhD training 
 
   
General courses 
- Good clinical practice 
- Scientific writing 
- Integrity in Science for PhD students Erasmus MC 
 
 
2014 
2015 
2016 
 
15 
28 
10 
 
0.5 
1.0 
0.4 
Specific courses 
- NIHES: Biostatistics for Clinicians 
- NIHES: Advanced analysis of prognosis studies 
- NIHES: Clinical trials 
 
 
2016 
2016 
2016 
 
20 
26 
20 
 
0.7 
0.9 
0.7 
Seminars and workshops 
- Jonge Oncologen avond 
- Symposium Borstkanker Behandeling Beter 2016 
 
 
2016 
2016 
 
2.5 
7.5 
 
0.1 
0.3 
Presentations 
- 9 presentations at group meetings Asz 
- 2 Poster presentations SIOG 
- Oral presentation Internistendagen 
- 2 presentations at Wetenschapslunch Asz 
- 2 presentations at Wetenschapsdag Asz 
- 1 presentation at Research Meeting Erasmus MC 
 
 
2014 – 2016 
2015 
2015 
2015 – 2016 
2015 – 2016 
2016 
 
 
40 
10 
5 
5 
10 
10 
 
1.4 
0.4 
0.2 
0.2 
0.4 
0.4 
International conferences 
- Internistendagen 
- International Society of Geriatric Oncology (SIOG) 
- European Cancer Congress (ECCO) 
- Sarcopenia, Cachexia and Muscle Wasting:  
9
th
 International Conference 
 
 
2014 – 2016 
2015 – 2016 
2015 
2016 
 
70 
50 
42 
17 
 
2.5 
1.8 
1.5 
0.6 
2. Teaching 
 
   
- Teaching residents Internal medicine 
Subject: Treatment patterns in breast cancer and the 
importance of muscle mass as a prognostic factor 
 
2015 
 
 
 
20 
 
 
 
0.8 
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- Supervising Master’s Thesis Danielle Bontekoe 
Resulted in a poster presentation at the Wetenschapsdag 
Asz as second author 
 
- Supervising Researcher Asz 
Subject: The prognostic value of low muscle mass and 
attenuation in non-Hodgkin Lymphoma 
 
2016 
 
 
 
2015 – 2016 
28 
 
 
 
48 
1.0 
 
 
 
1.7 
3. Other 
 
   
- Wetenschapslunch Asz 
 
- Local investigator CHARMING study 
Subject: The change of geriatric morbidity and muscle 
status in elderly cancer patients undergoing 
chemotherapeutic treatment 
 
2014 – 2016 
 
2014 - 2016 
36 
 
315 
1.3 
 
11.3 
- Peer reviews for several international journals in the 
field of Oncology 
2016 20 0.7 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
